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1 Introduction  
1.1 Principles of chemicals’ risk assessment and the need for improving 
efficiency of toxicity testing  
Chemicals are ubiquitous in our daily lives. The use of chemicals in several products and 
applications, such as food products, pharmaceuticals or cosmetics, creates great benefits to 
society. At the same time, humans and the environment are exposed to chemicals via a 
number of pathways. Depending on exposure concentrations, some chemicals can have 
harmful effects and can pose risks to human health and the quality of the environment (WHO, 
2016). The production of chemicals is expected to continue to increase in the coming years 
which may also increase human and environmental exposure and, consequently, the risks of 
adverse effects (OECD, 2012a). Controlling the risks from chemicals’ use and enforcing 
effective control strategies are key tasks of regulatory agencies, for example, the European 
Chemicals Agency (ECHA), the Organisation of Economic Co-operation and Development 
(OECD), and the World Health Organisation (WHO), who have put a lot of effort on the 
development of risk assessment and risk management processes. For instance the OECD, has 
been developing control strategies for consumer products such as risk assessment 
approaches in order to ensure harmonised strategies worldwide (OECD, 2016a). Likewise, the 
WHO and the Food and Agriculture Organization of the United Nations (FAO) have developed 
safety and control measures for pesticides (WHO/FAO, 2016a; WHO/FAO, 2016b).  
Risk assessment of chemicals describes the process by which information about the 
hazard identification of chemicals, the dose-response relationship (effects assessment), and 
exposure is collected and combined in order to characterise a chemical’s risks (WHO, 2004; 
van Leeuwen et al., 2007), see Figure 1.1. Based on the risk characterisation of chemicals, risk 
management measures for the control of risks to human health and the environment, can be 
adopted in order to allow the safe use of substances. The outcomes of risk management 
measures depend on information from the risk assessment of chemicals, but also consider the 
economic relevance of a chemical, the effectiveness of a measure, or its practicality, 
consistency and public acceptability (Krewski et al., 2009; Gabbert and Weikard, 2010; Tralau 
et al., 2015). Typical risk management measures are classification and labelling, safety 
standards, adjustments of the production technologies, restriction of use, or even a ban of the 
chemical compound (Hansen and Blainey, 2008).  
To ensure the protection of human health and the environment, the European 
Commission (EC) has established regulatory frameworks guiding the risk assessment of 
chemicals produced, manufactured or imported within the EU. In June 2007 the new 
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chemicals’ legislation “Registration, Evaluation, Authorisation and Restriction of Chemicals” 
(REACH) entered into force (EC, 2006). The key aims of REACH are: (i) “...to ensure a high level 
of protection of human health and the environment, including the promotion of alternative 
methods for assessment of hazards of substances....” (see Article 1 in EC, 2006) (ii) “the sharing 
and joint submission of information... in particular information related to the intrinsic properties 
of substances” (see Article 25 in EC, 2006) (iii) “...to ensure the good functioning of the internal 
market while assuring that the risks from substances of very high concern are properly 
controlled and that these substances are progressively replaced by suitable alternative 
substances ...” (see Article 55 in EC, 2006).  
To meet the information requirements defined by the REACH legislation, it is estimated 
that about 143,000 substances need to be tested, which is much more than the initial EU 
estimate of approximately 30,000 substances (Schoeters, 2010). Obviously, the traditional 
approach for assessing chemicals’ risks and hazards based on a “check-list” approach, where 
information about chemicals’ hazard is generated performing highly standardised in vivo or in 
vitro testing methods for every toxicological endpoint, is not able to fill information gaps 
within the deadlines defined in the REACH legislation. Furthermore, generating information 
about the hazardous properties of chemicals is resource consuming (Koch and Ashford, 2006; 
Bottini and Hartung, 2009). It has been estimated that fulfilling information requirements 
defined by REACH – if based on existing animal tests – would increase testing costs by several 
billions of Euros, depending on the toxicological endpoint and the number of chemicals that 
need to be tested for a given endpoint (Rovida and Hartung, 2009). The need to fill 
information gaps for large numbers of chemicals at low cost has stimulated research on 
developing new and efficient approaches to toxicity testing (Schaafsma et al., 2009; Andersen 
and Krewski, 2010; Hartung, 2010a).  
In addition to protecting human health and the environment through generating sufficient 
and adequate information, the REACH legislation emphasises the need to reduce animal 
testing (EC, 2003b; Hartung, 2010b). Article 25 of REACH legislation states that animal tests 
should be used as “a last resort”, supporting the “3R’s principle” i.e. the refinement, reduction 
and replacement of animal tests (Russell, 1959). Besides the REACH legislation, the European 
Cosmetics Regulation (EC, 2009), which was commenced in July 2013 and replaced the 
Cosmetics Directive (EC, 2003a), has adopted concrete steps to phase-out animal testing. 
Specifically, since 2009 the Cosmetics Regulation has prohibited to test finished cosmetic 
products on animals. Additionally, since July 2013 a full marketing ban of cosmetic products 
with ingredients tested in animals has been established. This stimulated the development of 
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testing methods which are not only able to generate relevant and sufficient information fast 
and less costly which replace animal testing. 
 
Figure 1.1: Steps of risk assessment of chemicals (adapted from van Leeuwen et al., 2007)  
 
Furthermore, it has been increasingly acknowledged that none of the available testing 
methods, including the animal tests, provides perfect information about a substance’s 
hazardous properties. Thus, information from testing is uncertain and consequently, there is a 
“cost of making errors”. An erroneous release of a hazardous substance can cause health 
damages resulting in costs to the society (Hartung, 2010a). Likewise, a false classification of a 
safe substance may prevent the realisation of marketing benefits (Grandjean, 2015). There is 
a need (i) to accelerate risk assessment of chemicals in order to fill information gaps for large 
numbers of chemicals according to the requirements of REACH legislation, (ii) to replace 
animal testing, and (iii) to account for the limitations of animal tests and standalone non-
animal testing methods for assessing chemicals’ hazardous properties. Therefore, several 
concepts for integrated approaches to testing have been proposed as an innovative solution 
for the improvement of toxicity testing of chemicals (Grindon et al., 2006a; Nordberg et al., 
2008; Jaworska and Hoffmann, 2010; Balls et al., 2012).  
Initially, a testing strategy integrating information from different testing methods, was 
defined as a “flexible sequence of steps ... covering the characterisation of the substance, the 
analysis of modes of action, the identification of possible analogues, and the evaluation of 
existing in vivo and in vitro testing data as well as of QSAR results” (Ahlers et al., 2008). By 
sequentially combining different testing methods in a testing strategy has been considered to 
allow for exploiting information about the hazardous properties of a substance from various 
sources, thus maximising information gains, while minimising or even avoiding animal use, 
Hazard 
identification
Effects 
assessment
Risk 
characterisation
Exposure 
assessment
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testing time, and costs (Jaworska et al., 2010). Early examples of testing strategies have been 
developed for various toxicological endpoints, such as developmental and reproductive 
toxicity (Grindon et al., 2008a), eye irritation (Grindon et al., 2008b), skin corrosion (Grindon 
et al., 2008c), repeated dose toxicity (Grindon et al., 2008d), skin sensitisation (Grindon et al., 
2008e). Whereas early studies addressing the development of testing strategies took the form 
of qualitative decision flow charts, there has been a scientific discussion on suitable criteria 
and principles for the development of testing strategies. Specific attention has been given to 
developing testing strategies using non-animal testing methods (Hartung et al., 2013; Rovida 
et al., 2015). In June 2016, the OECD published two reports (OECD, 2016b; OECD, 2016c) in 
which concepts related to testing strategies and risk assessment of chemicals were presented 
(see Table 2.1 in Chapter 2 of this thesis).  
The overall debate and the process of developing non-animal testing strategies have been 
characterised by fundamental conceptual questions addressing the principles of data 
integration for assessing hazards and risks of chemicals. In particular, the fundamental 
questions of (i) how to integrate information from different sources in a transparent and 
coherent way, (ii) how to update information gains across testing sequential steps, (iii) how to 
quantify and reduce uncertainty across sequential steps, (iv) with which testing method to 
start a testing sequence, and (v) when to stop testing, have been discussed (Jaworska and 
Hoffmann, 2010; Jaworska et al., 2011). Answering, however, these questions, is ultimately, an 
economic optimisation problem (Gabbert and Weikard, 2013). Exploring the possible optimal 
allocation of scarce resources in order to maximise output (e.g. social welfare) is a key 
economic principle called “efficiency” (Hurley et al., 2000; Wynand et al., 2000). Economics as 
a discipline in social sciences offers a set of approaches and tools to analyse the trade-offs 
between competing objectives, such as information gains from testing, testing costs, and 
animal welfare. The aim is to increase efficiency of testing strategies and avoid unnecessary 
testing and costs (Nordberg et al., 2008).  
Although the scientific and policy debate about the development of a “new toxicity testing 
paradigm” (Krewski et al., 2010), including the minimisation of animal tests, have been clearly 
driven by efficiency considerations, only a few studies approach the question of how to 
optimise toxicity testing, and the development of testing strategies, from an economic 
perspective. Cost-effectiveness analysis (CEA) has been applied in order to evaluate testing 
methods with regard to their information outcome expressed in terms of a testing method’s 
predictive accuracy and animals saved (Lave et al., 1988; Gabbert and van Ierland, 2010; 
Norlén et al., 2014). Other studies have addressed the optimisation of testing methods using 
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tiered approaches or sequences of testing methods from an expected utility theory 
perspective (Hansson and Rudén, 2007), and by using a Value of Information (VOI) analysis 
(Yokota et al., 2004; Yokota and Thompson, 2004; Gabbert and Weikard, 2013). However, 
these studies include animal tests and usually assume a pre-defined order of testing methods.  
1.2 Addressing the development of efficient toxicity testing strategies: The 
case of skin sensitisation  
During the past decade, a lot of attention has been dedicated to developing non-animal 
testing methods and testing strategies for the toxicological endpoint skin sensitisation 
(Jaworska and Hoffmann, 2010; Jaworska et al., 2011; Hartung et al., 2013; Rovida et al., 2015; 
Jaworska, 2016). Skin sensitisation is the toxicological endpoint assessing a substance’s ability 
to cause allergic contact dermatitis (ACD) (UNECE, 2011). ACD is responsible for causing 
contact allergies affecting 15% – 20 % of the human population at least once in a lifetime 
(Thyssen et al., 2007). Within REACH, assessing skin sensitisation is mandatory for all 
chemicals produced or imported in tonnage larger than one tone per year (EC, 2006), and it is 
a mandatory endpoint for all substances used in cosmetic products (EC, 2009). In particular, 
the development of testing strategies for the assessment of skin sensitisation potential (i.e. the 
classification of substances as “sensitisers/non-sensitisers”), and the assessment of skin 
sensitisation potency (i.e. the assessment of the concentration dependent severity of an 
adverse effect by characterising substances as low, moderate, strong or extreme sensitisers), 
has been advanced from qualitative flow charts (e.g. Grindon et al. (2008e)) to deterministic 
approaches such as the tiered testing strategies (van der Veen, et al., 2014), or integrated 
testing strategies (ITS) approaches (Bauch et al., 2012; Urbisch et al., 2015a) and to 
probabilistic, quantitative approaches such as the Bayesian networks (Jaworska et al., 2011; 
Jaworska et al., 2013). Skin sensitisation has become particularly relevant for exploring and 
developing non-animal testing methods and for integrating information into testing 
strategies, among other toxicological endpoints such as endocrine disruption or liver toxicity 
endpoints (Valérie Zuang, 2015).  
First, skin sensitisation is an economically relevant endpoint because the number of 
people suffering from ACD has been increasing world-wide for many years (Thyssen et al., 
2007). Second, ACD causes high direct and indirect costs to society (ECHA, 2014b). Several 
studies have assessed direct costs arising from ACD, e.g. costs for medical treatment (Augustin 
and Zschocke, 2001; Ricci et al., 2006; Sætterstrøm et al., 2014), and indirect costs such as loss 
of well-being and productivity (Hongbo et al., 2005; Nijsten, 2012). Third, skin sensitisation 
testing is costly. Conservative estimates on testing costs for assessing the skin sensitisation of 
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chemicals under REACH suggest 162.8 billion Euros for the total number of chemicals, 
considering a moderate scenario on the animal tests requirements (Rovida and Hartung, 
2009). Under the same moderate scenario, animal tests for skin sensitisation, such as the 
Local Lymph Node Assay (LLNA) (Kimber et al., 1994; Kimber et al., 2001) described in the 
OECD TG 429 (OECD, 2010) and guinea pig based tests described in the OECD TG 406 (OECD, 
1992), are estimated to require the use of about 823,891 animals in order to meet the 
requirements of REACH (Rovida and Hartung, 2009). To achieve cost minimisation in the 
development of testing strategies, it is important to further study the integration of 
information about direct testing costs, animal welfare considerations and indirect costs from 
the increasing occurrence of ACD, the clinically relevant effect of skin sensitisation, in the 
development of testing strategies for assessing skin sensitisation.  
Finally, it has been acknowledged that the precision of testing methods, including animal 
tests, is limited. As shown for the case of skin sensitisation potential assessment, technical and 
biological variability can lead to misclassifications (Kolle et al., 2013; Hoffmann, 2015; 
Dimitrov et al., 2016; Dumont et al., 2016). The impact of biological and technical variability of 
the LLNA on the misclassification of substances, is associated with the fact that the 
classification of substances as “sensitisers/non-sensitisers” is based on clear-cut thresholds 
(Hoffmann, 2015). Biological and technical variability have an impact of misclassifications 
when test results fall within the area around the classification threshold. This area has been 
defined by (Kolle et al., 2013) the borderline range, also called “grey zone” by (Dimitrov et al., 
2016), in which test results are discordant (also described as ambiguous, inconclusive, or 
borderline). Biological and technical variability can limit the precision of non-animal testing 
methods (Leontaridou et al., 2017a). Finally, limited precision due to the biological and 
technical variability can add to uncertainties underlying to measures of non-animals testing 
methods’ predictive accuracy (Worth and Cronin, 2001a). In particular, uncertainties occur 
due to variations of the size and composition of substances’ samples used to assess predictive 
accuracy. However, research to unravel the joint effect of different types of uncertainty on 
predictive accuracy metrics of non-animal testing methods is still lacking. 
Given both the economic and the toxicological relevance of the skin sensitisation 
endpoint, several non-animal methods for assessing skin sensitisation potential have been 
developed in recent years (Mehling et al., 2012; Reisinger et al., 2015). The Direct Peptide 
Reactive Assay (DPRA) (Gerberick et al., 2004; Gerberick et al., 2007), the Antioxidant 
Response Element - Nuclear Factor Erythroid 2 (ARE-Nrf2) luciferase testing methods 
covered by KeratinoSensTM (Emter et al., 2010; Natsch et al., 2011) and the Human Cell 
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Activation Test (h-CLAT) (Ashikaga et al., 2006; Sakaguchi et al., 2006; Ashikaga et al., 2010; 
Sakaguchi et al., 2010), which have been validated by the European Centre for Validation of 
Alternative Methods (ECVAM; Italy). The DPRA is described in the testing guideline (TG) 
OECD TG 442C (OECD, 2015a), the ARE-Nrf2 luciferase method in the OECD TG 442D (OECD, 
2015b) and the h-CLAT in the OECD TG442E (OECD, 2016d). The ARE-Nrf2 method is also 
covered by LuSens (Ramirez et al., 2014; Ramirez et al., 2016), which is currently under 
validation by ECVAM. In addition, we include the in-silico method called the OECD toolbox 
QSAR method which is developed by the OECD (OECD, 2012d) following the guidance 
document on the principles of Quantitative Structure-Activity Relationship (QSAR) models 
validation (OECD, 2007), in our analysis.  
Individual non-animal testing methods cover different “key events” of the adverse 
outcome pathway (AOP) (OECD, 2012b; OECD, 2012c) of skin sensitisation, which describes 
the sequence of biological events and their linkages leading to the expression of an adverse 
outcome (i.e. an ACD incident). Since non-animal testing methods are not considered suitable 
to provide sufficient information to draw conclusions upon the skin sensitisation potential of 
chemicals (Mehling et al., 2012; Reisinger et al., 2015), a solution suggested is to integrate 
information from different sources and testing methods by using hypothesis-based 
approaches such as Bayesian networks (Jaworska and Hoffmann, 2010; Jaworska et al., 2011; 
Hartung et al., 2013; Jaworska et al., 2013; Jaworska, 2016) or deterministic ITS approaches 
(Bauch et al., 2012; Urbisch et al., 2015a). For the development of integrated strategies 
assessing skin sensitisation potential and potency (Jaworska, 2016) different sets of criteria 
have been proposed including transparency, coherency, ambiguity, or cost effectiveness 
(Hartung et al., 2013; Rovida et al., 2015) which are applicable also for other toxicological 
endpoints (Jaworska et al. 2010). It has also been suggested that the combination of individual 
non-animal testing methods into batteries or sequential strategies should be guided by the 
skin sensitisation AOP (Vinken, 2013; Patlewicz et al., 2014). The OECD has suggested the use 
of AOP as a guiding tool for the development of the “Integrated Approaches to Testing and 
Assessment” (IATA) (OECD, 2008). As a guiding tool, the AOP aims at integrating information 
from different testing methods for testing strategies and overall assessment of substances. In 
2015, the European Chemical Industry Council (CEFIC) made a selection of IATA cases 
assessing skin sensitisation as validation reference (CEFIC, 2015). Besides these efforts to 
develop strategies for the assessment of skin sensitisation potential and potency (see Chapter 
2 of this thesis for a review), the concept of “Defined Approaches” (DA), as individual 
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information sources to be used in IATA for skin sensitisation, was recently suggested (OECD, 
2016c).  
For skin sensitisation potential and potency assessment criteria for developing non-
animal testing strategies have been suggested in the literature (Jaworska and Hoffmann, 
2010; Jaworska et al., 2011; Hartung et al., 2013; Rovida et al., 2015; Jaworska, 2016). 
Moreover, the need for efficient testing, i.e. balancing information gains against costs (Gabbert 
and Weikard 2013; Norlén et al., 2014; Hartung et al., 2013; Rovida et al., 2015), has been 
repeatedly emphasised. Still, an approach to optimising non-animal testing strategies and a 
comprehensive evaluation of their efficiency in relation to animal tests have not become 
available so far. Moreover, systematic assessments of non-animal testing methods’ precision 
and the impact of precision constraints on the predictive accuracy of these testing methods 
need to be further elaborated. 
1.3 Problem definition, research objectives and research questions  
In light of the challenges and knowledge gaps discussed above, this thesis addresses the 
problem how non-animal testing strategies can be optimised from an economic perspective. 
The focus is on non-animal testing strategies for assessing skin sensitisation potential. In 
order to address this problem we first need to gain insights into the criteria and the current 
status of non-animal testing strategies for skin sensitisation proposed in the literature. Based 
on the insights gained from this, an approach to optimising non-animal testing strategies, 
which allows balancing information gains and expected losses from testing, needs to be 
developed and its applicability needs to be tested. In addition, the precision of information 
derived from non-animal testing methods for assessing skin sensitisation potential needs to 
be assessed, and the uncertainties in the measures of predictive accuracy of non-animal 
testing methods assessing skin sensitisation potential due to limited precision, variation of 
sample size and sample composition needs to be evaluated. 
Given the problem definition explained above, two objectives can be spelled-out. This 
thesis aims at developing and applying an approach to the development of optimised non-
animal toxicity testing strategies assessing skin sensitisation potential that explicitly allow 
balancing information gains and expected costs. In this thesis, costs capture both monetary 
expenses for conducting non-animal toxicity testing methods, and societal costs arising from 
the erroneous release of a substance causing skin sensitisation called “costs of making errors”. 
In addition, it focuses on the analysis of the impact of biological and technical variability on 
the precision of testing methods and examines the uncertainties in measures of predictive 
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accuracy of non-animal testing methods due to limited precision, variation of sample size and 
composition. To this end, the thesis addresses the following research questions (RQ):  
RQ1: What are relevant criteria guiding the development of non-animal testing strategies for 
skin sensitisation potential and potency assessment? 
The first research question focuses on the current practices on integrating information 
from non-animal testing methods for the assessment of skin sensitisation potential and 
potency. We introduce the conceptual criteria and informational requirements, from an 
economic perspective, for the development of resources-efficient testing strategies. We 
evaluate if and how existing testing strategies for skin sensitisation assessment meet the 
suggested criteria. 
RQ2: How can non-animal toxicity testing strategies for assessing skin sensitisation potential be 
optimised?  
The second research question deals with the development of the conceptual framework 
for optimising non-animal testing strategies, for skin sensitisation potential assessment. 
Furthermore, the applicability of the framework needs to be tested.  
RQ3: How do technical and biological variability of non-animal testing methods influence the 
precision of non-animal testing methods for assessing skin sensitisation potential?  
The third research question focuses on the precision of information derived from non-
animal testing methods assessing skin sensitisation potential. In particular, it addresses the 
impact of biological and technical variability on information derived from non-animal testing 
methods after dichotomising continuous experimental data into binary test results.  
RQ4: How do limited precision, sample size and sample composition impact the predictive 
accuracy of non-animal testing methods for skin sensitisation?  
The predictive accuracy depends on the sample size (i.e. the number of substances which 
were tested to determine it), the sample composition, and the precision of a testing method. 
Usually, non-animal methods use prediction models to transform continuous read-outs of the 
test into dichotomous results by applying threshold values above and below which the test 
substance is assessed as positive or negative. Due to intra-test variability the precision of any 
testing method is limited. The fourth research question focuses on exploring the impact of 
limited precision and uncertainties due to varying sample size and sample composition on the 
predictive accuracy of non-animal testing methods. The impacts are analysed individually and 
in combination.  
The research questions are addressed in Chapters 2 to 5 of the thesis.  
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1.4 Methodology  
In Chapter 2 we address RQ1 by surveying the scientific literature regarding the 
development of non-animal toxicity testing strategies for assessing skin sensitisation. In 
particular, we identify key criteria suggested in the toxicological literature for the 
development of testing strategies aiming at combining individual non-animal testing methods. 
We propose the conceptual and informational criteria required to improve resource-efficiency 
in the development of testing strategies from an economic perspective. Furthermore, we 
discuss how the criteria proposed in the toxicological literature, for example coherency, 
transparency and ambiguity (Hartung et al., 2013; Rovida et al., 2015) have been practically 
implemented. We compare these criteria with the conceptual and informational criteria from 
an economic perspective in order to evaluate whether existing non-animal toxicity testing 
strategies for skin sensitisation allow for balancing information gains and losses. Based on 
that, we draw conclusions on whether testing strategies can be characterised as resource-
efficient and we provide suggestions in order to further improving efficiency. Finally, we 
discuss implications raised from the evaluation of existing approaches to develop non-animal 
toxicity testing strategies.  
In Chapter 3, we address RQ2 by developing a decision-theoretic model for the 
optimisation of non-animal toxicity testing strategies for assessing skin sensitisation potential 
using Bayesian Value-of-Information (VOI) analysis (Hirshleifer, 1971; Olson, 1990; Howson 
and Urbach, 1991; Claxton 1999). Performing a testing method is assumed to have value if 
and only if expected social net gains from an optimal decision with additional information 
derived from testing outweigh expected net gains from decision-making without evidence. 
The expected value of test information (EVTI) can be expressed as the probability weighted 
sum of social net gains under posterior beliefs that the substance is hazard and non-hazard, 
respectively. The probability of seeing a positive or negative test result is used as weights 
(Yokota et al., 2004; Yokota and Thompson, 2004; Gabbert and Weikard, 2013; Leontaridou et 
al., 2016). Clearly, a testing method, or a testing strategy consisting of a battery of sequential 
combinations of non-animal testing methods, should be performed if the EVTI is positive and 
exceeds testing costs. Quantifying the EVTI, allows for ranking testing methods and their 
combinations into testing strategies, from a social welfare perspective. Bayesian VOI analysis 
offers a guiding tool for the construction of sequential testing strategies which allows 
determining the initial testing method, the ordering of testing methods required for the 
collection of sufficient information and when testing should stop.  
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The model developed in Chapter 3 is applied to a set of validated or pre-validated non-
animal methods (i.e. the DPRA, the OECD Toolbox QSAR, ARE-Nrf2 luciferase method covered 
by KeratinoSensTM and LuSens, and the h-CLAT), seven battery combinations of these 
methods, and 236 sequential 2-test and 3-test strategies composed of these methods. Their 
EVTI net of testing costs is compared to that of the animal test LLNA and AOP based testing 
strategies suggested in the literature. Determining the societal gains and losses from releasing 
a hazardous or a non-hazardous substance requires estimating expected marketing benefits, 
and balancing them with expected direct and indirect health damage costs caused by ACD. The 
latter is assumed to be a function of the skin sensitisation prevalence of a substance (Schnuch 
et al., 2011; Peiser et al., 2012; Schnuch et al., 2012) within the EU. As a proof-of-concept case, 
the Bayesian VOI model is applied to the preservative Methylisothiazolinone which is used for 
the formation of Kathon CG, known which is an ingredient for cosmetic products with high 
skin sensitisation prevalence (Uter et al., 2013).  
In Chapter 4 we address RQ3 by assessing the influence of technical and biological 
variability on the precision of non-animal testing methods for assessing skin sensitisation. We 
analyse how the classification of a substance as “sensitiser/non-sensitiser”, by dichotomising 
experimental data from non-animal testing methods using clear-cut classification thresholds, 
can be influenced by the biological and technical variability of the testing method. Specifically, 
we develop a method for quantifying the range around the classification threshold of non-
animal testing methods within which a method is likely to deliver discordant test results for 
the binary classification of substances. This range has been called “borderline range” (Kolle et 
al., 2013) or “grey zone” (Dimitrov et al., 2016). Acknowledging that for any testing method, 
including the “first choice” animal tests (i.e. LLNA), the borderline range defines the area in 
which binary test results, as derived by dichotomising continuous experimental data, are 
discordant (inconclusive, ambiguous or borderline). This offers a new perspective to the 
evaluation of the precision of the prediction models using classification thresholds, of testing 
methods: Substances for which test results fall into the borderline range can neither be 
classified as positive, thus indicating an adverse effect, or negative. The classification is, 
therefore, inconclusive which indicates the need for further information in order to draw 
conclusion upon the skin sensitisation potential of the tested substance.  
The borderline range is determined by calculating the pooled standard deviation of 
experimental test results revealed from repeated testing of substances. The standard 
deviation was pooled across substances and concentrations. Then, the borderline range is 
applied as an additional classification rule together with the threshold criteria of testing 
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methods. In that way, we identify substances as positive (i.e. sensitisers), negative (i.e. non-
sensitisers) or discordant (i.e. substances yielding test results within the borderline range). 
Furthermore, the percentage of substances yielding discordant test results, thus within the 
borderline range, is used as a measure of a non-animal testing method’s precision constraint. 
This analysis was performed for selected non-animal testing methods used for assessing skin 
sensitisation potential, i.e. the DPRA, LuSens, the h-CLAT, and the “2 out of 3” Integrated 
Testing Strategy (ITS) formerly called “2 out of 3” weight of evidence (WoE) approach (Bauch 
et al., 2012; Urbisch et al., 2015a). We quantify the borderline range for sets of experimental 
results compared to the LLNA as the reference animal test.  
In Chapter 5, we address RQ4 by exploring the uncertainties in predictive accuracy 
metrics of testing methods by quantifying the impact of limited precision and variations in 
sample size and sample composition, on the predictive accuracy of non-animal testing 
methods assessing skin sensitisation potential. We analyse these impacts for selected 
accuracy metrics usually used to characterise the predictive accuracy of these methods. i.e. 
sensitivity, specificity and concordance (also called accuracy) (Krzanowski and Hand, 2009) 
by means of contingency tables which is a well-established way to assess the predictive 
accuracy of tests (Cooper et al., 1979). The impact of limited precision is determined by 
quantifying sensitivity, specificity and concordance based on experimental samples including 
substances yielding tests results within the borderline range (i.e. borderline substances), and 
comparing these with accuracy metrics derived from samples after borderline substances are 
excluded. Furthermore, the impact of variations in sample size and sample composition on 
predictive accuracy metrics is assessed for randomised samples of substances using the non-
parametric bootstrap resampling analysis (Jones et al., 2000; Wehrens et al., 2000). We 
calculate the confidence limits and standard deviations of the accuracy metrics, in order to 
provide estimates for the uncertainty related to accuracy metrics due to the use of samples 
with pre-defined compositions of substances. Besides sample composition, accuracy metrics 
are influenced by the number of substances (sample size) used for the assessment of accuracy 
metrics. The impact of limited precision and variations in sample size and composition 
(individually and in combination) on the predictive accuracy of the non-animal testing 
methods is assessed using the DPRA, LuSens, the h-CLAT and the “2 out of 3” ITS.  
1.5 Novelty  
It has been acknowledged that there is a need to fill in the information gaps considering 
the hazardous properties of thousands of substances (Ahlers et al., 2008; Krewski et al., 2009; 
Schaafsma et al., 2009; Krewski et al., 2010). At the same time there has been increasing 
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support for a systematic reduction and replacement of animal testing (Kinsner-Ovaskainen et 
al., 2009; Daston et al., 2015). The need for adequate and sufficient information derived from 
fast and less costly non-animal testing methods has emerged the development of testing 
strategies, integrating information from individual non-animal testing methods (Jaworska and 
Hoffmann, 2010; Jaworska et al., 2011; Hartung et al., 2013; Rovida et al., 2015; Jaworska, 
2016). From an economic perspective this requires to balance the informational gains from 
performing testing methods with costs such as testing costs and the costs of making errors. 
Obviously, balancing gains and losses from conducting toxicity testing can be considered as an 
economic problem.  
So far, however, only few studies have become available addressing the problem how to 
optimise toxicity testing from an interdisciplinary perspective, linking toxicology with 
economics (Olson, 1990). Chapter 2 reviews existing non-animal testing strategies for the 
assessment of skin sensitisation potential and potency. This chapter also identifies the criteria 
suggested in the toxicological literature for developing non-animal testing strategies 
(Jaworska, 2016) and further evaluates them from the economic perspective. Chapter 2 
introduces the standard economic approach by suggesting the conceptual and informational 
criteria necessary to establish resource-efficiency in the development of testing strategies. 
Although criteria for developing resource-efficient testing strategies for the assessment of 
skin sensitisation refer to cost effectiveness (Hartung et al., 2013; Rovida et al., 2015), this 
chapter offers novel insights on the practical implementation of optimisation methods for the 
development of resource-efficient testing strategies from an economic perspective. 
Further, Chapter 3 develops a decision-theoretic framework for the optimisation of 
sequential testing strategies using the Bayesian VOI analysis. While the theoretical 
foundations of the framework, i.e. expected-utility theory and Bayesian inference, are not new 
per se, there exist only few applications to the problem of sequential testing, focusing 
exclusively on selected endpoints, i.e. carcinogenicity (Yokota and Thompson, 2004) and 
mutagenicity (Gabbert and Weikard, 2013), where animal tests are usually included in the 
testing strategies suggests. In Chapter 3, we apply for the first time the Bayesian VOI analysis 
to the optimisation of non-animal testing strategies for the assessment of skin sensitisation 
potential. We provide an evaluation of the EVTI of non-animal testing methods and strategies 
in comparison to the EVTI of the animal test. The Bayesian VOI model suggested in Chapter 3 
guides the construction of sequential testing strategies determining which non-animal testing 
method should be performed first, how many non-animal testing methods should be include 
into the strategy and when testing should stop. Further, we examine the role of the adverse 
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outcome pathway of skin sensitisation as a guide for developing optimal sequential non-
animal testing strategies.  
Besides developing and applying the Bayesian VOI model, this thesis provides novel 
insights on the informational outcomes derived from conducting non-animal testing methods. 
In particular, we introduce a methodology for estimating the influence of technical and 
biological variability on the precision of non-animal testing methods, in Chapter 4. The 
uncertainty of information derived from toxicity testing has been frequently discussed in the 
toxicology literature (Paparella et al., 2013; Heringa et al., 2015). For example, the impact of 
technical and biological variability on test results derived from testing methods (Kolle et al., 
2013; Hoffmann, 2015; Dimitrov et al., 2016; Dumont et al., 2016; Leontaridou et al., 2017a), 
and the effect of overfitting experimental data from testing (Kopp-Schneider et al., 2013) have 
been discussed. However, the estimation of non-animal testing methods’ borderline range and 
the identification of substances yielding borderline test results provide a novel approach to 
classify substances, to identify discordant test results and to decide if additional information 
is needed.  
Chapter 4 highlights the problem of using clear-cut thresholds for the binary classification 
of substances without considering the borderline range of testing methods. This, however, has 
not been sufficiently linked to the implications that may occur, if these substances (i.e. 
substances classified based only on clear-cut thresholds) are used to assess the predictive 
accuracy of testing methods. As a consequence, the impact of substances yielding test results 
within the borderline range of testing methods is highly relevant for drawing conclusions 
about a non-animal testing method’s predictive accuracy, which is addressed in Chapter 5. 
The uncertainty related to the assessment of predictive accuracy of testing methods (Worth 
and Cronin, 2001a) has been previously discussed. The predictive accuracy metrics are 
usually calculated based on available samples of substances and they are used as point 
estimates, thus without accounting for uncertainties. Besides predictive accuracy being 
influenced by the limited precision of the testing methods, expressed in number of substances 
which yield test results within the borderline range; the sample size and sample composition 
can impact the uncertainty in accuracy metrics of non-animal testing methods. Chapter 5 
examines the uncertainties underlying to the predictive accuracy metrics due to limited 
precision of non-animal testing methods. Furthermore, it analyses the impact of the variations 
in sample size and the sample composition on predictive accuracy metrics of non-animal 
testing methods. Finally the effect of varying sample size and sample composition in 
combination with the limited precision of non-animal testing methods is examined.  
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1.6 Outline of the thesis  
The remaining thesis chapters are structured as follows (Table 1.1): Chapter 2 surveys the 
state-of-the-art and the construction criteria currently suggested in the toxicological 
literature for developing toxicity testing strategies for assessing skin sensitisation. 
Furthermore, suggestions for the conceptual and informational criteria for increasing the –
resource-efficiency in the development of non-animal toxicity testing strategies are proposed. 
Chapter 3 describes the Bayesian VOI model for the evaluation of toxicity testing methods. 
The model is applied on the evaluation of sequential testing strategies for the assessment of 
skin sensitisation potential. Chapter 4 describes the quantification of the borderline range of 
testing methods. The borderline range is applied as an additional classification rule, next to 
the threshold criteria of non-animal testing methods assessing skin sensitisation potential, in 
order to identify the substances as positive, negative or discordant in case test results fall into 
the borderline range. Chapter 5 addresses the uncertainties underlying to the predictive 
accuracy metrics for non-animal testing methods assessing skin sensitisation due to limited 
precision by calculating accuracy metrics with and without considering the borderline range 
in the prediction models of non-animal testing methods. Further the impact of variations in 
sample size and sample composition on uncertainties in the predictive accuracy metrics is 
assessed. Chapter 6 summarises the results of this thesis answering the research questions, 
discusses the main findings and addresses the policy relevance of this thesis. Finally, 
limitations of the methods applied in this thesis are discussed, and suggestions for further 
research are proposed.  
Table 1.1: Outline of the remaining chapters of this thesis  
Focus on the improvement of the efficiency of non-animal toxicity testing strategies 
Ch. 2 
A review of concepts and tools for integrating information from non-animal testing methods: The 
case of skin sensitisation. 
Ch. 3 Evaluation of non-animal methods for assessing skin sensitisation hazard: A Bayesian Value-of-
Information analysis. 
Focus on the information from non-animal testing methods and strategies 
Ch. 4 The borderline range of prediction models of testing methods for skin sensitisation potential 
assessment: Quantification and implications for evaluating non-animal testing methods’ precision. 
Ch. 5  
Uncertainties in measures of predictivity: The impact of precision, sample size and sample 
composition on the predictive accuracy of non-animal methods for skin sensitisation. 
Closing chapter  
Ch. 6 Synthesis: Main findings of this thesis, general discussion, limitations of this thesis, conclusions and 
suggestions for further research. 
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2 A review of concepts and tools for integrating information 
from non-animal testing methods: The case of skin sensitisation 1 
Integrating information from in vitro, in silico and in chemico methods into non-animal 
toxicity testing strategies has been widely considered an innovative way of phasing-out 
animal testing. At the same time, non-animal testing strategies are considered to provide 
adequate and relevant information about chemicals’ hazardous properties in a resource-
efficient way. The aim of this chapter is to identify the conceptual criteria for developing 
resource-efficient testing strategies, and at evaluating existing testing strategies under these 
criteria. This chapter provides an overview of the definitions proposed in the scientific 
toxicological literature to characterise the process of integrating information into strategies 
for hazard and risk assessment of chemicals. We, further, present the general conceptual 
criteria which have been suggested in the scientific toxicological literature for guiding the 
process of data integration. Next, we propose a set of conceptual and informational criteria for 
combining information from different methods into strategies in a resource-efficient way. 
This explicitly acknowledges that resource efficiency, being is fundamental economic concept, 
requires balancing the gains and losses from using scarce resources. Finally, we evaluate 
whether existing testing strategies, addressing skin sensitisation, meet the suggested resource 
efficiency criteria. We conclude that existing testing strategies focus predominantly on 
maximising toxicity information, whereas direct and indirect testing costs (including also 
welfare losses for society in case of unintended health or environmental damage) are either 
ignored or only addressed in a non-quantitative way.  
 
  
                                                        
1 Chapter 2 is based on the manuscript in preparation: Leontaridou M., Gabbert S., Landsiedel R., (2017). A 
review of concepts and tools for integrating information from non-animal testing methods: The case of skin 
sensitisation. 
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2.1 Introduction  
Non-animal testing methods and toxicity testing strategies aim at a subsequent reduction 
of the number of animal tests used and, ultimately, a full replacement of animal testing (Ahlers 
et al., 2008; Hartung, 2010a; Adler et al., 2011; Reisinger et al., 2015). During the past decade, 
non-animal testing strategies have been developed for several toxicological endpoints. In 
addition to developing individual methods such as in vitro methods, in silico and in chemico 
methods, experts in science, industry and regulatory agencies have put a lot of effort in 
combining non-animal testing methods into toxicity testing strategies (Tollefsen et al., 2014). 
Integrating information from various sources for human health endpoints (ECHA, 2014a; 
Gocht et al., 2015; Worth and Patlewicz, 2016) such as skin sensitisation and eye irritation 
(Sauer et al., 2016), repeated dose toxicity and toxicity to reproduction (Gocht et al., 2015) as 
well as environmental endpoints such as fish toxicity (Nendza et al., 2014) have received a lot 
of attention. Basically, a testing strategy is an integrated combination of different testing 
methods for achieving an adequate assessment of the hazardous properties of substances. 
Different conceptual approaches for combining information from in silico, in vitro or in 
chemico methods have been proposed in the scientific toxicological literature. The suggested 
approaches have been characterised as “Integrated Testing Strategies” (ITS), “Sequential 
Testing Strategies” (STS), “Weight of Evidence” (WoE) and “Integrated Approach to Testing and 
Assessment” (IATA). Definitions of these approaches showed terminological overlaps and 
made a clear delineation difficult. For example, IATAs have been described as overarching 
“...data integration approaches... e.g. ITS, STS, WoE or other IATA strategies...” (Tollefsen et al., 
2014). Furthermore, the WoE approach has been closely related to the concept of ITS or DA, 
with the difference being that “...the WoE approach is usually based on existing data while ITS 
should prospectively address which assays need to be performed ...” (Rovida et al., 2015). 
Hartung et al., (2013) emphasized the need to “... understand that WoE and ITS are two 
different concepts although they combine the same types of information! In WoE there is no 
formal integration, usually no strategy, and often no testing...” (Hartung et al., 2013), while the 
concept of ITS “...enables an integrated and systematic approach to guide testing such that the 
sequence...is tailored to the chemical-specific situation...adapted and optimized for meeting 
specific information target” (Jaworska and Hoffmann, 2010). Despite terminological 
differences between the WoE concept and the ITS concept, both attempt to integrate 
information (Balls et al., 2006; Rovida et al., 2015). In June 2016 the OECD published guidance 
documents to clarify terminology (OECD, 2016b; OECD, 2016c), see Table 2.1.  
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Table 2.1: Definition of terminologies used to describe different schemes of integrating 
information from different sources into strategies for hazard and risk assessment  
Schemes Definition Reference 
IATA 
“An Integrated Approach to Testing and Assessment is an approach based 
on multiple information sources used for the hazard identification, hazard 
characterisation and/or safety assessment of chemicals. An IATA 
integrates and weights all relevant existing evidence and guides the 
targeted generation of new data, where required, to inform regulatory 
decision-making regarding potential hazard and/or risk.” 
Paragraph 1 
OECD, (2016c)  
WoE 
“A Weight of Evidence determination means that expert judgement is 
applied on an ad hoc basis to the available and scientifically justified 
information bearing on the determination of hazard or risk” 
Paragraph 4 
OECD, (2016c)  
DA 
“A Defined Approach to testing and assessment consists of a fixed data 
interpretation procedure used to interpret data generated with a defined 
set of information sources, that can either be used on its own, or together 
with other information sources within an IATA” 
“Defined Approaches to testing and assessment can be designed in 
different ways, and may take for example the form of a Sequential Testing 
Strategy (STS) or an Integrated Testing Strategy (ITS)” 
Paragraph 5 and 10 
OECD, (2016c)  
ITS 
“An Integrated Testing Strategy is an approach in which multiple sources 
of data or information are assessed at the same time by applying a variety 
of specific methodologies to convert inputs from the different information 
sources into a prediction” 
Paragraph 11 
OECD, (2016c)  
STS 
“A Sequential Testing Strategy is a fixed stepwise approach for obtaining 
and assessing test data, involving interim decision steps, which, depending 
on the test results obtained, can be used on their own to make a prediction 
or to decide on the need to progress to subsequent steps. At each step, 
information from a single source/method is typically used by applying a 
prediction model associated with that source/method” 
Paragraph 12 
OECD, (2016c)  
 
This chapter focuses on DAs, which were introduced by the OECD as a component of an 
IATA which comprises different approaches to integrate information from computational, in 
vitro and in chemico testing methods, and which can be designed as ITS or STS (OECD, 2016b; 
OECD, 2016c).  
Besides replacing or reducing animal testing, a key driver for the development of DAs has 
been the need to acquire sufficient and relevant information about chemicals’ hazardous 
properties with less time and at lower costs than the traditional animal tests (Gabbert and 
Weikard, 2010; Gabbert and Weikard, 2013; Hartung et al., 2013; Rovida et al., 2015). Clearly, 
maximising the information outcomes from testing, decreasing the time needed to attain 
hazard and risk information, reducing costs of testing, and minimising or even avoiding the 
use of animals are competing objectives. Balancing competing objectives is a fundamental 
economic principle which guides the optimal, i.e. resource efficient, use of scarce resources in 
order to either maximise information outcomes at a given resource endowment, or to 
minimise costs for achieving a given outcome target (Clemen and Reilly, 2001). Criteria and 
conceptual requirements for developing resource efficient testing strategies have been 
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proposed in the toxicological literature (Jaworska and Hoffmann, 2010; Krewski et al., 2010; 
Hartung et al., 2013; Rovida et al., 2015). So far, however, a systematic review of criteria that 
define “resource efficient” testing, and an evaluation of DAs with regard to these criteria has 
not been provided.  
The aims of this chapter are, therefore, twofold. First we provide a systematic review of 
criteria that were proposed in the scientific toxicological literature for constructing DAs to be 
used for hazard and risk assessment of chemicals. Second, we suggest the conceptual and 
informational criteria that guide resource efficient data integration into DAs. Then we 
evaluate existing DAs with respect to the conceptual and informational criteria. This 
evaluation focuses on DAs for assessing skin sensitisation potential (i.e. hazard identification) 
and potency (i.e. sub-categorisation into weak, moderate, strong and extreme sensitisers). 
Skin sensitisation is the clinically relevant endpoint for assessing allergic contact dermatitis 
(ACD) (UNECE, 2011). Approximately 15 - 20% of the human population suffer from an ACD 
incident once in their life (Thyssen et al., 2007). Assessing chemicals’ ability to cause ACD – i.e. 
their skin sensitisation potential or potency – is, therefore, a key requirement for the safety 
assessment chemicals falling under the European chemicals’ legislation REACH (EC, 2006) 
and the European Cosmetics Regulation (EC, 2009). Skin sensitisation can, therefore, be used 
as an illustrative case for the fundamental challenge on how toxicity testing should be 
conducted resource-efficiently and without animal use. 
Chapter 2 is structured as follows. A systematic overview of the criteria suggested for 
developing DAs is presented in Section 2.2. Section 2.2.1 presents conceptual criteria for 
developing DAs which were proposed in the toxicological literature of the past decade. Section 
2.2.2 suggests conceptual and informational criteria for developing optimal, i.e. resource-
efficient DAs, from an economic perspective. Section 3, then, describes qualitative (Section 
3.1) and quantitative (Section 2.3.2) methodological approaches used for integrating different 
types of information into DAs. Section 2.4 offers a detailed evaluation of DAs for skin 
sensitisation potential and potency assessment with regard to the conceptual and 
informational criteria which are suggested in Section 2.2.2. Section 2.5 concludes and 
provides suggestions for further improvement of the DAs to ensure resource efficient and 
animal-free testing. 
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2.2 Criteria for developing non-animal defined approaches 
2.2.1 Aims and conceptual criteria for developing defined approaches suggested in the 
toxicological literature 
The overall goal of integrating information from different sources, in particular non-
animal experimental or computational methods, is to generate adequate information at low 
cost, and with a minimum or no animal use (Jaworska et al., 2010; Jaworska and Hoffmann, 
2010; Hartung et al., 2013; Rovida et al., 2015). The integration of information is 
characterised as a dynamic process which progresses along with development of non-animal 
testing methods and the mechanistic understanding of endpoints (Tollefsen et al., 2014; 
Jaworska, 2016). In the scientific toxicological literature of the past decade a number of 
criteria have been suggested, seeking to explain “what the ITSs should be” (Jaworska and 
Hoffmann, 2010), “what the ITS should contain” (Rovida et al., 2015), “what the DAs should be 
associated with” (OECD, 2016b). These criteria are summarised in Table 2.2. 
Criteria, thus far, focus on (i) selecting and integrating reliable and accurate information 
from scientifically robust sources and testing methods (ii) guiding the final interpretation of 
the informational outcomes from a DA into decisions about the hazardous properties of 
substances (iii) evaluating the performance of the selected individual sources of information 
and the strategies themselves. Publications discussing criteria for developing optimal testing 
strategies often refer to ITS, however, sets of criteria have also been proposed and discussed 
for IATA, see e.g. (Tollefsen et al., 2014), and for DA, see e.g. (OECD, 2016b). As explained in 
the introduction, we will use in the following the term DA (i.e. defined approaches) as an 
overarching concept. 
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Table 2.2: Criteria for guiding the development of defined approaches (DAs) proposed in the 
scientific toxicological studies of the past decade 
Criteria to be considered in the development of DAs References 
Criteria related to generating information 
Optimal extraction and use of information from existing 
data. 
Schaafsma et al., 2009; Jaworska et al., 2010; 
Jaworska and Hoffmann, 2010; Schoeters, 2010; De 
Wever et al., 2012 
Combination of different types of information (e.g. in 
vitro, in silico, in chemico; use of in vivo only if 
necessary). 
Hoffmann et al., 2008; Dellarco et al., 2010; De 
Wever et al., 2012 
Use of scientifically valid (accurate, reliable) and 
adequate information. 
Hoffmann and Hartung, 2006; Ahlers et al., 2008; 
Schaafsma et al., 2009; Krewski et al., 2010; 
Schoeters, 2010; De Wever et al., 2012 
Evaluation of the performance (e.g. predictivity, 
goodness-of-fit, robustness) of individual testing 
methods and strategies. 
Jaworska and Hoffmann, 2010; Tollefsen et al., 
2014; Rovida et al., 2015 
Criteria related to costs and resource use 
Reduction/minimisation of direct testing costs for 
generating information and indirect costs i.e. testing 
time, costs of misclassifications, costs for regulatory 
validation of testing methods and strategies.  
 Lewis et al., 2007; Kinsner-Ovaskainen et al., 2009; 
Schaafsma et al., 2009; Krewski et al., 2010; De 
Wever et al., 2012 
Protect animal welfare; reduce/minimise the number of 
animal used in testing or animal suffering when animal 
testing is considered unavoidable. 
Hoffmann and Hartung, 2006; Lewis et al., 2007; 
Hoffmann et al., 2008; Schaafsma et al., 2009; 
Krewski et al., 2010 
Evaluation of cost-effectiveness or efficiency.  
Hoffmann and Hartung, 2006; Lewis et al., 2007; 
Hoffmann et al., 2008; Schaafsma et al., 2009; 
Krewski et al., 2010 
Conceptual requirements for DA development 
Data integration and final conclusion based on a 
coherent methodology (e.g. unambiguous algorithm). 
Jaworska and Hoffmann, 2010; De Wever et al., 
2012; Basketter et al., 2013; Rovida et al., 2015 
Specifications on the applicability domain, endpoint 
assessed and regulatory purpose (hazard or potency 
assessment). 
Kinsner-Ovaskainen et al., 2009; Krewski et al., 
2010; De Wever et al., 2012; Basketter et al., 2013; 
Tollefsen et al., 2014; Rovida et al., 2015 
Transparency regarding all information sources used, 
including testing costs, animal numbers, uncertainty; 
data processing, evaluation target (hazard/dose-
response information), endpoint. 
Lewis et al., 2007; Ahlers et al., 2008; Kinsner-
Ovaskainen et al., 2009; De Wever et al., 2012; 
OECD, 2016b 
Flexibility regarding the integration of new information, 
(e.g. hypothesis-driven approach). 
Kinsner-Ovaskainen et al., 2009; Jaworska et al., 
2010; Jaworska and Hoffmann, 2010; De Wever et 
al., 2012 
Final decision based on a weight-of-evidence approach. 
Jaworska et al., 2010; Jaworska and Hoffmann, 
2010; Basketter et al., 2013 
Address/document/reduce uncertainty of information 
generated from individual testing methods and 
uncertainty of extrapolations to effects in humans. 
Lewis et al., 2007; Ahlers et al., 2008; Schaafsma et 
al., 2009; OECD, 2016b 
Use of mechanistic information; relate construction of 
DA to mechanistic understanding of an endpoint (e.g. 
AOP). 
Ankley et al., 2010; Dellarco et al., 2010; Basketter 
et al., 2013; Landesmann et al., 2013; Vinken, 2013; 
Rovida et al., 2015; OECD, 2016b 
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According to the criteria presented in Table 2.2, information revealed from testing should 
be reliable, accurate, precise and fit-for-purpose. Uncertainties should be transparently 
addressed and documented. Furthermore, different cost components need to be 
acknowledged, in particular welfare losses from misclassifications (Hoffmann and Hartung, 
2006), monetary costs of regulatory validation of testing strategies (Schaafsma et al., 2009), 
animal welfare loss (Hartung et al., 2013; Rovida et al., 2015) and direct testing costs 
(Krewski et al., 2010; Hartung et al., 2013; Rovida et al., 2015). Jaworska and Hoffmann 
(2010) indicated that the process of integrating information from toxicity testing should allow 
for evidence maximisation while considering factors such as costs, animal welfare and test 
complexity for an optimal selection of information sources (computational, in chemico and in 
vitro methods). Although efficiency (Kinsner-Ovaskainen et al., 2009), optimisation (Rovida et 
al., 2015) or cost effectiveness (Lewis et al., 2007; Hoffmann et al., 2008; Hartung et al., 2013) 
are mentioned in the toxicological literature, the required methodological approaches for 
addressing these criteria in the process of developing a DA are not addressed. While the 
possible trade-offs occurring when developing DAs are acknowledged, still it has largely 
remained unclear how these trade-offs can be made transparent and how they should be 
addressed to ensure resource-efficient DAs. Krewski et al. (2010) emphasised the “...the 
difficulty in simultaneously meeting four objectives ...” when developing DAs, e.g. minimise 
testing costs, the number of laboratory animals, the time to perform testing methods and 
simultaneously provide sufficient information (also see (Nordberg et al., 2008; Gabbert and 
van Ierland, 2010). 
2.2.2 An economic perspective to developing optimal defined approaches 
The term “resource efficiency” is a key economic decision-criterion for guiding the 
allocation of scarce resources. In the economics’ literature “resource efficiency” denotes an 
allocation of resources that allows achieving a given outcome target with a minimum of 
resources (Clemen and Reilly, 2001). Toxicological testing of substances aims at generating 
new information about the hazardous properties of substances. The ultimate goal of toxicity 
testing is to allow for adopting better-informed decisions upon chemicals’ use. Depending on 
the toxicological effect of interest (the so-called “endpoint”), toxicological testing requires a 
variety of resources, in particular appropriate laboratory equipment or computational 
capacities, manpower, laboratory animals, and time. The challenge is, therefore, to distribute 
available resources such that a maximum of output – i.e. hazard information – can be 
achieved, or, to use a dual formulation, that a certain information outcome can be achieved 
with a minimum of resources (Norlén et al., 2014). Thus, efficient or optimal testing can be 
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characterised as a process where a maximum of information can be achieved at the lowest 
cost. 
The European chemicals’ legislation REACH requires large numbers of industrial 
chemicals to be tested within defined time-frames (EC, 2006). Acknowledging that existing 
testing capacities are tight, several studies pointed to the urgent need to structure the testing 
process more efficiently (Jaworska and Hoffmann, 2010; Krewski et al., 2010; Hartung et al., 
2013; Rovida et al., 2015). Corresponding to the efficiency definition provided above this 
requires specifying key criteria for efficiency evaluations of testing. A basic distinction can be 
made between (i) conceptual and methodological criteria for balancing gains and costs from 
testing and (ii) informational criteria (Table 2.3). 
 
Table 2.3: Key criteria for evaluating the resource efficiency of defined approaches (DAs)  
Informational criteria Possible assessment parameters 
Specification of information gain/outcome.  
x Accuracy parameters (e.g. sensitivity/specificity) for 
characterising the ability of a method to assess 
hazard/potency classes. 
x Reliability parameters (intra- and inter-laboratory 
reproducibility). 
x Mechanistic information (e.g. mode of action or coverage of 
key events in the AOP). 
x Combinations of different parameters (e.g. entropy). 
Specification of costs. 
x Direct testing costs (laboratory equipment or 
computational capacities, animal welfare loss, testing time, 
labour costs). 
x Indirect testing costs (i.e. validation costs). 
Conceptual criteria Possible methods/approaches 
Valuation of information gains and costs. 
x Monetary valuation. 
x Non-monetary valuation. 
Purpose of the assessment.  x Hazard identification, potency sub-categorisation. 
Approach to balance information gains and 
costs.  
x Qualitative approach (e.g. multi criteria analysis). 
x Quantitative approach (e.g. cost-effectiveness analysis, cost-
benefit analysis). 
Assessment of uncertainties of parameters 
assessing information gains and testing 
costs. 
x Frequentist statistics’ approaches (e.g. calculation of 
confidence intervals). 
x Bayesian inference methods. 
x Approaches for assessing testing method’s precision. 
Stopping rule for testing. 
x Decision-theoretic approaches (e.g. Value-of-Information 
analysis). 
x Mechanistic relevance driven approaches (e.g. the adverse 
outcome pathway AOP). 
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Efficiency evaluations of individual testing methods and DAs require, first of all, specifying 
information gains and costs. Then we need to select appropriate quantifiable parameters for 
both components. Testing costs can be further distinguished into direct and indirect costs. 
Direct costs consist of i.e. (i) laboratory equipment or computational capacities for conducting 
a testing method which are directly required for conducting a testing method or a 
combination of methods, (ii) laboratory animal welfare loss (in case of an animal test) and (iii) 
testing time. Indirect testing costs include, for example, expenditures, resources and time 
needed for the validation of a (non-animal) testing method, or switching costs for cases where 
new technologies have to be adopted (Norlén et al., 2014). 
First, for quantifying information gains from testing different metrics can be used. For 
example, a testing method’s information outcome can be characterised in terms of its 
predictive accuracy, describing “the closeness of agreement between test method results and 
accepted reference values” (OECD, 2015a). Common accuracy metrics are sensitivity (i.e. the 
proportion of hazardous substances correctly classified as hazardous by a testing method) 
and specificity (i.e. the proportion of non-hazardous substances correctly classified as non-
hazardous by the testing method). In addition, information gains from testing can be 
characterised by a testing method’s reliability, denoting a testing method’s ability to be 
reproduced within and between laboratories over time and usually expressed in terms of a 
testing method’s intra- and inter- reproducibility. Finally, information about the coverage of 
specific key events in the adverse outcome pathway (AOP) of a particular in vivo adverse 
outcome by a specific testing method is important to quantify the informational gains from 
testing. 
Second, efficiency evaluations require defining a mechanism to balance information gains 
from testing with costs. How to do this depends, ultimately, on how information gains and 
costs are valued. Basically, two possibilities exist, i.e. monetary and non-monetary valuation. 
In case of a non-monetary valuation information or cost parameters are expressed in terms of 
their natural units (e.g. the proportion of positive chemicals correctly classified in case of 
sensitivity). A monetary assessment requires transferring information or cost parameters into 
Euro or Dollar values. While direct costs, e.g. expenditures for conducting a test, are usually 
expressed in monetary terms, a monetary valuation of other cost components (e.g. animal 
welfare loss) is less common and also often not wanted. Likewise, monetising information is 
not straightforward. In economics, different approaches have been suggested for 
quantitatively balancing information gains from testing with costs, some of which have also 
been applied to the field of toxicity testing (see Section 2.3 for a detailed discussion).  
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Third, evaluating the efficiency of testing methods, and guiding the development of 
optimal DA, must account for the uncertainty underlying to information gains and costs. In 
particular, since any testing method, including the animal test, is a model representation of 
human or environmental endpoint considered, information outcomes from testing are 
uncertain. Ideally, if different (non-animal) testing methods are combined into a DA, 
uncertainty will be reduced throughout the strategy. Again, different options exist for 
assessing uncertainty of test information and costs. A distinction can be made between 
frequentist and Bayesian approaches. Frequentist approaches, e.g. the calculation of 
confidence intervals of predictivity parameters, require the underlying datasets to be of a 
sufficient size to be meaningful. Bayesian inference methods explicitly account for a decision-
makers subjective (prior) beliefs and allow for updating information about uncertainty if new 
data become available. Finally, given that a DA is a framework that combines individual non-
animal testing methods, integrating data from individual testing methods into a DA requires 
to determine a stopping rule for testing (Gabbert and Weikard, 2013; Leontaridou et al., 
2016).  
2.3 Methodological approaches for data integration into defined approaches 
2.3.1 Qualitative approaches 
2.3.1.1 Descriptive weight of evidence (WoE) based approaches  
Descriptive Weight of Evidence (WoE) is a qualitative process for evaluating existing 
information and deciding whether or not further testing is necessary (Grindon et al., 2006b). 
Testing includes in silico, in chemico, and in vitro methods. Animal tests (in vivo) can be used 
as a “last resort” if evidence from non-animal methods is considered insufficient (Vermeire et 
al., 2013). For example the overview of the assessment strategy for skin sensitisation (EHCA, 
2016), the decision tree described in (Patlewicz et al., 2015) or even the earlier suggestion 
from (Grindon et al., 2008e) for assessing skin sensitisation guides the collection and 
evaluation of existing information and decision-making for further testing by means of 
graphical flowcharts. In a descriptive WoE approach, testing methods are performed either in 
combination or in a sequential order following flowcharts which indicate the order of tests to 
be conducted depending on whether information already collected is sufficient. Testing 
outcomes are usually characterised by their predictive accuracy measures, however, the 
starting point and the number of testing methods to be performed is decided by expert 
judgment.  
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2.3.1.2 Mode of action (MoA) based approaches  
The Mode of Action (MoA) concept describes a series of key events which are causally 
related to a toxic effect. The MoA concept was first applied to assessing potential carcinogens 
(EPA, 2005) and later it was extended to analysing non-cancer toxic effects (Boobis et al., 
2008). It has been suggested as a guiding tool to evaluate existing information and to 
integrate information from in-silico, in chemico, and in-vitro methods (Lilienblum et al., 2008; 
Dellarco et al., 2010; Dellarco and Fenner-Crisp, 2012; Simon et al., 2014) into DA 
frameworks. The MoA approach combines information from testing methods depending on 
the biological relevance of key events addressed by non-animal testing methods, which are 
assumed to lead to toxic effects on organs responses (Vonk et al., 2009). The MoA concept has 
been considered a promising tool to guide toxicity testing because it can be used for 
prioritising substances and for evaluating information from testing based on their 
mechanistic-relevance to humans. Therefore, the MoA concept can, first of all, guide toxicity 
testing with respect to the applicability domain of substances. Second, it can guide the 
development of testing strategies based on the mechanistic relevance of information derived 
from non-animal methods regarding the toxic effect on organs.  
2.3.1.3 Adverse outcome pathway (AOP) based approaches  
The adverse outcome pathway (AOP) concept describes the biological (key) events and 
their linkages which ultimately lead to the expression of an adverse effect at the level of an 
organism (OECD, 2012b; OECD, 2012c). Conceptually, the AOP broadens the scope of the MoA 
by considering adverse effects at an organism- or population- level rather than organ- level 
addressed by the MoA (Ankley et al., 2010; Vinken, 2013). The AOP has been suggested as a 
criterion for guiding data collection, and for the organisation and evaluation of relevant 
information derived from non-animal testing methods (Ankley et al., 2010; Landesmann et al., 
2013; Vinken, 2013; Kleinstreuer et al., 2016) in order to develop DAs. The advantage of using 
the AOP concept as a guiding tool for the construction of testing strategies is its ability to 
guide the collection and combination of specific pieces of information about key events in a 
biologically consistent manner (Gocht et al., 2015). AOP-based approaches aim at the full 
replacement of the animal tests with mechanistically-relevant combinations of non-animal 
testing methods addressing specific key events in the AOP (Schultz et al., 2016). 
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2.3.2 Quantitative approaches 
2.3.2.1 Machine learning approaches 
Machine learning approaches encompass computational algorithms developed to predict 
hazardous properties of substances and to reduce uncertainties underlying to the assessment 
of the hazardous properties. During the past years machine learning approaches have been 
increasingly suggested and applied to identify the types of information, called variables, which 
have to be combined to draw conclusions about the hazardous properties of substances. 
Applications of machine learning methods to the construction of DAs are Bayesian networks 
(BN) (Jaworska et al., 2011; Jaworska et al., 2013), Artificial Neural Networks (ANN) (Hirota 
et al., 2013; Tsujita-Inoue et al., 2014; Hirota et al., 2015; Tsujita-Inoue et al., 2015), Naïve 
Bayes Algorithms (NB), Support Vector Machines (SVM) and Classification and Regression 
Trees (CART) (Matheson, 2015; Asturiol et al., 2016; Kleinstreuer et al., 2016). Using machine 
learning approaches is considered a suitable approach to optimise DAs because they allow for 
a quantification of uncertainties at any stage of the testing strategy, and they allow for 
learning (i.e. updating the assessment) if new information (e.g. about the molecular structure 
of a substance) is received. Since existing applications of machine learning approaches focus 
exclusively on the information side of testing these approaches can also be denoted 
information-theoretic, in contrast to decision theoretic methods which are explained below. 
2.3.2.2 Cost analysis approaches 
Contrary to machine learning approaches, MoA- and AOP- based approaches, cost analysis 
approaches allow for balancing informational gains from testing with costs. If information 
gains and costs of testing can be expressed in monetary terms a cost-benefit analysis (CBA, 
see Bergstrom and Varian, (2003)) can be applied. Testing methods and DAs can be ranked 
according to their (expected) net benefits. In absence of monetary values for information 
gains or cost components, cost effectiveness analysis (CEA) is used (Hurd, 2015). CEA has 
been proposed and repeatedly been used as a decision-support tool for test selection in a 
regulatory context (Lave et al., 1988; Omenn, 1995; Bjørner and Keiding, 2004) and for 
evaluating toxicity testing strategies (Gabbert and van Ierland, 2010). Information outcome 
may be quantified in terms of a testing method’s performance metrics (Gabbert and van 
Ierland, 2010; Norlén et al., 2014).  
2.3.2.1 Decision theoretic approaches 
Decision theory approaches aim at quantifying expected net gains of a process (e.g. a 
policy intervention, a medical treatment), acknowledging that within this process different 
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decisions/actions can be adopted and that the outcomes of a decision/action are uncertain. 
Value of Information (VOI) analysis has been proposed as a decision-theoretic tool to 
prioritise and optimise testing (Lave et al., 1988; Yokota et al., 2004; Gabbert and Weikard, 
2013; Leontaridou et al., 2016). Based on expected utility theory, VOI analysis quantifies the 
expected payoff of any possible decision adopted with and without information from testing 
(Claxton, 1999). Payoffs can be expressed as welfare gains and losses resulting from decisions 
upon the use of a substance (e.g. ban or release). In a Bayesian inference framework, VOI 
analysis allows for incorporating a decision maker’s beliefs about the true hazardous 
properties of a substance and to update beliefs if new information becomes available (Gabbert 
and Weikard, 2013; Leontaridou et al., 2016). A decision-theoretic framework based on the 
expected utility maximisation theory has proposed (Hansson and Rudén, 2007), using 
frequencies to describe the accuracy metrics of testing methods. Since the expected value of 
test information is a quantitative measure it allows for ranking testing methods and 
strategies. In addition VOI analysis can be used to guide the construction of testing strategies 
because it offers an endogenous rule when testing should stop (i.e. the expected value of test 
information exceeds testing costs, see Leontaridou et al. (2016)). When a monetisation of test 
information is not possible, Multi Criteria Decision Analysis (MCDA) can be used. MCDA has 
been suggested as an approach to integrate evidence from different sources (Linkov et al., 
2011; Linkov et al., 2015) for the optimisation on assessments for nanoparticles (Hristozov et 
al., 2014).  
2.4 Evaluating defined approaches addressing skin sensitisation according to 
resource efficiency criteria  
To date, none of the non-animal testing methods can provide sufficient information to 
fully replace the animal tests used for skin sensitisation hazard identification and potency 
assessment as standalones (ECHA, 2016). Instead, a combination of in vitro, in chemico and in 
silico methods has been considered a good way to generate sufficient information and 
eventually replace in vivo tests (Kinsner-Ovaskainen et al., 2009; Casati et al., 2013). During 
the past years, several testing strategies have been proposed for the assessment of skin 
sensitisation potential and potency (Jaworska, 2016; OECD, 2016c). Strategies complying with 
the definition of a DA proposed in (OECD, 2016b) are summarised in (OECD, 2016c) and they 
are extensively described in the Annex I (OECD, 2016e) of the respective report. Note that 
these strategies have been also characterised as IATAs (Urbisch et al., 2015b) SEURAT-1 
annual report in 2015 (CEFIC, 2015).  
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DAs for skin sensitisation potential and potency assessment use different conceptual and 
methodological approaches to integrate information from the individual testing methods. 
Hence, they are presented in different ways, for example in the form of qualitative flowcharts 
(Grindon et al., 2008e; Mekenyan et al., 2010; ECHA, 2014a; Patlewicz et al., 2015), 
probabilistic approaches (machine learning) applying Artificial Neural Networks (Hirota et al., 
2013; Tsujita-Inoue et al., 2014; Hirota et al., 2015) or Bayesian Networks (Jaworska and 
Hoffmann, 2010; Jaworska et al., 2013; Jaworska et al., 2015), and as deterministic 
approaches based on a “majority vote” decision rule for batteries of testing methods (Bauch et 
al., 2012; van der Veen et al., 2014a; van der Veen et al., 2014b; Urbisch et al., 2015a) or score-
based batteries of testing methods (Ellison et al., 2010; Nukada et al., 2013; Takenouchi et al., 
2015). In addition, a regression analysis model (Natsch et al., 2015) and a quantitative model 
using the toxico-kinetics and toxico-dynamics modelling (MacKay et al., 2013) are used. Based 
on the criteria defined in Table 2.3 existing DAs for assessing skin sensitisation can be 
evaluated and compared regarding the resource efficiency of data integration. Table 2.4 
shows DAs that were selected as reference examples in (OECD, 2016c). 
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Regarding the information outcomes from testing each individual testing method used in 
a DA is characterised in terms of its predictive accuracy. For determining the predictive 
accuracy the sets of substances used are well documented and most commonly compared 
with the reference animal tests such as the LLNA or human data when available. DAs use 
testing methods for which reliability measures, accounting for inter- and intra- 
reproducibility of the testing methods are determined, however, they are not always 
explained in detail. For assessing the reliability of probabilistic DAs cross-validation statistical 
tools are suggested to cross check the robustness of DAs. For example, for the IDS the 
reliability of the strategy to predict the LLNA classification, thus the final decision outcome, 
was checked using the leave-one-out validation (Strickland et al., 2016). For the ANN-ITS, the 
ability of the model to predict the final decision outcome on the skin sensitisation potential 
was validated using the 10-fold cross validation approach (Hirota et al., 2013). Probabilistic 
approaches for the assessment of potency or potential offer the statistical tools to combine 
information of different parameters such as the BN ITS with the use of Mutual Information 
(MI) metrics (Jaworska et al., 2010; Jaworska et al., 2013; Jaworska et al., 2015). The 
mechanistic understanding of the information collected from each source of information is 
based on identifying key events covered in the skin sensitisation AOP. Generally, it is assumed 
that covering the first three key events of the AOP is sufficient to draw conclusions on a 
substance’s skin sensitisation potential. This is the case for most DAs presented in Table 2.4 
(Jaworska et al., 2013; van der Veen et al., 2014a; Jaworska et al., 2015; Urbisch et al., 2015a). 
However, some DAs focus on selected key events only. For example, Kao DA (Nukada et al., 
2013; Takenouchi et al., 2015) covers the first and third key event, whereas the EC-JRC DA 
covers the molecular initiating event (MIE) only (Dimitrov et al., 2005; Asturiol et al., 2016), 
which is considered to determine the final conclusion on the skin sensitisation potential 
(Asturiol et al., 2016). Given that only animal tests can provide information on the fourth key 
event (i.e. T-cell proliferation), animal welfare considerations do not allow the direct 
assessment of the fourth key event. The IATA case (Patlewicz et al., 2014) covers the fourth 
key event with the use of LLNA when necessary and the SARA case (MacKay et al., 2013) 
predicts this key event using modelling approaches.  
Considering direct and indirect testing costs we observe that only one DA, i.e. the RIVM 
STS, reported direct testing cost estimates (van der Veen et al. 2014). In case of probabilistic 
DAs (Natsch et al. 2015; Matheson et al. 2015; Hirota et al. 2015; Hirota et al. 2013; Tsujita-
Inoue et al. 2015), it is indicated that due to the saving unnecessary testing will also save 
costs. Furthermore, the Bayesian network (Jaworska et al. 2013) and the “2 out of 3” ITS 
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(Bauch et al. 2012; Urbisch et al. 2015a) suggest that a non-animal testing method would be 
avoided if information collected as a certain step of the strategy would be sufficient to 
conclude on the skin sensitisation potential. This implies saving additional testing costs. 
However, cost savings are not quantified and, consequently, are not considered an explicit 
variable for DA development. As DAs for skin sensitisation usually aim at fully replacing 
animal testing, only in a few cases (e.g. the non-testing pipeline approach (Patlewicz et al., 
2014; Patlewicz et al. 2015)) the animal test LLNA is proposed as a “last resort”.  
Regarding the conceptual criteria, the purpose of the assessment for which a DA is 
conducted is to asses either skin sensitisation potential or potency. The DAs presented in 
Table 2.4 document the information outcomes exclusively in a non-monetary way. 
Specifically, information outcomes are expressed in terms of predictive accuracy metrics. The 
final decision, i.e. the conclusion whether testing information is sufficient, or whether further 
testing is required, requires an exogenous decision rule. For example, the “2 out of 3” ITS 
(Bauch et al. 2012; Urbisch et al. 2015b) is based on a majority vote where the decision 
follows the outcome of two concordant test results. Similarly, the RIVM STS (van der Veen et 
al. 2014) uses as a first step a Bayesian QSAR approach, described in (Rorije et al., 2013), 
which is followed by tiers of non-animal testing methods. The overall conclusion is also based 
on a majority vote from test results from sequential steps in the strategy. The Artificial Neural 
Network (ANN) concept (Hirota et al. 2015; Hirota et al. 2013; Tsujita-Inoue et al. 2015) or 
the Bayesian networks (Jaworska et al., 2010; Jaworska and Hoffmann, 2010; Jaworska et al., 
2013; Jaworska et al., 2015) offer probabilistic approaches to predict skin sensitisation 
potential or potency using different physicochemical properties and information from non-
animal testing methods. The IDS DA (Matheson, 2015; Strickland et al., 2016) uses different 
machine learning approaches, i.e. ANN, Naïve Bayes algorithm (NB), Classification and 
regression tree (CART), Linear discriminant analysis (LDA), Logistic regression (LR), Support 
vector machine (SVM). The SVM is considered to be the most accurate (Matheson, 2015; 
Strickland et al., 2016) and combines information from non-animal testing methods (i.e. h-
CLAT), computational methods and physicochemical properties. The EC-JRC DA uses the 
Classification Trees (CT) machine learning approach based on in silico information to predict 
skin sensitisation potential (Dimitrov et al., 2005; Asturiol et al., 2016). Machine learning 
models are developed as information maximising approaches and the stopping rule is not 
clearly defined. It is rather exogenously set by the information target.  
Direct or indirect testing costs are in most cases not reported. None of existing DAs 
incorporate a mechanism that balances information gains and costs. As shown in Leontaridou 
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et al. (2016), information from testing cannot be considered regardless costs. In particular, 
testing costs are decisive for determining when testing should stop (Gabbert and Weikard 
2013). Hence, ignoring testing costs means that existing DAs do not provide an endogenous 
stopping rule to testing. Rather, the stopping rule for deterministic approaches such as the “2 
out of 3” ITS (Bauch et al. 2012; Urbisch et al. 2015b), the RIVM STS (van der Veen et al., 
2014a; van der Veen et al., 2014b) and the Kao DA suggestions (Nukada et al., 2013; 
Takenouchi et al., 2015) is often based on exogenous decision rules such as AOP coverage. In 
probabilistic DAs such as the BN-ITS (Jaworska et al., 2010; Jaworska et al., 2013; Jaworska et 
al., 2015), the stopping rule is exogenously determined setting information targets i.e. the 
prediction of the skin sensitisation potential using the LLNA results as a reference. We argue, 
however, that the stopping rule should not be pre-defined assuming for example covering 
most key events in the AOP is a sufficient condition to ensure robust predictions from a 
testing strategy. Instead, decision-theoretic approaches should define rules under which 
testing should stop when information no longer contributes to the existing knowledge.  
The uncertainty underlying to relevant parameters for information outcomes is assessed 
in a variety of ways. The BN-ITS proposed by (Jaworska et al., 2010; Jaworska et al., 2013; 
Jaworska et al., 2015), for example, offers an elaborate uncertainty assessment with regard to 
predictive accuracy of each individual method, and the precision, being the ability of a method 
to produce concordant results from repeated testing. Uncertainty is based on Bayesian 
inference and mutual information theory. In case of deterministic approaches, the majority 
vote is frequently applied to test results without explicitly assessing uncertainties. Individual 
testing methods reproducibility, interchangeability and reliability is assessed for methods 
used in, for example, the “2 out of 3” ITS (Bauch et al., 2012; Natsch et al., 2013; Urbisch et al., 
2015a) and the RIVM STS (van der Veen et al., 2014a; van der Veen et al., 2014b).  
2.5 Conclusions and recommendations 
This chapter reviews the state-of-the-art regarding the development DAs denoting 
approaches to integrate information from different testing and computational methods to 
determine the hazardous properties or risks of substances. According to the OECD, DAs are 
defined “rule-based [approaches] and can either be used on their own ... or considered together 
with other sources of information in the context of IATA” (OECD, 2016b). We identified criteria 
that were suggested in the toxicological literature as normative principles for constructing 
DAs. One criterion that has frequently been suggested is cost-efficiency. We defined key 
criteria for evaluating the resource-efficiency of DAs, and explain economic approaches that 
have been used or suggested for improving resource efficiency of DAs. Using these criteria we 
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evaluated DAs suggested for the assessment of skin sensitisation potential and potency, and 
presented in a recent OECD guidance document(OECD, 2016b).  
Based on our evaluation we can conclude that none of the existing DAs integrate both 
information and cost parameters. Instead, DAs predominately focus on maximising 
information, while the reduction of testing costs is often mentioned to be an important aim of 
DAs. Still, direct or indirect costs components were not systematically incorporated in the 
construction of testing strategies. Furthermore, the uncertainty of test information, which can 
originate from different sources (Worth and Cronin, 2001b; Kolle et al., 2013; Hoffmann, 
2015; Leontaridou et al., 2017a; Leontaridou et al., 2017b) are assessed only in some of the 
existing DAs. Basically, ignoring direct and indirect testing costs implies that the resource 
efficiency of DAs cannot be evaluated. In particular, DAs discussed in this paper do not allow 
for identifying the trade-offs between generating information from testing, and the costs for 
resources required to attain new information from testing.  
As a consequence, it remains unclear whether DAs indeed allow for optimising 
toxicological testing compared to animal tests, if “optimising” is interpreted in terms of 
economic resource efficiency. Moreover, suggested DAs for skin sensitisation testing lack an 
endogenous stopping rule. Evaluating the resource efficiency of DAs requires, first, to 
document both information outcomes and costs of testing. In addition, information gains must 
be balanced with costs. This can be achieved by means of integrating cost information in the 
construction method of a DA. In particular, machine learning approaches offer the possibility 
to weighing costs and information gains while accounting for uncertainties of both 
parameters at any stage of the DA. In a recent paper by Leontaridou et al. (2016) Bayesian VOI 
analysis has been applied to optimising DAs for skin sensitisation testing. Their approach 
showed that DAs are more resource efficient compared to the animal test LLNA. Alternatively, 
the resource-efficiency of DAs can be evaluated ex post, i.e. after the strategy was developed, 
using cost analysis methods, i.e. CBA or CEA. Both methods have been widely used for 
efficiency assessments of, for example, medical treatments, where conceptual challenges to 
identify the best performing alternative are very similar to toxicity testing (Claxton, 1999; 
Cunningham, 2001; Bergstrom and Varian, 2003; Claxton et al., 2004). It is important to note 
that optimal, i.e. resource-efficient, testing does not require that all relevant parameters are 
monetised. However, further research is require to assess direct and indirect costs of toxicity 
testing to ensure that cost information can be integrated in the construction of DAs. We 
believe that this is a prerequisite for developing optimal testing approaches which ensure 
valid safety assessments chemicals without animal testing, and low cost.  
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3 Evaluation of non-animal methods for assessing skin 
sensitisation hazard: A Bayesian Value-of-Information analysis2 
This chapter offers a Bayesian Value-of-Information (VOI) analysis for guiding the 
development of non-animal testing strategies, balancing information gains from testing with 
the expected social gains and costs from the adoption of regulatory decisions. Testing is 
assumed to have value, if and only if, the information revealed from testing triggers a welfare-
improving decision on the use (or non-use) of a substance. As an illustration, our VOI model is 
applied to a set of five individual non-animal testing methods used for skin sensitisation 
hazard assessment, seven battery combinations of these methods, and 236 sequential 2-test 
and 3-test strategies. Their expected values are quantified and compared to the expected 
value of the local lymph node assay (LLNA) as the animal method. We find that battery and 
sequential combinations of non-animal testing methods reveal a significantly higher expected 
value than the LLNA. This holds for the entire range of prior beliefs. Furthermore, our results 
illustrate that the testing strategy with the highest expected value does not necessarily have 
to follow the order of key events in the sensitisation adverse outcome pathway (AOP). 
  
                                                        
2 Chapter 3 is published as: Leontaridou M., Gabbert S., et al., (2016). Evaluation of non-animal methods for 
assessing skin sensitisation hazard: A Bayesian Value-of-Information analysis. ATLA Alternatives to Laboratory 
Animals vol. 44(3), pp. 255-269. 
Bayesian Value of Information analysis  
38 
 
3.1 Introduction  
Skin sensitisation denotes an immunological response that results in allergic contact 
dermatitis (ACD) after repeated exposure to a sensitising substance (Kimber et al., 2002; 
ECHA, 2014a). Besides being a key endpoint for safety evaluations of cosmetic ingredients, 
skin sensitisation testing is mandatory for all substances produced or marketed in volumes 
larger than 1 tonne per year under the European REACH legislation (EC, 2003a; EC, 2006). 
Although REACH does not prescribe a strict replacement of animal testing, it bases testing 
requirements on the paradigm of using in vivo testing only “as a last resort” ((EC, 2006), 
Article 25). In addition to REACH, the Cosmetics Regulation enforced a phasing-out of toxicity 
testing in animals by establishing a marketing ban for finished cosmetic products with 
ingredients tested in animals, which came into force in March 2013 (EC, 2003a; Hartung, 
2010a). This fostered the development of new, animal- free testing methods for assessing skin 
sensitisation hazard. 
Several non-animal testing methods for predicting skin sensitisation have been developed 
(see (Reisinger et al., 2015), for a detailed overview). Of these, one in chemico method and two 
in vitro methods were formally validated, i.e. the Direct Peptide Reactivity Assay (DPRA; 
(Gerberick et al., 2007)), the human Cell-Line Activation Test (h-CLAT; (Sakaguchi et al., 
2006)) and the ARE-Nrf2 luciferase method covered by KeratinoSensTM (Emter et al., 2010). 
The last-named testing method is also covered by LuSens (Ramirez et al., 2014), for which 
validation is still pending. Organisation for Economic Co-operation and Development (OECD) 
Test Guidelines (TGs) have been adopted for the DPRA (OECD TG 442C; (OECD, 2015a)) and 
the ARE-Nrf2 luciferase method (OECD TG 442D; (OECD, 2015b)). Nevertheless, none of the 
available non-animal methods satisfy the requirements for being accepted as an individual 
replacement of the animal-based method. The main reasons are that non-animal methods 
usually cover only selected steps of the entire adverse outcome pathway (AOP) for inducing 
an allergic reaction in the skin, and existing non-animal methods are unable to deliver 
information on skin sensitisation potency (Goebel et al., 2012; Worth et al., 2014). 
The lack of full replacement options has shifted attention to possibilities for combining in 
vitro, in silico and in chemico methods into batteries and sequential (integrated) testing 
strategies (Rovida et al., 2015). Ultimately, the development of integrated approaches for 
testing and assessment (IATAs) should solve fundamental problems, in particular, which 
testing methods to select and how to combine different methods in a strategy (Patlewicz et al., 
2014); the latter issue also includes the problem of defining the optimum number of steps 
required. In recent studies on integrated testing strategies for skin sensitisation, the selection 
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and sequential ordering of non-animal testing methods has been guided by the AOP for skin 
sensitisation (Patlewicz et al., 2014; van der Veen et al., 2014a). This implies that covering all 
consecutive events in an AOP delivers more-reliable information about a substance’s 
properties. Furthermore, the few studies offering a quantitative evaluation of the 
performance of non-animal testing strategies focus exclusively on information gains from 
testing, being either expressed as discrete predictivity estimates for skin sensitisation hazard 
classification (van der Veen et al., 2014a; Vinken et al., 2014), or as probability predictions for 
substances belonging to a specific potency class (Jaworska et al., 2013).  
This chapter argues that the criteria for guiding the construction of non-animal testing 
strategies, and their evaluation as replacements of animal tests should be based on an 
approach that accounts for testing costs and the social gains and losses from possible 
regulatory decisions, rather than solely on information gains from testing. This is motivated 
by three arguments. First, despite the progress in AOP development during recent years 
(Vinken, 2013; Tollefsen et al., 2014; Patlewicz et al., 2015), for many adverse outcomes the 
knowledge of the AOP is still rudimentary. For endpoints for which the AOP is well 
characterised, there is no plausible reason why a testing strategy should necessarily cover all 
the key events. On the contrary, it could be preferable to start a testing strategy with the most 
informative method. Second, none of the available methods, including animal tests, deliver 
perfect information. Thus, irrespective of the information metric used, test information is 
uncertain. In several studies, test information has been interpreted from a Bayesian 
perspective as conditional probabilities that update a decision-maker’s beliefs about the 
hypothesis that a substance has a specific property. As shown in (Gabbert and Weikard, 
2013), the construction of non-animal testing strategies with regard to information gains 
alone is insufficient, because it lacks an intrinsic rule of when testing should stop. Third, 
testing is costly (Koch and Ashford, 2006). Hence, assuming that the ultimate goal of testing is 
to inform regulatory decision-making, which, in turn, aims at improving social welfare, an 
evaluation of non-animal testing methods and testing strategies must balance information 
gains against costs.  
The objectives of Chapter 3 are twofold. Our first objective is to introduce a decision-
theoretic Value-of-Information (VOI) approach for developing and evaluating non-animal 
testing strategies. We assume that testing has a ‘value’, if, and only if, the information revealed 
from testing triggers a welfare-improving decision on the use (or non-use) of a substance, 
compared to decision-making in the absence of additional information from testing. Thus, in 
contrast with information-theoretic approaches such as Bayesian Networks, Hidden Markov 
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or quantitative Weight-of-Evidence approaches (Rorije et al., 2013; van der Veen et al., 2014a; 
Luechtefeld et al., 2015; Rovida et al., 2015), VOI analysis explicitly considers expected social 
gains and costs (called “payoffs”) from any possible decision on the use of a substance, while 
accounting for the uncertainty of test information. Quantifying the VOI provides a tool which 
guides the choice and sequencing of methods in a testing strategy. By comparing the VOI of 
different testing methods and testing strategies, the tool offers insight into the fundamental 
question of whether, and under what conditions, the VOI of a non-animal testing strategy 
outperforms the VOI of an animal test. 
The second objective is to illustrate the features of our model by applying it to the case of 
skin sensitisation hazard assessment. This complements and expands the information-
theoretic literature on the development of non-animal testing strategies for skin sensitisation 
(Jaworska and Hoffmann, 2010; Jaworska et al., 2011; Jaworska et al., 2013) by also 
incorporating societal benefits and costs of testing into the analysis. The VOI is calculated for a 
set of individual non-animal testing methods, including in vitro, in silico and in chemico 
methods, seven battery combinations, 62 two-test and 174 three test sequential combinations 
of these non-animal testing methods (Urbisch et al., 2015a). Their VOIs are compared to the 
VOI of the local lymph node assay (LLNA) as the animal test (Mehling et al., 2012; Basketter et 
al., 2014; Urbisch et al., 2015a). 
3.2 Method: A decision-theoretic approach to assessing the value of testing  
VOI analysis is a decision-analytic method that calculates expected gains and losses from 
gathering additional information. It has been widely applied to problems of decision-making 
surrounded by uncertainty in many different domains, such as medical diagnosis and 
healthcare decision-making, environmental technology assessment, environmental pollution 
management and the prioritisation of regulatory strategies (Claxton, 1999; Claxton et al., 
2004; Yokota et al., 2004; Yokota and Thompson, 2004). Several studies applied VOI analysis 
to the problem of chemical risk management (Lave et al., 1988; Yokota et al., 2004; Gabbert 
and Weikard, 2010; Gabbert and Weikard, 2013) of which two studies offer applications to 
sequential combinations of tests, focusing on carcinogenicity and mutagenicity hazard 
assessments (Yokota and Thompson, 2004; Gabbert and Weikard, 2013). However, Yokota 
and Thompson (2004) pre-defined the selection and ordering of tests. Also, the sets of non-
animal testing methods addressed by Gabbert et al. (2013) and by Yokota and Thompson 
(2004) were confined to in vitro methods only, and the animal test is combined with non-
animal testing methods into a sequential testing strategy. A comprehensive evaluation of 
different non-animal testing methods and their combinations, assessing their potential to 
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replace the animal test, has not been conducted so far. In this paper, the value of collecting 
additional information is assessed from a social welfare perspective, where gains and losses of 
both producers and consumers are considered. Depending on exposure, a substance can lead 
to the manifestation of an adverse effect on human health or on ecosystems (an “endpoint”; 
(van Leeuwen et al., 2007; Wallace and Ernest, 2012)). The simplest approach is to identify an 
adverse effect with a binary “hazardous/non-hazardous effects” assessment (van der Schouw 
et al., 1995; Hoffmann and Hartung, 2005; Rovida et al., 2015). In the following, we will use τ = 
1 for denoting that a substance has the potential to cause a hazardous effect, and τ = 0 if it 
does not. Depending on a decision-maker’s beliefs about the state of the substance, they must 
decide whether the substance can be used. For simplicity, we assume that the set of 
regulatory decisions contains only two options: “release” (i.e. allow access to the market) and 
“ban” (i.e. prohibit access to the market). Depending on τ and the set of regulatory actions, the 
use of a substance can have benefits, but also costs, to society. 
Assuming a competitive market, the social benefits of releasing a non-hazardous 
substance are the sum of the producer’s expected marketing benefits Bp (being the difference 
between revenue and costs; (Bergstrom and Varian, 2003), and expected intermediate 
consumer benefits Bc (intermediate consumers are companies who use a substance as 
ingredient for their products). The release of a hazardous substance, in contrast, can cause 
health and environmental damages, which are costly for society. Social costs, D, comprise 
health and environmental damage costs from the use of a substance. Thus, benefits and costs 
of the use of chemicals are incurred by different economic factors. If a substance is released, 
expected social damage costs must be subtracted from expected social benefits. If a substance 
is banned, we assume zero social benefits, irrespective of the true hazardous properties of the 
substance. Clearly, expected payoffs are substance- specific. Table 3.1 summarises expected 
payoffs for the possible states of a substance and the set of regulatory actions, i.e. the action 
space. 
Table 3.1: Payoffs from substances’ use 
 State of substance 
Ac
ti
on
 
sp
ac
e  ߬ = 1 ߬ = 0 
Ban 0 0 
Release ܤ௉
 + ܤ஼
 − ܦ  ܤ௉
 + ܤ஼
  
߬ = 1: Substance is hazardous; 
߬ = 0: Substance is non-hazardous;  
BP = Marketing benefits of chemical producer;  
BC = Marketing benefits of intermediate consumer; 
D = expected health damage costs.  
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Prior to testing, a decision-maker’s beliefs about the state of a substance depend on 
available information about τ. This could be based on information about a substance’s 
structure (e.g. taken from an OECD profiler screening), earlier studies, evidence of the 
prevalence of toxic health effects, or expert judgement. In the absence of any information, 
prior beliefs can be completely subjective (Held and Bové, 2014). Prior beliefs that a 
substance is hazardous are denoted ݌଴, and (1 – ݌଴) if the substance is believed to be non-
hazardous. Based on prior beliefs, a substance should be released if, and only if, 
 
݌଴(ܤ௉
 + ܤ஼
 − ܦ ) + (1 − ݌଴)(ܤ௉
 + ܤ஼
 ) > 0 (3.1) 
 
According to Eq.3.1, a chemical should be marketed if the probability-weighted sum of 
payoffs is positive. Assuming that decision-makers aim at maximising expected payoffs, the 
value of decision-making under uncertainty, i.e. without information from testing, is: 
 
଴ܸ = ݉ܽݔ ൣ0; ൫݌଴(ܤ௉
 + ܤ஼
 − ܦ ) + (1 − ݌଴)(ܤ௉
 + ܤ௖
 )൯൧ (3.2) 
 
That is, a ban will be preferred if the expected payoff (0, left expression in square brackets 
in Eq. 3.2) exceeds the expected payoff from releasing the substance. The latter is the sum of 
probability-weighted payoffs for marketing a hazardous and a non-hazardous substance, 
respectively (right expression in square brackets in Eq. 3.2). Testing reveals additional 
information, which reduces uncertainty about the true status of the substance, provided that 
the methods used are reliable and relevant. For hazard identification, the continuous dose–
response curve resulting from testing is often dichotomised into a binary hazardous/non-
hazardous classification (van der Schouw et al., 1995; Hoffmann and Hartung, 2005). We 
define ݐ 
+ as a positive test outcome, indicating that a substance is hazardous. A negative test 
outcome is denoted ݐ 
ି. So far, neither the animal test nor the available non-animal testing 
methods provide perfect information. Thus, testing may reduce, though not fully resolve, 
uncertainty. The predictive capacity of a non-animal testing method has usually been 
expressed by means of a 2 × 2 contingency tables (Cooper et al., 1979), which shows the 
proportion of correct (sensitivity s, and specificity r) and false classifications, i.e. the false 
negative rate (1 – s) and false positive rate (1 – r), based on a pre-defined training set of 
substances with known properties (Table 3.2; (Bauch et al., 2012; Urbisch et al., 2015a)). 
From a Bayesian perspective, the proportion of correct and false classifications can be 
interpreted as conditional probabilities of seeing a positive or negative test result, given that 
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the chemical is hazardous or non-hazardous, p(t│τ) (Jaworska et al., 2010; Jaworska et al., 
2013; Rorije et al., 2013).  
 
Table 3.2: Conditional probabilities ࢖(࢚|࣎) of seeing a testing result t, given the true state of the 
substance ࣎ 
  State of the substance 
 ݌(ݐ|߬) ߬ = 1 ߬ = 0 
Te
st
 o
ut
co
m
e 
ݐ 
ା 
ݏ  
Probability of a true positive 
outcome (Sensitivity) 
1 − ݎ  
Probability of a false 
positive outcome 
ݐ 
ି 
1 − ݏ  
Probability of a false 
negative outcome 
ݎ  
Probability of true negative 
outcome (Specificity) 
߬ = 1: Substance is hazardous;  
߬ = 0: Substance is non-hazardous; 
߬ 
ା : Test outcome is positive;  
߬ି: Test outcome is negative.  
 
Additional information may change a decision maker’s beliefs about the state of the 
substance. Using Bayes’ theorem (Eq. 3.3), which is the standard approach for probabilistic 
information update and learning (Howson and Urbach, 1991), the decision-maker’s prior 
beliefs ݌଴can be revised into posterior beliefs on the state of the substance ݌(߬|ݐ), given the 
outcomes from testing (Table 3.3): 
 
݌(߬|ݐ) =
௣బ௣(ݐ|߬)
௣బ௣(ݐ|߬)ା(ଵି௣బ)൫ଵି௣(ݐ|߬)൯
. (3.3) 
Table 3.3: Posterior probability ࢖(࣎|࢚ ) of a substance being hazardous or non-hazardous after 
seeing evidence from testing 
  State of the substance 
 ݌(߬|ݐ) ߬ = 1 ߬ = 0 
Te
st
 o
ut
co
m
e 
ݐା ݌ା =
݌଴ݏ 
݌଴ݏ + (1 − ݌଴)(1 − ݎ)
 1 − ݌ା =
(1 − ݌଴)(1 − ݎ)
(1 − ݌଴)(1 − ݎ) + ݌଴ݏ
 
ݐ  
ି ݌ି =
݌଴(1 − ݏ)
݌଴(1 − ݏ) + (1 − ݌଴)ݎ
 1 − ݌ି =
(1 − ݌଴)ݎ
(1 − ݌଴)ݎ + ݌଴(1 − ݏ)
 
߬ = 1: Substance is hazardous; ߬ = 0: Substance is non-hazardous;  
ݐ 
ା : Test outcome is positive; ݐି: Test outcome is negative;  
݌଴: Prior probability that a substance is hazardous; (1 − ݌଴): Prior probability that the substance is non-hazardous;  
ݏ: Probability of a true positive outcome (sensitivity); (1 − ݏ): Probability of a false negative outcome; 
ݎ: Probability of a true negative outcome (specificity); (1 − ݎ): Probability of a false positive outcome;  
݌ା: Posterior probability that the substance is hazardous after seeing a positive test outcome;  
1 − ݌ା: Posterior probability that the substance is hazardous after seeing a negative test outcome; 
݌ି: Posterior probability that the substance is non-hazardous after seeing a positive test outcome;  
1 − ݌ି: Posterior probability that the substance is non-hazardous after seeing a negative test outcome. 
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In the specific case that prior beliefs are equivalent to the prevalence of toxic health 
effects, the posterior probability of a substance being hazardous or non-hazardous coincides 
with a testing method’s positive and negative predictive value, respectively. The expected 
value of taking an optimal action under posterior beliefs is, then, 
 
௜ܸ
ା ≡ max ൣ0; ൫݌ା(ܤ௉
 + ܤ஼
 − ܦ ) + (1 − ݌
ା)(ܤ௉
 + ܤ஼
 )൯൧, (3.4) 
 
in case of a positive test result, and  
 
௜ܸ
ି ≡ max ൣ0; ൫݌ି(ܤ௉
 + ܤ஼
 − ܦ ) + (1 − ݌
ି)(ܤ௉
 + ܤ஼
 )൯൧ (3.5) 
 
in case of a negative test result. 
The expected value of performing test ݅ is the weighted sum of V௜
ା and V௜
ି, with the probability 
of seeing a positive and a negative test outcome (Prା, Prି) being the weights: 
 
௜ܸ = ܲݎ
ା
௜ܸ
ା + ܲݎି ௜ܸ
ି, (3.6) 
 
where 
ܲݎା = ݌଴ݏ + (1 − ݌଴)(1 − ݎ) (3.7a) 
 
denotes the probability of seeing a positive test outcome, and  
 
ܲݎି = ݌଴(1 − ݏ) + (1 − ݌଴)(ݎ) (3.7b) 
 
denotes the probability of seeing a negative test outcome.  
It follows from Eq. 3.2 and Eq.3.6 that a test ݅ should be performed if the expected value 
from an optimal decision with additional information from testing, ௜ܸ, exceeds the expected 
value of an optimal decision without information from testing, ଴ܸ. Thus, the expected value of 
test information (ܧܸܶܫ௜) is 
 
ܧܸܶܫ௜ = ௜ܸ − ଴ܸ. (3.8) 
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Since testing is costly, a test ݅ should be performed if, and only if, its expected value exceeds 
testing costs: 
  
ܧܸܶܫ௜ − ݇௜ ≥ 0, (3.9) 
with ݇௜  denoting monetary testing costs (Norlén et al., 2014). Note that Eq. 3.9 provides the 
rule for testing to be stopped. 
The higher the ܧܸܶܫ௜ net of testing costs, the higher the expected social benefits arising 
from the use of a substance, given additional information from test ݅. For a set of non-animal 
testing methods, the one revealing the highest ܧܸܶܫ௜ net of costs, will be preferred. A decision-
maker will stop testing as soon as the ܧܸܶܫ௜ net of testing costs becomes negative (Eq. 3.9). 
This also holds if the decision maker is a social planner (e.g. a member of a regulatory agency). 
Although regulators do not bear testing costs, we assume that they adopt a social welfare 
perspective, because they must consider all types of costs and benefits from the use of a 
chemical. Bayesian inference allows the calculation of information gains in terms of posterior 
beliefs about a substance being hazardous or non-hazardous at any stage of the sequence. 
Thus, Eq. 3.9 offers a quantitative measure for comparing and ranking individual non-animal 
testing methods, as well as sequential or battery combinations of these methods. A key feature 
of sequential testing strategies is that the decision of whether or not to continue testing is 
conditional on information gains at earlier stages in the sequence. This involves the possibility 
to save tests and, consequently, costs. 
3.3 Application: Optimised testing strategies for assessing skin sensitisation 
hazard of cosmetic ingredients  
The applicability of the Bayesian VOI model is illustrated for the case of skin sensitisation 
hazard assessment of cosmetic ingredients. Given the important role of this endpoint in 
various regulatory frameworks (Basketter et al., 2012; Luechtefeld et al., 2015), several 
studies have proposed probabilistic approaches for data integration and the development of 
hypothesis-driven testing strategies. These studies focus on information gains from testing 
(Jaworska and Hoffmann, 2010; Jaworska et al., 2011; Jaworska et al., 2013; van der Veen et 
al., 2014a). This paper complements existing approaches by adopting a social welfare 
perspective, where information gains from testing are balanced with societal benefits and 
costs from decisions on the use (or non-use) of a substance. 
The set of testing methods consists of five non-animal testing methods, seven battery 
combinations of these methods, and the LLNA as the animal test (Basketter et al., 2012; 
Mehling et al., 2012; Urbisch et al., 2015a). The non-animal testing methods include the DPRA 
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(Gerberick et al., 2007), the OECD profiler toolbox v3.2 (denoted hereinafter as “OECD 
Toolbox”; (OECD, 2012d)), the ARE-Nrf2 luciferase method covered by KeratinoSensTM 
(Emter et al., 2010) and LuSens (Ramirez et al., 2014), and the h-CLAT (Sakaguchi et al., 
2006). The predictive capacities of all the non-animal testing methods and the LLNA were 
evaluated on human data (subset B in (Urbisch et al., 2015a), derived mainly from (Basketter 
et al., 2014)), using a sample of 114 substances (Table 3.4). In the skin sensitisation AOP, the 
DPRA captures the first key event (protein binding), KeratinoSensTM and LuSens the second 
key event (epithelial responses), and the h-CLAT captures the third key event (dendritic cell 
activation; (OECD, 2012a)). Note that the cellular non-animal testing methods inherently 
cover cysteine reactivity and thus mechanistically overlap with the DPRA (Natsch et al., 2013). 
Finally, we included the OECD Toolbox in the analysis (OECD, 2012d) by using the protein-
binding profilers based on OECD and OASIS algorithms, the “auto-oxidation profiler” and the 
“skin metabolism profiler” (Urbisch et al., 2015a). The analysis was performed for individual 
non-animal testing methods, selected battery combinations of these methods, and all possible 
two-test and three test sequences that can be constructed from the five non-animal testing 
methods in our set. This revealed a total number of 236 sequential testing strategies for 
assessing skin sensitisation hazard; note that we did not consider combinations of methods 
where an individual method would be applied repeatedly. 
 
Table 3.4: Predictive capacity and testing costs for individual methods and battery 
combinations  
Testing methods Sensitivity [%] Specificity [%] Testing costs
a 
[Euro/substance] 
LLNAb 91 64 5,500 
OECD toolboxb 89 64 500 
DPRAc 84 84 3,000 
KeratinoSensTM c 82 84 4,000 
LuSensc 78 79 4,000 
hCLAT 89 64 4,500 
DPRA + LuSens b 93 100 7,000 
DPRA + KeratinoSensTM d 100 82 7,000 
DPRA + hCLATb 94 88 7,500 
LuSens + hCLATb 96 91 8,500 
KeratinoSensTM + hCLATb 93 92 8,500 
DPRA + KeratinoSensTM + hCLATd 90 90 11,500 
DPRA + LuSens + hCLATd 90 89 11,500 
Test batteries are indicated by ‘+’; 
a Estimated average costs 2015 (unpublished); 
b BASF (2015), personal communication; 
c(Urbisch et al., 2015a); 
d Suggested as an AOP-based testing strategy for skin sensitisation hazard assessment,  
also called the “2-out-of-3ITS”. 
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Table 3.4 shows that battery combinations of non-animal testing methods have a higher 
sensitivity/specificity than the LLNA, but are more expensive. The decision-analytic VOI 
model accounts for the possible trade-offs between information and costs. Quantifying social 
benefits and costs, in particular, expected health and environmental damage costs caused by 
the release of a hazardous substance, has been a major challenge in empirical VOI applications 
(Ennever et al., 1990; Omenn, 1995; Yokota and Thompson, 2004; Gabbert and Weikard, 
2013). 
A substance that is known to be a skin sensitiser can cause allergic skin reactions (allergic 
contact dermatitis [ACD]; (Kimber et al., 2002; Park and Zippin, 2014)). Given uncertain test 
outcomes, there is a risk of harm from ACD, even if the substance has been classified a non-
sensitiser. These “costs of making errors” are the monetary health damage costs to society 
(Table 3.1) — in the following, denoted ܦ஺஼஽ . Focusing on non-occupational exposure, health 
damage costs of an individual suffering from ACD (i.e. ܦ஺஼஽௜௡) consist of direct costs for 
primary and secondary healthcare (i.e. treatments provided by general practitioners and 
dermatologists), and of indirect costs (for example, loss of productivity and quality of life). 
Estimates of health costs caused by ACD provided in the literature vary depending on the 
severity of ACD (usually expressed in terms of the categories ‘mild’, ‘moderate’ or ‘severe’) 
and the population group considered (Verboom et al., 2002; Ricci et al., 2006; Halvarsson and 
Loden, 2007; Stein et al., 2007; Witt et al., 2009; Sætterstrøm et al., 2014). More importantly, 
empirical cost assessments usually cover only a fraction of overall costs caused by ACD, 
because several cost components (e.g. loss of quality of life) are difficult to quantify and 
monetarise. To exemplify the features of our model, we used the mean estimate of health 
damage costs to an individual adult, as published in (Sætterstrøm et al., 2014), of 973 Euros 
per person and per year. This estimate includes the direct costs of medical treatment and 
costs of productivity loss. This value can, of course, differ considerably across individuals 
within a country and across countries. Furthermore, assessments of health damage costs vary 
according to the endpoint (see, for example, (Yokota et al., 2004; Yokota and Thompson, 
2004)). An alternative approach to estimating the welfare loss of people suffering from ACD 
would be to determine their “willingness to pay” (WTP) to avoid skin allergies caused by 
cosmetics. Conducting a revealed preference study is, however, time and resource consuming 
and was beyond the scope of this paper. WTP estimates provided in a recent ECHA study 
(ECHA, 2014b) considered, in addition to cosmetic ingredients, a mixed set of allergens, and 
were based on direct health costs only. 
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Calculating expected health damage costs to society requires health costs to individuals to 
be aggregated. Clearly, individuals suffering from ACD caused by specific cosmetic ingredients 
account for only a fraction of the total population affected by ACD. This is expressed by a 
substance’s sensitisation prevalence ߩ, this being the proportion of people in a sample 
showing positive human patch test reactions to the application of a specific substance 
(Schnuch et al., 1997; Natsch et al., 2013). Multiplying individual health damage costs (ܦ஺஼஽௜௡) 
by the prevalence- weighted population (ߩ * N) provides an estimate of the expected health 
damage costs (ܦ஺஼஽) caused by ACD. Since our study focuses on Europe, N denotes inhabitants 
within the European Union (EU28) (EC - Eurostat). 
 
ܦ஺஼஽ = ܦ஺஼஽௜௡ ߩ ܰ. (3.10) 
 
Prior to the testing of an uncharacterised substance, the ‘true’ prevalence will be 
unknown. If a substance belongs to a certain group of contact allergens (e.g. disinfectants, 
dyes, fragrances, preservatives), a mean prevalence for this group can be used (Schnuch et al., 
2011; Leiva-Salinas et al., 2014). If no information is available, a mean prevalence value for 
contact allergens can be applied (Schnuch et al., 2011). 
To calibrate the model, we use the case of methylisothiazolinone. It is used for the 
formation of Kathon CG, which is a preservative that has been widely used in cosmetic 
products and is known to be a sensitiser (Uter et al., 2012). Values for the prevalence of 
sensitisation to MI and Kathon CG have been reported in the literature (Schnuch et al., 2011; 
Schnuch et al., 2012), and vary, depending on population sample size and composition, 
between 1.2% and 4.2%. To illustrate the impact of prevalence estimates on the ܧܸܶܫ௜, and on 
the ranking of testing methods and testing strategies included in our analysis, we calculated 
health damage costs for four different sensitisation prevalence estimates, therefore capturing 
a range between optimistic and conservative estimates (Table 3.5). 
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Table 3.5: Prevalence estimates and prevalence-weighted health damage costs caused by ACD 
within the European Union (EU28) 
Sensitisation 
prevalence 
[%] 
Source Prevalence calculation 
ࡰ࡭࡯ࡰ࢏࢔ 
Euro/person and 
year 
0.7 
(Schnuch et al., 
2012) 
Sensitisation prevalence of N-Isopropyl-N’-phenyl-
p-phenylenediamine (IPPD), typically low 
prevalence observed for contact allergens 
7 
2.8 
(Uter et al., 
2013) 
Prevalence derived from the MOAHLFA index for 
Kathon CG corrected by the fraction of people 
suffering from atopic contact dermatitis 
27 
3.8 
(Uter et al., 
2013) 
Prevalence for Kathon CG from a sample of 28,922 
patch test results conducted in the period of 2009-
2012 
37 
15 
(Schnuch et al., 
2012) 
Sensitisation prevalence of Nickel Sulphate, highest 
prevalence observed for contact allergens 
146 
 
Finally, applying the VOI model requires the determination of expected producer and 
consumer benefits from a substance’s release (ܤ௉ and ܤ஼; Table 3.1). Since data on substance 
specific revenue and production costs are not available, industry’s marketing benefits of 
Kathon CG were approximated by assuming profits to be 15% of marketing revenues in 2014. 
For Kathon CG, we used an average price of 1.635 Euros/kg, calculated from monthly prices 
for the solution of Kathon CG between January 2013 and May 2015 (Zauba). The quantity of 
Kathon CG marketed in the EU was assumed to be 1000 tonnes per year, which is the upper 
limit of the REACH tonnage band (100–1000 tonnes/year; (EC, 2006) Article 12). 
Intermediate consumer benefits, Bc, refer to the marketing gains of companies using a 
cosmetic ingredient — in our case Kathon CG — in their products. Empirical data on the profit 
share of single cosmetic ingredients are not available. Therefore, it was not possible to 
quantify Bc directly. Assuming that, prior to testing and in the absence of adequate toxicity 
information, a decision-maker will likely decide not to release a substance, we approximated 
Bc as the threshold benefit at which a ban would still just be the optimal action. For 
uninformative prior beliefs (݌଴ = 0.5) and re-arranging Eq. 3.1, the threshold consumer 
benefit is 
 
ܤ஼෢ = (݌଴ܦ஺஼஽ − ܤ௉) −1. (3.11) 
  
Bayesian Value of Information analysis  
50 
 
3.4 Results 
Applying the VOI model to the set of five non-animal testing methods and the LLNA, seven 
battery combinations and 236 sequential testing strategies of non-animal methods, and 
considering four sensitisation prevalence estimates, we obtained a rank list of non-animal 
methods and testing strategies according to their net ܧܸܶܫ௜ of testing costs (see Eq. 3.1). For 
ease of presentation, the discussion of results is confined to outcomes for sensitisation 
prevalences of 2.8% and 15%. Furthermore, we show ܧܸܶܫ௜ results for two selected prior 
beliefs, ݌଴ = 0.2 and ݌଴ = 0.7. The first value approximates the prevalence of sensitisers in 
REACH registration dossiers (Thyssen et al., 2007), the latter denotes beliefs which are 
slightly more conservative than the percentage of sensitisers in the human data set presented 
in (Urbisch et al., 2015a). A complete rank list of all individual testing methods, battery 
combinations and sequential testing strategies for all prior beliefs and prevalence estimates is 
documented in a supplementary file (available from the website, www.atla.org.uk). The file 
also includes a numerical example of calculating the ܧܸܶܫ௜ net of testing costs for an 
individual testing method. 
Generally, we find that a higher sensitisation prevalence - all other parameters being the 
same - increases the expected value of testing. The reason is that a higher prevalence causes 
expected social health damage costs, ܦ஺஼஽ , to increase. Consequently, testing becomes more 
relevant, because it reduces uncertainty and, thus, the probability of the erroneous release of 
a substance. This is reflected by a higher ܧܸܶܫ௜.  
Table 3.6 lists the non-animal testing strategies taking the first ten positions: a) for ݌଴= 
0.2, indicating weak prior beliefs that a substance is a sensitiser; and b) for ݌଴ = 0.7, indicating 
moderate prior beliefs that a substance is a sensitiser. A “+” between two non-animal testing 
methods denotes a testing battery, and arrows indicate a sequential combination of testing 
methods. In addition to documenting the testing methods in the ranking, Table 3.6 presents 
numerical values of their ܧܸܶܫ௜ net of testing costs and the incremental difference of the 
ܧܸܶܫ௜ net of testing cost between subsequent rank positions. 
We find that individual testing methods and the LLNA are positioned at the end of the 
ranking. This holds for the entire range of prior beliefs and across all sensitisation prevalence 
estimates (see the supplementary file for a complete ranking of all testing methods and 
testing strategies). For very low and very high prior beliefs (݌଴ = 0.1; ݌଴ = 0.9), the ܧܸܶܫ௜net of 
testing costs of the LLNA and the individual testing methods equals zero. Thus, testing has no 
value because expected information from the testing will not change the decision made on the 
use of the substance, compared to the situation without additional testing information. For 
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prior beliefs ݌଴ ≤ 0.4, the battery DPRA + LuSens reveals the highest ܧܸܶܫ௜ net of testing costs 
(see Table 3.6 and the supplementary file). For prior beliefs ݌଴ ≥ 0.4, sequential testing 
strategies perform best. More specifically, for prior beliefs in the range 0.4 ≤ ݌଴ ≤ 0.8 the 
sequence consisting of DPRA + LuSens, the OECD Toolbox, and KeratinoSensTM + h-CLAT takes 
the first five rank positions. This holds for all prevalence scenarios considered. As shown in 
Table 3.6 for ݌଴ = 0.7, differences in the ܧܸܶܫ௜ net of costs across these rank positions are 
relatively small. The reason is that the ܧܸܶܫ௜ difference between two sequences that differ 
only in the order of testing methods cannot exceed the difference in testing cost between the 
cheapest and the most expensive test in the sequence. In contrast, the difference of the ܧܸܶܫ௜ 
net of testing costs between strategies with a different composition of non-animal testing 
methods is usually much larger (see, for example, the strategies on rank position 7 and 8 for 
݌଴ = 0.7, and the strategies on rank position 5 and 6 for ݌଴ = 0.7 in Table 3.6). 
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The better performance of sequential testing strategies compared to batteries of non-
animal testing methods can be explained by their potential to reduce the number of tests 
needed, and, hence, to reduce testing costs. This can be demonstrated by looking into the 
belief updating process of each branch in a sequence. Figure 3.1 illustrates the sequential 
structure of the first ranked obtained for ݌଴= 0.7, being DPRA +LuSens → OECD Toolbox → 
KeratinoSensTM +h-CLAT. If DPRA + LuSens would reveal a positive result (DPRA + LuSens: 
ݐଵ
ା), conducting the OECD Toolbox at the second stage and KeratinoSensTM + h-CLAT at the 
third stage of the sequence would not sufficiently shift posterior beliefs in order to change the 
optimal action from “Ban” to “Release”. As a consequence, the expected value of the OECD 
Toolbox and KeratinoSensTM + h-CLAT would be zero, irrespective of whether their outcome 
would be positive or negative. 
If the use of the battery DPRA + LuSens would reveal a negative result (ݐଵ
ି), the ܧܸܶܫ௜ net 
of testing costs of the OECD Toolbox would be negative. This can be explained as follows: At 
the second stage of the sequence, the expected value of the OECD Toolbox is equivalent to the 
expected value of the battery DPRA + LuSens at the first stage ( ଵܸ
ି = ଶܸ| ଵܸ
ି = 4970 million 
Euros). Hence, one would expect the ܧܸܶܫ௜ after the second stage of the sequence to be zero. 
However, conditional on seeing a negative result of the OECD Toolbox, a positive outcome of 
KeratinoSensTM + h-CLAT at the third stage of the sequence, would shift the action from 
“Release” to “Ban”. This is reflected by a positive ܧܸܶܫ௜ after the third stage of the sequence 
(ܧܸܶܫଷห ଵܸ,ଶ
ିା = 1455 million Euros). Conducting KeratinoSensTM + h-CLAT at the third stage 
implies that the second testing stage must have been conducted as well, and the costs of the 
second testing method would be incurred. Therefore, the ܧܸܶܫ௜ of the OECD Toolbox is 
negative and equivalent to its costs (–500 Euros). Thus, whereas in a battery all testing 
methods are conducted (therefore incurring testing costs of all methods), in the case of a 
sequence, whether a testing method of a follow up stage will be conducted or not depends on 
the outcomes observed at previous stages. 
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As illustrated in Table 3.7, the ܧܸܶܫ௜ of testing strategies depends on a decision-maker’s 
prior beliefs. This emphasises the need to carefully evaluate all available information prior to 
testing, e.g. from screening methods or expert consultation, in order to determine meaningful 
prior probabilities. Comparing numerical ܧܸܶܫ௜results of the first ranked strategies at 
different prior beliefs with that of the LLNA underlines that — given the assumptions and 
data discussed in the Method section — the ܧܸܶܫ௜ of battery and sequential combinations of 
non-animal testing methods is significantly higher. To put our results in the context of AOP-
based prediction models for skin sensitisation hazard assessment suggested in the literature 
(29, 45), we compared the ܧܸܶܫ௜ net of costs of first-ranked strategies with that of the “‘2 out 
of 3” ITS, where the classification for skin sensitisation is based on congruent results of at 
least two of three non-animal testing methods (Urbisch et al., 2015a). Here, we considered the 
DPRA, KeratinoSensTM and the h-CLAT (see also Table 3.4). Our results demonstrate that the 
ܧܸܶܫ௜net of testing costs of this strategy, though being higher than that of the LLNA, is lower 
than the ܧܸܶܫ௜net of testing costs of the first-ranked strategies in Table 3.6 for all prior 
beliefs. Hence, if used as a battery (as in (Urbisch et al., 2015a)), the “2 out of 3” ITS, despite 
its high joint sensitivity and specificity, is outperformed by sequential combinations of non-
animal testing methods. 
 
Table 3.7: ࡱࢂࢀࡵ࢏ − ࢑࢏ (Million Euros) of the first- ranked testing strategy for different prior 
beliefs (࢖૙), and for a sensitisation prevalence of 2.8% a 
࢖૙ First-ranked testing strategy 
ࡱࢂࢀࡵ࢏ − ࢑࢏ of 
first-ranked 
strategy 
ࡱࢂࢀࡵ࢏ − ࢑࢏ of 
LLNA 
ࡱࢂࢀࡵ࢏ − ࢑࢏ 
of “2 out of 3” ITS ´b 
0.1 
DPRA + LuSens 
642,754,005 0 0 
0.2 1,285,515,010 0 691,129,366 
0.3 1,928,276,014 145,134,082 1,382,270,231 
0.4 
DPRA + LuSens → OECD Toolbox → 
KeratinoSensTM + hCLAT 
2,611,781,558 1,022,882,981 2,073,411,096 
0.5 3,314,491,729 1,900,631,879 2,764,551,961 
0.6 2,634,920,170 1,396,099,048 2,073,411,095 
0.7 1,955,348,612 891,566,216 1,382,270,230 
0.8 1,275,777,053 387,033,384 691,129,365 
0.9 
DPRA + KeratinoSensTM → OECD Toolbox → 
LuSens + hCLAT 
830,318,758 0 0 
a Results of the first-ranked strategy are compared to the (ܧܸܶܫ௜ − ݇௜) of the LLNA and of the “2-out-of-3” ITS, as 
suggested in (Bauch et al., 2012; Urbisch et al., 2015a)  
b This approach consists of the DPRA, KeratinoSensTM and the hCLAT. The conclusion on a substance’s hazardous 
properties is based on a majority vote; the h-CLAT will be conducted only if the first two prediction methods are in 
disagreement (Bauch et al., 2012; Urbisch et al., 2015a). 
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Finally, our results illustrate that testing strategies do not necessarily have to follow the 
order of key events in an AOP, nor do all key events have to be covered. Looking into the list of 
methods taking the ten top positions in the ranking (Table 3.6), we observe that testing 
strategies for assessing skin sensitisation hazard do not have to start with methods covering 
protein activation, nor do all events in the AOP for skin sensitisation have to be covered 
(Figure 3.2). A possible explanation for this finding is that combinations of testing methods 
reduce the variation in predictions of either method, which increases the overall predictive 
capacity of the testing strategy. This underlines that key events in an AOP, if sufficiently 
known, cannot be understood as a construction rule for testing. Instead, with which non-
animal testing method (or combination of methods) a testing strategy should start, and in 
which order to conduct testing methods, depend on the interplay between prior beliefs, the 
predictive capacity of methods, and the specification of payoffs and testing costs. The strength 
of the VOI framework is to offer a transparent analysis of whether, and under what conditions, 
a non-animal testing strategy provides sufficient and adequate hazard information for optimal 
decision-making without full coverage of all AOP events. 
 
 
Figure 3.2: Schematic representation of key events in the skin sensitisation AOP covered by 
the first-ranked testing strategies for prior beliefs of ࢖૙= 0.2 and ࢖૙= 0.7, and a skin 
sensitisation prevalence of 2.8% 
 
  
Event 1: 
Protein activation  
Event 2: 
Keratinocyte activation 
Event 3: 
Dendritic cell activation 
Optimal testing strategy for prior beliefs ࢖
૙
= ૙. ૛: 
Optimal testing strategy for prior beliefs ࢖
૙
= ૙. ૠ: 
1st step: DPRA + LuSens 
1st step: DPRA + LuSens 
2nd step: OECD Toolbox 3rd step: KeratinoSensTM + hCLAT 
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3.5 Discussion and conclusions 
Bayesian VOI analysis is a decision-theoretic tool for assessing a testing method’s 
potential for improving decision-making on the use of a substance. Testing has a value, if 
expected social net gains from an optimal decision with additional evidence outweigh 
expected net gains from decision making without such evidence. Hence, a testing method, or 
any combination of methods, should be performed if the ܧܸܶܫ௜ is positive, and if it exceeds 
testing costs. The ܧܸܶܫ௜ net of testing costs can be quantified for individual testing methods, 
and battery and sequential combinations of methods. VOI analysis can therefore be used for 
comparing and ranking different testing options. In addition, the VOI framework guides the 
construction of sequential testing strategies, because it permits the determination of which 
order of methods reveals the highest ܧܸܶܫ௜ net of testing costs, and when testing should stop. 
This chapter complements the existing literature on developing and optimising integrated 
testing strategies. During recent years, several studies have addressed the challenge of 
constructing non-animal testing strategies for skin sensitisation hazard classification and 
potency assessment. These studies have focused on the maximisation of informational gains 
from sequential testing strategies and batteries (Jaworska and Hoffmann, 2010; Jaworska et 
al., 2011; Jaworska et al., 2013; van der Veen et al., 2014a). The role of social benefits and 
costs for developing testing strategies, and how to balance information gains against theoretic 
costs, have not been addressed. In order to complement existing information-theoretic 
approaches, our paper applies decision-theoretic VOI analysis which integrates information 
gains and costs of chemical use. Moreover, it adopts a social welfare perspective. 
As an illustration, we applied the model to the problem of skin sensitisation hazard 
assessment. We quantified the ܧܸܶܫ௜ net of testing costs for a set of validated or pre-validated 
non-animal methods (including the DPRA, the OECD Toolbox, the ARE-Nrf2 luciferase method 
covered by KeratinoSensTM and LuSens, and the h-CLAT), seven battery combinations of these 
methods, and 236 sequential 2-test and 3-test strategies composed of these methods. Their 
ܧܸܶܫ௜ net of testing costs was compared with that of the animal test LLNA. Social benefits and 
costs from the release of cosmetic ingredients to the market were calculated by estimating 
industry’s marketing gains and health damage costs caused by ACD. Clearly, the numerical 
estimates used in our study and, in particular, estimates of marketing benefits and health 
damage costs, may vary across countries and between chemicals. 
The impact of variations in health damage costs was analysed by means of a sensitivity 
analysis. Moreover, the predictive capacity of non-animal testing methods and their 
combinations depends on the number and the selection of substances in the training set. 
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Therefore, ܧܸܶܫ௜ estimates can vary if training sets are composed differently. In addition, 
conditional dependence between individual non-animal testing methods may affect their joint 
sensitivity and specificity when used in combination. Accounting for this uncertainty, e.g. by 
using categorical data analysis (Zauba), might change the predictive capacity of testing 
methods and, following on from this, their ܧܸܶܫ௜. Since the main purpose of our study was to 
illustrate the features of decision-theoretic VOI analysis, a detailed assessment of these 
uncertainties is beyond the scope of this paper, but remains an interesting aspect for further 
research. 
Our results warrant a number of interesting conclusions. Firstly, the value of 
combinations of non-animal testing methods outweighs that of the LLNA. This is a robust 
result, because it holds for both battery and sequential combinations, for the entire range of 
prior beliefs, and for all the sensitisation prevalence estimates considered. Furthermore, 
sequential combinations of batteries can outperform individual battery combinations of non-
animal methods. In our case study, this became already apparent at relatively low prior 
beliefs. One explanation for this result is the higher predictive capacity of battery 
combinations in comparison to individual non-animal methods, which reduces the probability 
of adopting erroneous decisions. More importantly, sequential testing strategies offer the 
possibility to save on testing methods, and, therefore, on testing costs. The reason is that, 
depending on the outcomes at previous stages in the sequence, follow-up testing methods 
would not be conducted in any case. This “cost-saving potential” of sequential testing 
strategies results in a higher ܧܸܶܫ௜ compared to battery combinations of testing methods. 
Secondly, for given predictive capacities of non-animal methods, payoff estimates and 
testing costs, the optimal order of tests is highly sensitive to a decision-maker’s prior beliefs. 
Hence, unlike the approach suggested in REACH and recent studies on the testing of skin 
sensitisation (Bauch et al., 2012; Basketter et al., 2012; van der Veen et al., 2014a), our results 
underline that there cannot be a pre-defined ‘best approach’ to testing. In contrast, 
determining the optimal testing strategy must consider the trade-offs between expected gains 
and costs, while accounting for the uncertainties inherent in all parameters. 
Finally, our results illustrate that full coverage of all key events in the skin sensitisation 
AOP is neither a necessary nor a sufficient condition for combinations of non-animal testing 
methods revealing a higher ܧܸܶܫ௜ net of testing costs than the LLNA. However, this only holds 
if the key events of an AOP are known. Therefore, further research should address possible 
extensions of the decision-theoretic VOI model to permit the identification of the optimal 
combination of methods for endpoints where knowledge about the AOP is still incomplete. 
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Likewise, there is no reason to assume that a non-animal testing strategy must necessarily 
cover each key event in the sensitisation AOP just once. Since information outcomes of 
individual non-animal testing methods are uncertain, there is a probability that the prediction 
is wrong. If different non-animal testing methods are combined into a battery, uncertainties of 
individual methods can compensate each other, which reduces the probability of erroneous 
predictions. As our results show, it can therefore be optimal to combine batteries of non-
animal methods into a sequence, even though this might repeatedly address the same key 
event in the AOP. In other words: From a decision-analytic perspective, the AOP concept can 
neither be understood as a rule for the combination nor for the order of non-animal testing 
methods in a sequence. 
Clearly, the numerical results of our analysis depend on model assumptions and the 
quality of the data used. Furthermore, we focused on non-occupational exposure for the 
calculation of sensitisation prevalence. The inclusion of occupational exposure may increase 
estimated health damage costs, which changes the ܧܸܶܫ௜ of the testing methods. Since this 
applies symmetrically to all testing methods and testing strategies, the ranking of methods 
will remain unchanged. The calculation of expected payoffs was based on simplified 
assumptions due to lacking data, for example about substance-specific benefits for 
intermediate consumers. The model can, however, be used straightforwardly, to investigate 
the impact of increasing or decreasing social benefits and costs on the ܧܸܶܫ௜ net of testing 
costs — for example, if in-house marketing data for substance groups or particular substances 
are available, or if testing costs change over time. Finally, although our case study was 
characterised by high health damage costs in relation to marketing benefits and testing costs, 
this may not hold for all endpoints. Hence, expanding the analysis to other endpoints and non-
animal testing methods will offer further insights into the potential of non-animal testing 
methods to replace animal testing. 
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4 The borderline range of prediction models for skin 
sensitisation potential assessment: Quantification and 
implications for evaluating non-animal testing methods’ 
precision3 
Testing methods to assess the skin sensitisation potential of a substance usually use 
threshold criteria to dichotomise continuous experimental read-outs into “yes/no” 
conclusions. The threshold criteria are prescribed in the respective OECD test guidelines and 
the conclusion is used for regulatory hazard assessment, i.e. classification and labelling of the 
substance. Due to biological and technical variability we can identify a borderline range (BR) 
around the classification threshold within which test results are non-conclusive. We quantify 
the BR of the prediction models of the non-animal testing methods DPRA, LuSens and h-CLAT. 
The borderline ranges were between r 10% and r 30% of the respective testing methods’ 
thresholds. We find that of the 199, 79 and 40 substances tested 20, 5 and 8 (10%, 6% and 
20%) were borderline with the DPRA, LuSens and the h-CLAT, respectively. If the results of 
individual non-animal test methods are combined into integrated testing strategies (ITS), 
borderline test results of individual tests can affect the overall assessment of the skin 
sensitisation potential of the testing strategy. This was analysed for the “2 out of 3” ITS: Four 
out of 40 substances (10%) were actually borderline. This compares to six out of the 22 
(27%) performance standard substances of the LLNA. Based on our findings we propose 
expanding the standard binary classification of substances into “positive/negative” or 
“hazardous/non-hazardous” by adding a “borderline” or “‘non-conclusive” alert for cases 
where test results fall within the borderline range. 
 
  
                                                        
3 Chapter 4 is an earlier version of the manuscript: Leontaridou M., Urbisch D., Kolle S.N., Ott K., Mulliner D.M., 
Gabbert S. and Landsiedel R., (2017). The borderline range of toxicological methods: Quantification and 
implications for evaluating precision (ALTEX in press doi: 10.14573/altex.1606271.). 
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4.1 Introduction  
Skin sensitisers are substances that can lead to an allergic response following skin contact 
(UNECE, 2011). An individual will be sensitised upon first contact. Subsequent contact can 
then provoke allergic contact dermatitis (ACD). It is estimated that ACD affects about 20% of 
the European and North American population at least once in their lifetime, although there is 
considerable variation of skin sensitisation prevalence between different age-sex groups 
(Thyssen et al., 2007). Data on skin sensitisation potential have to be provided for all 
substances produced or manufactured above one tonne per year under the European 
chemicals legislation REACH, and for classification and labelling of substances under the 
European CLP regulation (ECHA, 2016). The assessment of a substance’s skin sensitisation 
potential has been traditionally based on data derived from animal tests such as the guinea 
pig based tests described in OECD TG no. 406 (OECD, 1992) or the murine local lymph node 
assay (LLNA) described in OECD TG no. 429 (OECD, 2002; OECD, 2010). However, animal 
welfare concerns, and the regulatory enforcement e.g. by the Cosmetics Regulation (EC, 2009) 
and the REACH legislation (EC, 2006) have driven efforts to move away from animal to non-
animal testing. A number of non-animal testing methods have been developed (Mehling et al., 
2012; Reisinger et al., 2015), two of which, namely the Direct Peptide Reactivity Assay (DPRA) 
(Gerberick et al., 2004; Gerberick et al., 2007) and the antioxidant response element - nuclear 
factor erythroid 2 (ARE-Nrf2) luciferase testing methods covered by KeratinoSensTM (Natsch 
et al., 2011), have been validated by the European Centre for Validation of Alternative 
Methods (ECVAM; Italy) and are described in the OECD TG no. 442C and no. 442D (OECD, 
2015a; OECD, 2015b). LuSens (Ramirez et al., 2014; Ramirez et al., 2016) also covers the ARE-
Nrf2 luciferase testing method and is currently undergoing validation. Another non-animal 
testing method, the human cell line activation test (h-CLAT) (Ashikaga et al., 2006; Sakaguchi 
et al., 2006; Ashikaga et al., 2010; Sakaguchi et al., 2010) has recently been validated by 
ECVAM and is described in OECD TG no. 442E (OECD, 2016d). The sequential structure of 
molecular and cellular mechanisms causing ACD is represented by the “adverse outcome 
pathway” (AOP) for skin sensitisation, consisting of eleven causally linked steps, four of which 
were defined to be essential and specific “key events” (OECD, 2012b; OECD, 2012c). The 
DPRA, the ARE-Nrf2 testing methods and the h-CLAT cover the first three key events of the 
skin sensitisation AOP.  
For hazard classification purposes, i.e. for assessing skin sensitisation potential, 
continuous data obtained from animal tests or from non-animal testing methods are 
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dichotomised into binary “positive/negative” information (van der Schouw et al., 1995; 
Hoffmann and Hartung, 2005). The prediction models used for the DPRA, LuSens and the h-
CLAT are described in OECD TG no. 442C (OECD, 2015a), Ramirez et al. (2014 and 2016), and 
in the OECD TG no. 442E (OECD, 2016d), respectively. Based on the threshold for 
classification a testing method’s accuracy, i.e. the percentage of true positive and true negative 
classifications, can be determined (see for example (Cooper et al., 1979)and (Yerushalmy, 
1947)). 
The experimental data obtained from a testing method are, however, subject to biological 
and technical variability. As a consequence, repeated testing may result in discordant 
classification results. This impacts the precision of a testing method, defined as the ability of a 
testing method to deliver concordant results in repeated applications. The problem of intra- 
and inter-assay variability of in vitro methods has been observed earlier (see Hothorn (2002 
and 2003)). Luechtefeld et al. (2016) pointed to a limited intra-assay reproducibility of skin 
sensitisation potential and potency data. 
This chapter focuses on the intra-assay variability of testing methods for skin sensitisation 
potential assessment. Specifically, we analyse limitations with regard to the reproducibility of 
results when continuous dose-response data are transformed into “toxic/ non-toxic” 
outcomes. Kolle et al. (2013), Hoffmann (2015), Dumont et al., (2016), and Dimitrov et al. 
(2016) analysed the intra-assay variability of the LLNA. Kolle et al. (2013), showed that 
outcomes of repeated testing of a substance are not always concordant. Specifically, for those 
substances for which the estimated concentration (EC3) leads to a simulation (SI) index value 
which was relatively close to the threshold for classification (i.e. SI = 3; Kolle et al., 2013), 
different classifications: Positive or negative for skin sensitisation can result. Kolle et al. 
(2013), defined a range around the classification threshold of the LLNA, within which 
discordant outcomes can be expected, by determining coefficients of variation based on 
individual animal data. This range is called “borderline range” (BR) (Kolle et al., 2013), or 
“grey zone” (Dimitrov et al., 2016). The percentage of substances falling into the BR of a 
testing method’s prediction model can be used as a measure of the, i.e. the intra-assay 
variability, i.e. the testing method’s limited precision. 
Analyses of the BR for non-animal testing methods used for skin sensitisation potential 
assessment have not been conducted so far. Furthermore, a comparative evaluation of the 
precision of non-animal testing methods and the LLNA has not become available. The aim of 
this chapter is, therefore, to fill this gap by examining the impact of technical and biological 
variability on the precision of selected non-animal testing methods for skin sensitisation 
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potential assessment. Moreover, we compare the precision of the non-animal testing methods 
with that of the animal test LLNA. For this purpose the BR was quantified for the non-animal 
testing methods DPRA, LuSens, h-CLAT and the LLNA, based on results revealed from a large 
number of experiments (Appendix A). The approach for quantifying the BR and the decision 
rules for detecting borderline substances in experimental samples are explained in Section 
4.2. Results from quantifying the BR for each individual testing method are presented in 
Section 4.3.1. Borderline substances detected in the experimental samples of individual 
testing methods are shown in Section 4.3.2. Finally, Section 4.3.3 shows borderline substances 
for the “2 out of 3” ITS. Section 4.4 discusses implications from considering the BR in non-
animal testing methods’ prediction models and the “2 out of 3” ITS, respectively. Section 4.5 
concludes. 
4.2 Materials and methods  
4.2.1 Testing methods 
The three non-animal testing methods DPRA, LuSens, and h-CLAT were developed to 
address the three key events of the AOP in order to assess a substance’s skin sensitisation 
potential. We compared our findings to those of the LLNA as in vivo reference test to evaluate 
the precision of these methods. The samples used for quantifying the BR contained 42 
substances in case of the DPRA, 26 substances in case of LuSens, 13 substances in case of the 
h-CLAT, and 22 substances in case of the LLNA, respectively. The BR was quantified using 
results from a large number of runs of each testing method. Information about the samples 
used for determining the BR for each non-animal testing method and the LLNA, the number of 
runs conducted and the substance concentrations used in the experiments is provided in 
Appendix A, Tables A1-A4. Where substance names could not be provided due to data 
confidentiality substances were numbered consecutively. 
The experimental samples to which the BR concept was applied in order to detect 
borderline substances consists of 199 substances in case of the DPRA, 79 in case of LuSens, 40 
in case of the h-CLAT, and 22 substances in case of the LLNA; see Bauch et al. (2012) and 
Urbisch et al. (2015a, 2016). The composition of these samples is presented in Appendix B, 
Tables B1-B5. 
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4.2.1.1 Local lymph node assay 
The Local Lymph Node Assay (LLNA) is the “first choice” animal test for the assessment of 
skin sensitisation potential (Kimber et al., 1994). It is described in OECD TG 429, which was 
first published in 2002 (OECD, 2002)and updated in 2010 (OECD, 2010). In the LLNA, the 
proliferation of lymphocytes in auricular draining lymph nodes induced by substances is 
quantified by comparing the mean proliferation in each test group to the mean proliferation in 
the vehicle treated control group. The ratio of the mean proliferation in each treated group to 
that in the concurrent vehicle control group, termed the Stimulation Index (SI), is determined. 
The classification threshold of the LLNA is SI = 3. If SI > 3 a substance is classified a skin 
sensitiser.  
4.2.1.2 Direct peptide reactivity assay 
The Direct Peptide Reactivity Assay (DPRA) was developed by (Gerberick et al., 2004; 
Gerberick et al., 2007). The DPRA has been formally validated and the OECD Testing Guideline 
TG 442C (OECD, 2015a) was adopted in 2015. In the DPRA, depletions of two model peptides 
containing a cysteine- or lysine- residue as a reactive nucleophilic centre are measured after 
incubation with a test substance. The classification threshold of the DPRA is the mean 
depletion of 6.38% of the two peptides compared to the depletion in the reference 
controls(OECD, 2015a). If the mean lysine- and cysteine- peptide depletion is above this 
threshold, a test substance is considered to be peptide reactive. According to OECD TG 442C 
the DPRA can be used, together with complementary information, to discriminate sensitisers 
and non-sensitisers. Depending on the regulatory framework a positive result of the DPRA can 
serve as standalone information for classifying substances into Category 1 for skin 
sensitisation. However, as emphasised in the ECHA Guidance on information requirements 
and Chemical Safety Assessment Chapter R.4a (ECHA, 2016) the DPRA should not be used in 
isolation for identifying a skin sensitiser or non-sensitiser. 
4.2.1.3 ARE-Nrf2 luciferase method 
The ARE-Nrf2 luciferase method utilises the gene induction regulated by the antioxidant 
response element (ARE) in transgenic human keratinocyte cell lines. The OECD Test Guideline 
TG 442D (OECD, 2015b) was adopted in 2015. The ARE-Nrf2 luciferase method is covered by 
KeratinoSensTM (Natsch et al., 2011) and LuSens (Ramirez et al., 2014). In this study the 
LuSens assay is used. In ARE-Nrf2 luciferase methods the keratinocyte activating potential is 
determined by measuring luciferase induction after treatment with a test substance treatment 
relative to concurrent vehicle controls. A statistically significant fold induction (FI) of the 
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luciferase activity above 1.50 is considered to indicate a keratinocyte activating potential of a 
test substance. The classification threshold for LuSens is FI = 1.50, above which a substances 
is considered to have a keratinocyte activating potential. Similar to the DPRA, LuSens is not 
considered suitable for classifying substances as skin sensitisers or non-sensitisers when used 
in isolation (ECHA, 2016). 
4.2.1.4 Human cell line activation test  
The human Cell Line Activation Test (h-CLAT) (Ashikaga et al., 2006; Sakaguchi et al., 
2006; Ashikaga et al., 2010; Sakaguchi et al., 2010) determines the dendritic cell activating 
potential by measuring the induction of the expression of the cell surface markers CD54 and 
CD86 after treatment with a test substance relative to concurrent vehicle controls in 
immortalised human monocytic leukemia THP-1 cells as a surrogate of DCs. As indicated in 
the OECD testing guideline TG 442E (OECD, 2016d) a two-fold induction of the CD54 
expression and/or 1.50 fold induction of CD86 expression at relative cell viabilities of at least 
50% is considered to indicate a dendritic cell activating potential of a test substance. The 
classification thresholds for h-CLAT are CD54FI = 1.50 and CD86FI = 2.00. Like for the DPRA 
and LuSens, the method only addresses a specific key event of the skin sensitisation AOP. 
Consequently, it should not be used in isolation for classifying skin sensitisation potential 
(ECHA, 2016). 
4.2.1.5 The “2 out of 3” ITS for characterising skin sensitisation potential 
The “2 out of 3” ITS (Bauch et al., 2012; Urbisch et al., 2015a; OECD, 2016b; OECD, 2016c) 
is an integrated testing strategy for the assessment of skin sensitisation potential. According 
to this approach, 2 out of 3 concordant test results using the DPRA, the ARE-NrF2 luciferase 
method, and the h-CLAT determine the prediction. The ARE-NrF2 luciferase method can be 
covered by LuSens or KeratinoSensTM. The “2 out of 3” ITS addresses the first three 
consecutive key events of the AOP for skin sensitisation and it is a selected case study for 
integrated approaches to testing and assessment (IATA) (Urbisch et al., 2015a). Applying the BR 
concept to the “2 out of 3” ITS provides a measure for evaluating the performance of this 
specific DA case.  
4.2.2 Approach to quantify the borderline range (BR) 
The first step of the variability assessment was to quantify the BR. The BR denotes the 
area around the classification threshold for which a testing method’s prediction model may 
deliver discordant results. For each non-animal testing method considered, and for the animal 
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test LLNA, we derived the BR (Eq. 4.1) from the pooled standard deviation ܵܦ௣ (Eq. 4.2) of a 
testing method’s results (Appendix A), pooled across substances ݅ and concentrations ݆ used 
(i.e. the dose in case of the LLNA). For the specific case that test results are normally 
distributed, and the classification threshold is at the mean of the distribution, the BR covers 
~68% of the probability mass under the distribution of all test results. Note that the BR 
approach used in this paper goes beyond Kolle et al. (2013), who calculated the BR only for 
the LLNA and based on individual animal data. We use the pooled standard deviation ܵܦ௣ (Eq. 
4.2) to define the BR (Eq. 4.1) around a prediction model’s classification threshold T. Using the 
notation shown in Table 4.1 the BR is calculated as follows: 
 
ܤܴ = ൛ܶ − ܵܦ௣, ܶ + ܵܦ௣ൟ. (4.1) 
 
The pooled standard deviation of experimental results, retrieved from testing different 
substances and concentrations, is calculated as follows: 
 
ܵܦ௣ = ඨ
∑ ∑  ൫௥೔,ೕିଵ൯∗ఙ೔,ೕ
మೖ೔
ೕసభ
೙
೔సభ
∑ ∑ ൫௥೔,ೕିଵ൯
ೖ೔
ೕసభ
೙
೔సభ
, (4.2) 
 
where ߪ௜,௝
ଶ  is the variance of the testing methods’ test results for substance i and concentration 
݆. The standard deviation per substance i and concentration ݆ is given by  
 
ߪ௜,௝ =  ඨ
∑ (௬೔,ೕ,೗ିݕത݅,݆)
మ
ೝ೔,ೕ
೗సభ
(௥೔,ೕିଵ)
 . (4.3) 
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Table 4.1: Notation for calculating the pooled standard deviation ࡿࡰ࢖ of experimental results 
per substance and concentration (dose in case of the LLNA) according to Eq. 4.2 
Notation Explanation 
T Classification threshold in a testing method’s prediction model 
i Substance (݅ = 1, … , ݊) 
݊ Number of substances 
j Concentration tested per substance i (݆ = 1, … , ݇௜) 
݇௜  Number of concentrations per substance in the sample 
ݎ௜,௝  Number of runs per substance i and concentration j 
݈ Run per substance i and concentration j (݈ = 1, … , ݎ௜,௝) 
ݕ௜,௝,௟  Test result of substance I, concentration j and run ݈ 
ݕത௜,௝ Arithmetic mean of test results for substance i and concentration j  
 
The BR in case of the DPRA was quantified using results from repeatedly testing n = 42 
substances, yielding 446 runs (i.e. individual results) for different concentrations including 
the positive control (see Appendix A, Table A1), performed in a GLP-certified laboratory of 
BASF SE. The cysteine depletion of a given run was combined with the lysine depletion of a 
random run. This revealed pairs of cysteine and lysine depletion values. For each pair we 
determined the mean peptide depletion per substance and concentration. The BR was then 
calculated for test results revealing mean peptide depletion values between 3.38% and 9.38%. 
The BR in the prediction model of LuSens was calculated for test results from n = 26 
substances, including the positive and negative control, yielding 2206 runs (i.e. individual 
results) from different concentrations (see Appendix A, Table A2). Again, experiments were 
conducted in a GLP-certified laboratory of BASF SE (using the Multimode Reader TriStar2 
luminometer - Berthold Technologies, Germany), applying the classification threshold ܨܫ =
1.50. For each experiment, the BR was calculated for test results with luciferase fold-induction 
(FI) values up to 3.00 (ܨܫ < 3.00), and for test substance concentrations affording at least 
70% relative viability. For assessing whether an unknown substance should be classified 
borderline (or not) we first investigated whether results from each concentration tested in a 
certain run fell into the BR (or not). Following to this we defined a decision rule for concluding 
on the overall assessment across runs within experiments (see Section 4.2.3, Table 4.2). In a 
second step we defined a decision rule was determined guiding conclusions on the overall 
assessment (borderline/non borderline) across experiments (Section 4.2.3, Table 4.3). 
The BR around the classification threshold of the h-CLAT was calculated for test results 
from testing n = 13 substances during routine (in house) test applications, yielding 528 runs 
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(i.e. individual results) covering different concentrations (see Appendix A, Table A3). The BR 
was quantified for test results of fold inductions (FI) up to 3.00 fold for CD54 (CD54FI < 3.00) 
and up to 3.00 fold for CD86 (CD86FI < 3.00) for substance concentrations affording at least 
50% relative viability. Since according to the testing protocol (OECD, 2016d) an experiment 
does not have to be conducted for different concentrations we first classified the result from 
each run (positive, negative, borderline). In a follow-up step we defined a decision rule to 
conclude on the overall assessment across experiments (see also Section 4.2.3).  
Finally, the BR of the LLNA was quantified for test results from testing the n = 22 
performance standard (PS) substances (ICCVAM, 2009) according to good laboratory practise 
(GLP), yielding 479 runs (i.e. individual results) for substances at different concentrations, 
applying the classification threshold of ܵܫ = 3 (see Appendix A, Table A4). For determining 
the BR only those chemicals with an SI in the range between (2 ≤ SI ≤ 4) were considered. The 
reason is that chemicals with an SI far above or below SI = 4 were observed to be of no or only 
marginal impact on the BR. 
4.2.3 Decision rules for identifying borderline substances tested with individual non-
animal methods 
Given the BR around the classification threshold of each testing method we defined 
decision rules which guide, corresponding to the prediction model applied in each method, 
the identification of borderline substances in an experimental sample. 
In case of the DPRA, substances for which the mean depletion rate was found to be 
between 4.86% and 7.90% were defined borderline. The prediction model of LuSens as 
described in Ramirez et al. (2014) requires that two consecutive concentrations per run 
reveal results above (below) the classification threshold in order to assess the test substance 
as positive (negative). Thus, a complete experiment reveals at least two independent results. 
If they are discordant, a third run has to be conducted and the conclusion on a substance’s 
skin sensitisation potential is based on the majority outcome. For LuSens we established 
decision rules for determining the final result across all concentrations considered in 
repeated runs of an experiment (Table 4.3). Given the BR around the classification threshold 
of the LuSens prediction model (1.26 ≤ ܨܫ ≤ 1.74, see also Table 4.2) the outcome of an 
experiment was concluded to be positive (negative) if all results were above (below) the 
upper (lower) margin of the BR. If the first concentration (denoted x in Table 4.2) gave a 
negative result and the consecutive concentration (x+1) was either tested borderline or 
negative, it was concluded that the overall test outcome is negative. If LuSens revealed a 
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borderline result for a certain concentration x and the follow-up concentration (x+1) was 
tested borderline or positive, the substance was decided to be a borderline substance. 
 
Table 4.2: Decision rule for concluding on the overall test result of LuSens after two 
consecutive concentrations in a run 
Concentration x Concentration (x+1) Overall test result 
Non-animal testing 
method results 
N N N 
P P P 
B B B 
N B N 
B P B 
N: Negative test result, indicating that a substance has not a keratinocyte activating potential;  
P: Positive test results, indicating that a substance has a keratinocyte activating potential;  
B: Substances which fall within the BR.  
 
In case of the h-CLAT, at least one of the test results of either the CD54 expression or the 
CD86 expression from at least one of the runs in an experiment has to fall into the BR for 
qualifying an experimental result as borderline. Hence, the conclusion on the overall result of 
the experiment (positive, negative) is based on results from just one concentration. 
Finally, we established a decision rule allowing to conclude on the overall test result 
across experiments. This was necessary because the testing protocols for LuSens and the h-
CLAT require conducting two or more runs in order to classify a substance according to the 
results. The decision rules for the final conclusion on a substance’s skin sensitisation potential 
across all possible runs conducted are shown in Table 4.3: 
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Table 4.3: Decision rules for LuSens and the h-CLAT to conclude on the overall test result after 
seeing results from repeated runs 
Number of runsa 1 2 3 4 Overall conclusion 
Non-animal testing 
method result 
N N N N N 
P P P P P 
N N B B B 
P P B B B 
N N P B B 
P P N B P 
N P B B B 
N N B - N 
P P B - P 
N P B - B 
N: Negative test result, i.e. a substance does not have a keratinocyte activating potential for 
LuSens or a dendritic cell activating potential for h-CLAT;  
P: Positive test result, i.e. a substance has a keratinocyte activating potential for LuSens or a 
dendritic cell activating potential for h-CLAT;  
B: Substances for which test results fall within the BR for either LuSens or h-CLAT. 
a Test results 1, 2,3 and 4 don’t not imply fixed combinations. 
 
4.2.4 Decision rules for identifying borderline substances tested with the “2 out of 3” 
ITS 
Considering the BR of the prediction models of non-animal testing methods changes the 
possible outcomes of each method to be negative, positive, or borderline/ambiguous. Since 
test results of borderline substances can (by definition) not unambiguously be denoted 
positive or negative the respective substances cannot be compared with results from a 
reference animal test in order to conclude whether the test result is FP (i.e. erroneously 
classified as positive) or FN (i.e. erroneously classified as negative). The skin sensitisation 
potential is, however, assessed by a combination of the results of non-animal testing methods 
addressing different steps of the adverse outcome pathway (Jaworska, 2016; Kleinstreuer et 
al., 2016; Strickland et al., 2016). One of the simplest, yet successful, ways to do this, is the “2 
out of 3” ITS (Bauch et al., 2012; Urbisch et al., 2015a). The “2 out of 3” ITS uses dichotomised 
results of individual non-animal testing methods (i.e. positive or negative). If a 
borderline/ambiguous outcome of an individual testing method is considered in the “2 out of 
3” ITS, its overall conclusion of the skin sensitisation potential of a test substance may as well 
be borderline/ambiguous (or negative or positive). The “2 out of 3” ITS assigns equal weights 
to each testing method. Hence, the order of results of the individual methods does not matter. 
Consequently, one testing method yielding a borderline/ambiguous result will not change the 
overall result of the “2 out of 3” ITS, if the other two methods provided concordant – negative 
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or positive – results. If test results of prediction models of two non-animal testing methods fell 
into the BR, the overall outcome was borderline likewise, if the three methods yielded 
positive, negative and borderline/ambiguous results, respectively. Table 4 lists the overall 
outcome of the “2 out of 3” ITS depending on the results of the prediction models of the 
individual non-animal testing methods. 
 
Table 4.4: Decision rules to conclude on the overall result using the “2 out of 3” ITS when 
considering borderline substances in individual non-animal testing methods 
Non-animal 
testing methodsa 
First test 
result 
Second test 
result 
Third test 
result 
Overall 
conclusion 
Non-animal 
testing method 
results1 
N N N N 
P P P P 
B B B B 
N B N N 
P B P P 
N N B N 
P P B P 
N B B B 
P B B B 
N B P B 
N: Negative test result, i.e. a substance does not have a peptide reactivity potential for DPRA or 
a keratinocyte activating potential for LuSens or a dendritic cell activating potential for h-
CLAT;  
P: Positive test result, i.e. a substance has a peptide reactivity potential for DPRA or 
keratinocyte activating potential for LuSens or a dendritic cell activating potential for h-CLAT;  
B: Substances which fall within the BR for either the DPRA, LuSens or the h-CLAT. 
a The order of test results does not imply the order of performing the non-animal testing methods.  
 
4.3 Results  
4.3.1. Quantification of the borderline range (BR) for the DPRA, LuSens, the h-CLAT and 
the LLNA 
To quantify the BR around the classification threshold we used test results from 
substances tested with the non-animal testing methods DPRA, LuSens and h-CLAT, and from 
the LLNA, respectively. The number of substances with known skin sensitisation potential 
used to quantify the BR, the number of runs conducted per testing method, and the BR values 
of the testing methods’ prediction models, are shown in Table 4.5.  
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Table 4.5: Borderline range  (۰܀) around the classification threshold of the animal test LLNA, 
and of the non-animal testing methods DPRA, LuSens, and h-CLAT 
Testing method Number of substances (and runs) used for quantifying the BR* Borderline range (BR) 
LLNA 22 (96 runs) SI: 2.41 – 3.59 
DPRA 42 (76 runs) Mean peptide depletion: 4.86%– 7.9% 
LuSens 26 (473 runs) Luciferase FI: 1.26–1.74 
h-CLAT 
13 (513 runs) CD54 FI: 1.83–2.17 
13 (474 runs) CD86 FI: 1.27– 1.73 
BR: Borderline range;  
SI: Stimulation index;  
FI: Fold induction;  
CD54, CD86: Cell surface markers;  
See the Appendix A for a list of substances included in the experimental samples.  
* For details about the composition of the samples see also Appendix A, Tables A1-A4. 
 
If a substance is tested with any of the testing methods shown in Table 4.5, and if the 
result falls within BR of its prediction-model, a clear-cut conclusion about the substance’s skin 
sensitisation potential is not possible. If, for instance, a substance tested with the DPRA 
reveals a mean peptide depletion between 4.86% and 7.90%, the result can neither be 
concluded to be negative nor to be positive. Instead, such test result would have to be 
qualified as “borderline” because results from repeated runs of the DPRA for this substance 
are likely to vary. For the specific case that test results are distributed normally, and that the 
BR is the mean of the distribution, the likelihood that a randomly selected substance is 
borderline is ~68%. 
4.3.2 Identification of borderline substances in experimental samples tested with the 
non-animal testing methods DPRA, LuSens and h-CLAT, and with the animal test LLNA 
Substances for which test results fell within the BR of the prediction models of the non-
animal testing methods and the LLNA are listed in Table 4.6. We found that 6 out of 22 
substances tested in the LLNA (i.e. 27%) were identified as borderline.  
Of the borderline substances identified in the sample tested with the DPRA 9 revealed 
negative and 11 positive test results in the LLNA. Most substances with a negative test result 
were non-sensitisers based on LLNA potency classes. Four of the five substances for which 
test results were within the BR of LuSens revealed positive results in the LLNA. Of these, one 
was a weak, one a moderate and two strong sensitisers. Within the BR of h-CLAT all 
substances were positive when compared to the LLNA, three of which were weak sensitisers, 
one a moderate sensitiser, three were strong and one an extreme sensitiser.  
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Table 4.6: Borderline substances for the LLNA, the DPRA, LuSens, and the h -CLAT 
Testing 
method Borderline substances 
Sensitisation potentiala in 
mice or humans 
(by conventional approach, 
assessed without BRb) 
Potency class (based 
on LLNA) 
  LLNA Human  
LLNA Salicylic acidc N N Non-sensitiser 
 Methyl salicylatec N N Non-sensitiser 
 Chlorobenzenec N - Non-sensitiser 
 Nickel chloridec N P Non-sensitiser 
 Phenyl benzoatec P P Weak 
 Methyl methacrylatec P P Weak 
DPRA Salicylic acidc N N Non-sensitiser 
 α-Hexyl cinnamic aldehydec P - Weak / Moderate 
 Geraniol P P Non-sensitiser 
 Benzyl alcohol N P Non-sensitiser 
 Tween 80 N N Moderate 
 
3-Dimethylamino 
propylamine 
P P Weak 
 Cis-6-Nonenal P - Non-sensitiser 
 Ethyl vanillin N - Weak 
 Undecylenic acid P P Moderate 
 2-methoxy-4-methylphenol P - Non-sensitiser 
 Ethyl benzoylacetate N - Moderate 
 Dihydroeugenol P - Weak 
 N,N-Diethyl-m-toluanimde N - Non-sensitiser 
 Penicillin G P P Weak 
 d,l-Citronellol P N Weak 
 Pentachlorophenol P P Weak 
 
p-tert-Butyl-alpha-ethyl 
hydrocinnamal (Lilial) 
P P Weak 
 1-Bromobutane N - Non-sensitiser 
 Fumaric acid N N Non-sensitiser 
 Glucose N N Non-sensitiser 
LuSens 1-Butanol N N Non-sensitiser 
 Benzoyl peroxide P P Weak 
 4-Allylanisole P - Extreme 
 Methyldibromo glutaronitrile P P Strong 
 Imidazolidinyl urea P P Strong 
h-CLAT 4-phenylenediaminec P P Strong 
 Phenyl benzoatec P P Weak 
 Ethylene diaminec P P Moderate 
 Aniline P P Weak 
 Farnesal P - Weak 
 Methyldibromo glutaronitrile c P P Strong 
 p-Benzoquinone P P Extreme 
 Propyl gallatec P P Strong 
a Prediction based on (Urbisch et al., 2015a), human data were extracted from (Basketter et al., 2014); 
b N=negative, P=positive. 
c Performance Standards (PS) substances of the OECD TG no. 429 (ICCVAM, 2009; OECD, 2010). 
In case of the DPRA the percentage of substances falling into the BR was 10%, 6% in case of LuSens and 20% in case of the 
h-CLAT. 
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4.3.3 Identification of borderline substances in the experimental sample tested with 
the “2 out of 3” ITS 
We found four substances out of 40 (10%) of the substances tested with the “2 out of 3” 
ITS to be borderline (Table 4.7), which is equal or less than the percentages revealed in case 
of the DPRA and the h-CLAT individually. All substances were positive in the LLNA. Of these, 
one is a weak one is a moderate and two substances are strong sensitisers according to the 
LLNA potency classes.  
Table 4.7: Borderline substances in the experimental sample tested with the “2 out of 3” ITS  
Borderline substances Sensitisation potential
a in 
mice or humans 
Potency classes 
(based on LLNA) 
 LLNA Human  
Phenyl benzoate P P Weak 
Ethylene diamine P P Moderate 
Methyldibromo 
glutaronitrile P P Strong 
Propyl gallate P P Strong 
a Prediction based on (Urbisch et al., 2015a) human data were extracted from  
Basketter et al., (2014). 
 
4.4 Discussion  
4.4.1 Identification of borderline substances and implications of the BR for assessing 
substances’ skin sensitisation potential 
The BR defines the area around a testing method’s classification threshold within which 
repeated testing will likely show discordant results. That is, within the BR a testing method is 
not precise due to its intra-assay variability. Given the BR, conclusions about a borderline 
substance’s skin sensitisation potential are not possible. If a substance reveals test results 
falling within the BR, further testing is required to allow for a robust discrimination between 
a positive and a negative test outcome. The probability of an unknown substances to reveal a 
borderline result depends on the distribution of test results. For the specific case that test 
outcomes are normally distributed, and that the classification threshold is the mean of the 
distribution, the probability of seeing a borderline result is p = 0.68. This may differ for other 
types of distributions. Clearly, irrespective of the distribution of test outcomes the precision of 
a testing method is the higher (lower) the smaller (larger) the BR. 
In this study we quantified the BR for prediction models of three non-animal testing 
methods as the pooled standard deviation around the testing method’s classification 
threshold, the animal test LLNA, and the “2 out of 3” ITS. We find that 6 out of 22 (i.e. 27%) of 
the performance standard (PS) substances tested with the LLNA fall into its BR. This is slightly 
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higher than results obtained from the variability assessment in Hoffmann (2015), which may 
be explained by considering that Hoffmann (2015) determined the BR from EC3 values. 
For the DPRA 20 out of 199 (10%) substances were identified as borderline, of which four 
were positive and seven negative in the LLNA. Applying the BR concept to LuSens required 
two steps to identify borderline substances (i.e. BR quantification within and across runs of 
experiments, see Tables 4.2 and 4.3). LuSens has a stringent prediction model (Ramirez et al., 
2014; Ramirez et al., 2016). This may be a reason why LuSens revealed a relatively small 
percentage of borderline substances (6%, i.e. 5 out of 79). The application of the BR concept to 
the prediction model of the h-CLAT revealed 8 out of 40 substances (20%) being borderline. It 
should be noted that the prediction model of h-CLAT (Bauch et al., 2012) does not require 
concordant test results in consecutive concentrations of the same run to conclude on the 
substance’s skin sensitisation potential. Furthermore, concordant test results with either cell 
surface markers CD54 expression or CD86 expression from at least two runs within the same 
experiment are required to conclude on a positive or negative test result (OECD, 2016d). 
Compared to the h-CLAT, the prediction model of LuSens is more elaborate because for each 
run two consecutive concentrations must be tested to determine the final result. 
Consequently, the prediction model of h-CLAT (OECD, 2016d) identifies a larger number of 
positive results (Sakaguchi et al., 2010), which may explain why all borderline substances in 
the experimental sample of h-CLAT were sensitisers. 
 
4.4.2 Precision of non-animal testing methods compared to the LLNA  
Taking the percentage of borderline substances in an experimental sample as a measure 
of a testing method’s limited precision, we observe that this is considerably higher for the 
LLNA (27%) compared to the DPRA (10%), LuSens (6%) and the h-CLAT (20%). While this 
might be an indication for a larger imprecision of the LLNA compared to non-animal methods, 
the evidence provided in our study is not conclusive because experimental samples used 
differed across testing methods (24 PS substances in case of the LLNA, 199 substances for the 
DPRA, 79 substances for LuSens and 40 substances for the h-CLAT, respectively). Further 
research is required to examine the influence of sample size and composition on the 
quantification of the BR. 
Of the borderline substances in the experimental sample of the LLNA two (i.e. phenyl 
benzoate, methyl methacrylate) are weak sensitisers, and four (i.e. salicylic acid, methyl 
salicylate, chlorobenzene, nickel chloride) are non-sensitisers (Table 4.6). Most substances 
identified as borderline in the LLNA are also discussed in Kolle et al. (2013). Our study also 
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identified phenyl benzoate as borderline, causing the percentage of substances falling in the 
BR of the LLNA to be slightly higher (27%) compared to Kolle et al. (2013) (23%). Note, 
however, that Kolle et al. (2013) determined the BR by calculating coefficients of variation 
based on individual animal data and did not use pooled animal data in the LLNA. 
None of the substances identified as borderlines in the LLNA was borderlines in LuSens, 
one substance (salicylic acid) was also identified as borderline in the DPRA, and one 
substance (phenyl benzoate) was identified as borderline in the h-CLAT.  
4.4.3 Precision of the “2 out of 3” ITS 
Following the testing protocols for the DPRA (OECD, 2015a), LuSens (Ramirez et al., 2014; 
Ramirez et al., 2016) and the h-CLAT (OECD, 2016d) a single testing method cannot be used to 
predict skin sensitisation potential as a standalone method. The “2 out of 3” ITS has been 
suggested as a suitable approach for the overall assessment of the skin sensitisation potential 
based on the results of three individual testing methods (Urbisch et al., 2015a). Applying the 
BR concept to the “2 out of 3” ITS (Urbisch et al., 2015a) revealed four borderline substances 
in a set of 40 (10%), which is lower than that of the LLNA (27%). Our results, therefore, may 
indicate that the precision of the “2 out of 3” ITS is higher compared to the LLNA. Again, this 
result has to be treated with care because the experimental sample of the LLNA differed from 
that of the non-animal testing methods used in the “2 out of 3” ITS. Notwithstanding, the “2 
out of 3” ITS reduces the influence of borderline substances on the overall conclusion about a 
substance’s skin sensitisation potential for all cases where two of the three methods provide 
concordant results. This, in turn, increases the overall precision of the “2 out of 3” ITS 
compared to the precision of the individual non-animal testing methods. 
4.5 Conclusions 
Technical and biological variability of non-animal testing methods used for assessing skin 
sensitisation potential, and the animal test LLNA, influence the precision of these methods. It 
is important to recognise that neither the animal test LLNA, often considered “the gold 
standard”, nor non-animal testing methods perfectly predict effects in humans (due to limited 
accuracy) and do not always yield clear-cut results (due to limited precision). A testing 
method’s precision constraint caused by intra-assay variability can be captured by 
quantifying a BR around the classification threshold of the method’s prediction model, which 
are used to transform continuous experimental data into a dichotomous result, being either 
“positive” (indicating an effect) or “negative” (indicating no effect). Test substances for which 
results fall within the BR of a testing method could be assessed as positive or negative upon 
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re-testing; thus the result of the test is ambiguous. Quite obviously, any conclusion drawn 
from experimental data is constrained by uncertainties and this is often neglected in reporting 
the results. The BR may offer a simple and pragmatic way to take into account that not every 
experimental data allows for a definite conclusion. A measure of precision, such as the BR, 
should therefore be reported with every study result. Furthermore, when using prediction 
models which dichotomise data there should always be three potential outcomes: positive, 
negative or borderline. While the paper focused on skin sensitisation as a proof-of-concept 
case, the BR approach is a generic method and can be applied to other endpoints, tests, and 
ITSs. Further research should, for example, quantify the BR for a broader set of (non-animal) 
testing methods, and should also address the impact of the size and composition of 
experimental samples on the BR. Moreover, examining the precision of testing methods for 
continuous endpoints deserves further attention in order to provide complementary insights 
into testing methods’ precision regarding potency assessment (Slob, 2016). 
Another important issue for further research and discussion is how to deal with 
borderline test results in a regulatory context. One possible option could be to define 
borderline results per default as positive results. However, this would imply that the upper 
part of the BR is factually ignored. Alternatively, one could require additional testing. 
Decision-theoretic approaches such the Bayesian Value-of-Information approach introduced 
in Leontaridou et al. (2016) can help to determine the optimal follow-up test in a systematic 
and transparent way. Finally, the question how borderline substances impact testing 
methods’ predictive performance deserves further attention. Since for borderline substances 
the overall conclusion on their hazardous potential remains inconclusive, they cannot 
contribute unambiguously to the evaluation of a testing method’s accuracy. Ignoring a 
substance’s borderline result will, therefore, cause either over- or underestimation errors of, 
for example, a testing method’s sensitivity or specificity. Exploring the size and direction of 
this impact for different non-animal testing methods, and analysing the influence of the size 
and composition of experimental samples, will provide complementary insights into the 
implications of intra-assay variability. 
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5 Uncertainties in measures of predictivity: The impact of 
precision, sample size and sample composition on the predictive 
accuracy of non-animal methods for skin sensitisation 4 
The ability of non-animal methods to predict the outcome of in vivo testing is expressed in 
terms of a test's predictivity (or predictive accuracy) by comparing the results of both tests 
obtained with a given number of substances. The predictive accuracy depends on the sample 
size (i.e. the number of substances which were tested to determine it), the composition of the 
sample, and the precision of both methods. Non-animal methods use prediction models to 
transform continuous read-outs of the test into dichotomous results by applying threshold 
values above and below which the test substance is assessed as positive or negative. Due to 
intra-test variability the precision of any testing method is limited. This results in a 
“borderline range” rather than a clear-cut classification threshold. When calculating the 
predictivity of non-animal methods it is usually not taken into account that test results of 
substances falling into the borderline range are inconclusive. This chapter explores the impact 
of intra-test variability on the predictivity of non-animal testing methods for assessing skin 
sensitisation potential. We quantity the impact a method’s limited precision on the predictive 
accuracy of the DPRA assay, the ARE-Nrf2 luciferase method (covered by LuSens), the h-CLAT 
assay, and a combination of these methods into the “2 out of 3” integrated testing strategy. In 
addition, we examine impacts of intra-test variability on testing methods’ predictivity caused 
by limited precision in combination with varying composition and size of experimental 
samples. Our results underline that discrete “positive/negative” outcomes are of limited 
informational value for evaluations of non-animal testing methods’ predictivity. Instead, 
information on the variability, and the upper and lower limits of accuracy metrics should be 
provided to ensure transparent assessments and comparisons of testing methods’ 
predictivity. 
  
                                                        
4 Chapter 5 is based on the manuscript in preparation: Leontaridou M., Gabbert S., Landsiedel R., (2017) 
Uncertainties in measures of predictivity: The impact of precision, sample size and sample composition on the 
predictive accuracy of non-animal methods for skin sensitisation. 
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5.1 Introduction 
It has been widely acknowledged that binary “positive/negative” or “yes/no” outcomes 
have limited informational value regarding the “true” accuracy of non-animal testing methods, 
i.e. the degree of agreement between experimental results obtained and a corresponding 
(animal) reference test. Several studies pointed to possible biases in non-animal testing 
methods’ accuracy metrics due to inter- and intra-laboratory variability (Agnese et al., 1984; 
Margolin et al., 1984; Hothorn, 2002; Hothorn, 2003), which hampers a transparent 
comparison of non-animal testing methods predictivity with that of the animal test. Likewise, 
previous research revealed that animal test results can be biased due to technical and 
biological variability (Weil and Scala, 1971; Worth and Cronin, 2001b). 
Recent research has paid specific attention to the intra-test variability of methods used for 
assessing skin sensitisation potential. Specifically, for the classification of substances’ 
hazardous potential both animal and non-animal testing methods apply prediction models 
using defined threshold values that dichotomise continuous experimental results into binary, 
i.e. positive and negative, outcomes (van der Schouw et al., 1995; Hoffmann and Hartung, 
2005). Results from binary classifications are used to determine a testing method’s predictive 
accuracy compared to a reference test (e.g. the LLNA, (OECD, 2010)). Comparing experimental 
results obtained with a non-animal testing method with animal data allows quantifying the 
fractions of substances revealing true positive (TP), true negative (TN), false positive (FP), or 
false negative (FN) results (Krzanowski and Hand, 2009). Based on these fractions, a non-
animal testing method’s predictive accuracy, e.g. sensitivity, specificity, and concordance (also 
called “accuracy”) can be determined. Predictive accuracy metrics specify a non-animal 
testing method’s ability to correctly classify an unknown substance compared to the reference 
animal test. 
For the LLNA (Kolle et al., 2013; Hoffmann, 2015; Dumont et al., 2016) analysed the 
variability of classifications caused by a dichotomisation of continuous read-outs into discrete 
“positive/negative” data. In particular, Kolle et al. (2013) determined a range around the 
classification threshold within which the LLNA reveals discordant results in repeated 
applications. This range has been called “grey zone” (Dimitrov et al., 2016) or “borderline 
range” (BR) (Kolle et al., 2013). Hence, for substances yielding test results within the BR, 
clear-cut classifications of their skin sensitisation potential is not possible. This limits the 
LLNA’s precision, i.e. its ability to reveal concordant results in repeated applications. 
Leontaridou et al. (2017a) quantified the BR for the LLNA and the non-animal testing methods 
DPRA, LuSens and h-CLAT. Furthermore, their study determined borderline substances for 
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the “2 out of 3” integrated testing strategy (ITS), consisting of the non-animal testing methods 
mentioned above. The analysis showed that the number and percentage of substances 
considered borderline can be significant.  
Clearly, substances with ambiguous hazard classification cannot contribute to 
determining a testing method’s predictive accuracy. As a consequence, ignoring the BR in a 
testing method’s prediction model – and, hence, the limited precision – may bias the 
assessment of classification accuracy. This hampers meaningful comparisons of accuracy 
metrics between non-animal testing methods and the reference animal test, e.g. for regulatory 
validation purposes. Besides the specification of the classification threshold, testing methods’ 
accuracy depends on the size and composition of experimental samples. Apart from using 
defined reference substances (denoted “proficiency chemicals”) (see Annex 2 of the DPRA 
OECD guideline (OECD, 2015a), Annex 2 of the ARE-Nrf2 luciferase method OECD guideline 
(OECD, 2015b), and Annex 2 of the h-CLAT OECD TG no. 442E (OECD, 2016d)), the 
composition and the size of the experimental samples depend on various considerations, e.g. 
the availability of robust reference data (i.e. in vivo and human data if applicable) , the number 
of substances falling into each of the sensitisation potency classes and the number of 
sensitisers and non-sensitisers (ECVAM, 2012; ECVAM, 2013). Hence, the composition and the 
number of substances included in experimental samples can vary considerably. Furthermore, 
there is no defined minimum number of substances below which an experimental sample 
would be considered insufficient for robust evaluations of non-animal testing methods’ 
predictive accuracy. This induces additional bias, which can even interact with biases caused 
by testing methods’ limited precision. 
So far, however, the impact of possible biases in the calculation of the abovementioned 
predictive accuracy metrics has not been systematically analysed. The aim of Chapter 5 is to 
fill this gap. We examine the impact of the limited precision on sensitivity, specificity and 
concordance of the non-animal testing methods DPRA, LuSens, and the h-CLAT. Currently, 
none of these methods is considered to provide sufficient information for classification as a 
standalone method (Mehling et al., 2012; Reisinger et al., 2015; ECHA, 2016). Combinations of 
these methods, for example the “2 out of 3” ITS (Bauch et al., 2012; Urbisch et al., 2015a), are 
assumed to provide sufficient information for concluding on a substance’s skin sensitisation 
potential. We therefore also include the “2 out of 3” ITS in the analysis. 
The impact of classification bias is analysed in four steps: First, we examine the impact of 
non-animal testing methods’ limited precision on predictive accuracy metrics. This is done by 
comparing sensitivity, specificity and concordance derived from experimental samples 
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including borderline substances (i.e. the complete sample) with accuracy values obtained 
after borderline substances were excluded (i.e. the reduced sample). Second, we apply non-
parametric bootstrapping (Wehrens et al., 2000) to create randomised experimental samples 
for every non-animal testing method considered. This generates distributions of sensitivity, 
specificity and concordance. Quantifying the mean, the standard deviation, and the 95% 
confidence interval for all accuracy metrics and compare the mean accuracy metrics to those 
from deterministic samples illustrate the impact of sample composition on classification bias. 
Third, we examine the joint impact of limited precision and sample composition by comparing 
accuracy metrics from randomised complete samples (i.e. including borderline substances) 
with those retrieved from reduced samples (i.e. excluding borderline substances). Finally, the 
joint impact from variations of sample composition, size and limited precision on 
classification accuracy is analysed. 
The remainder of the chapter is structured as follows. Section 5.2 presents the 
methodological approach. We briefly explain the method to assess precision and document 
the experimental datasets used. In addition, we explain the scenarios for analysing the impact 
of classification bias on accuracy metrics. Section 5.3 discusses results from examining the 
impact of limited precision, sample size and sample composition on the predictive accuracy of 
non-animal testing methods. Section 5.4 discusses implication from our findings for assessing 
and comparing accuracy across non-animal testing methods, and between non-animal testing 
methods and the animal test. Section 5.5 concludes. 
5.2 Materials and methods  
5.2.1 Non-animal testing methods for assessing skin sensitisation potential  
Skin sensitisation is a key endpoint for safety evaluations of new and existing substances 
in different regulatory frameworks of the European Union (e.g. the REACH legislation (EC, 
2006), the Cosmetics regulation (EC, 2009)). Skin sensitisers cause allergic responses after 
contact (UNECE, 2011), from which about 15% to 20% of the population suffers at least once 
in a lifetime with increasing prevalence (Thyssen et al., 2007; Peiser et al., 2012). Responding 
to the urgent need to minimise animal testing, several non-animal testing methods and 
integrated testing strategies have been developed (Mehling et al., 2012; Reisinger et al., 2015; 
Urbisch et al., 2015a). Of these, the Direct Peptide Reactivity Assay (DPRA) (Gerberick et al., 
2004; Gerberick et al., 2007), and the ARE-Nrf2 luciferase method covered by KeratinoSensTM 
(Natsch et al., 2011), were validated by European Centre for Validation of Alternative Methods 
(ECVAM), and OECD test guidelines 442C and 442D (OECD, 2015a; OECD, 2015b) have been 
adopted. The ARE-Nrf2 luciferase method is also covered by LuSens (Ramirez et al., 2014; 
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Ramirez et al., 2016), which is currently under validation by ECVAM. The human cell line 
activation test (h-CLAT) (Ashikaga et al., 2006; Sakaguchi et al., 2006; Ashikaga et al., 2010; 
Sakaguchi et al., 2010) has recently been validated by ECVAM and is described in OECD TG no. 
442E (OECD, 2016d). The DPRA, KeratinoSensTM or LuSens and the h-CLAT cover the three 
“key events” of the skin sensitisation adverse outcome pathway (AOP) (OECD, 2012b; OECD, 
2012c).  
In case of the DPRA (Gerberick et al., 2004; Gerberick et al., 2007), depletions of two 
model peptides containing a cysteine- or lysine residue as a reactive nucleophilic centre are 
measured after incubation with a test substance. If the mean cysteine- and lysine- peptide 
depletion is above 6.38%, when compared to depletion in the reference control, the test result 
is positive and the substance is considered to be peptide reactive. 
For determining the keratinocyte activating potential induced by LuSens (Ramirez et al., 
2014; Ramirez et al., 2016), the luciferase induction after treatment with a test substance is 
assessed relative to concurrent vehicle controls. If a statistically significant fold induction (FI) 
of the luciferase activity is above 1.5, at relative cell viabilities of at least 70%, the test result is 
positive and the substance is considered to have a keratinocyte activating potential. 
In case of the h-CLAT (Ashikaga et al., 2006; Sakaguchi et al., 2006; Ashikaga et al., 2010; 
Sakaguchi et al., 2010) the induction of the expression of the cell surface markers CD54 and 
CD86 is measured after treatment with a test substance, relative to concurrent vehicle 
controls in immortalized human monocytic leukemia THP-1 cells as a surrogate of DCs. If at 
least a two-fold induction of the CD54 expression and/or a 1.50-fold induction of CD86 
expression are observed at relative cell viabilities of at least 50%, the test result is positive 
and the substance is considered to indicate a dendritic cell activating potential.  
The “2 out of 3” ITS (Bauch et al., 2012; Urbisch et al., 2015a) combines test results from 
the DPRA, the ARE-Nrf2 luciferase method (covered by either LuSens or KeratinoSensTM) and 
the h-CLAT. Equal weights are attached to each of the non-animal testing methods, which 
capture the three key events of the skin sensitisation AOP. The overall classification of a 
substance is determined by the majority of concordant test results from the DPRA, LuSens or 
KeratinoSensTM and the h-CLAT, respectively.  
5.2.2 Quantification of the borderline range 
Due to biological and technical variability we can identify a borderline range (BR) around 
the classification threshold within which test results can neither be classified positive or 
negative, but they must be reported as “non-conclusive” or “ambiguous” (Leontaridou et al., 
2017a). The BR, therefore, constraints a testing method’s precision. Leontaridou et al. (2017a) 
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quantified the BR around a testing method’s classification threshold (T) as the pooled 
standard deviation (ܵܦ௣) of test results from runs of testing methods, pooled across 
substance i and concentration j used. The quantification of the borderline rage is described in 
detail in Chapter 4 Section 4.3.1 of this thesis. 
Using experimental results for the DPRA, LuSens, the h-CLAT and for the “2 out of 3” ITS 
published in (Bauch et al., 2012; Urbisch et al., 2015a), Leontaridou et al. (2017a) identified 
20 substances out of 199 tested with the DPRA (10%), 5 out of 79 tested with LuSens (6%), 
and 8 out of 40 tested with the h-CLAT (20%) to be borderline when compared to results 
from the LLNA. For the “2 out of 3” ITS, 4 of 40 substances (10%) were identified as 
borderline. 
5.2.3 Calculation of testing method’s accuracy metrics 
The predictive accuracy of non-animal testing methods and of the “2 out of 3” ITS 
approach was determined by means of three accuracy metrics, i.e. sensitivity, specificity, and 
concordance. Using standard 2x2 contingency tables (Cooper et al., 1979) the number of true 
positive (TP), true negative (TN), false positive (FP), and false negative (FN) experimental test 
results of each non-animal testing method was determined when compared to LLNA and 
human data. The accuracy metrics sensitivity (ܵ݁), specificity (ܵ݌) and concordance (ܥ݋݊) 
were quantified as follows: 
 
ܵ݁ [%] =
்௉
்௉ାிே
∗ 100, (5.1) 
 
ܵ݌ [%] =
்ே
்ேାி௉
∗ 100, (5.2) 
 
ܥ݋݊ [%] =
்௉ା்ே
்௉ା்ேାி௉ାிே
∗ 100. (5.3) 
 
5.2.4 Scenarios for analysing the impact of limited precision, sample size and sample 
composition on non-animal methods’ predictive accuracy 
To examine the impact of limited precision, sample size and sample composition on 
classification bias of non-animal testing methods we defined different scenarios, which are 
summarised in Table 5.1. 
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Table 5.1: Scenarios for assessing the impact of variations of precision, sample composition 
and sample size on non-animal methods’ predictive accuracy metrics  
 
Experimental sample 
sample size = ࢔ 
Randomised sample 
sample size = ࢔ 
Randomised sub-samples 
sample size < ࢔ 
Complete sample 
(including borderline 
substances) Scenario 1: Impact of 
limited precision on 
predictive accuracy 
metrics 
Scenario 2a: Impact of 
varying sample 
composition on 
predictive accuracy 
metrics 
Scenario 3a: Joint impact of 
varying sample 
composition and sample 
size on predictive accuracy 
metrics 
Reduced samples 
(excluding borderline 
substances) 
Scenario 2b: Joint impact 
of varying sample 
composition and limited 
precision on predictive 
accuracy metrics 
Scenario 3b: Joint impact of 
varying sample 
composition and size, and 
limited precision on 
predictive accuracy metrics 
 
First, we determined sensitivity (Eq. 5.1), specificity (Eq. 5.2) and concordance (Eq. 5.3) 
using the experimental datasets revealed for the DPRA, LuSens, the h-CLAT and the “2 out of 
3” ITS, and compared to both the LLNA and to human reference data (Natsch et al., 2011; 
Bauch et al., 2012; Urbisch et al., 2015a) (Scenario 1 in Table 5.1). The composition of 
experimental samples is documented in Table B1-B4 in the Appendix B. The tables show 
experimental test results for the non-animal testing methods when compared to the LLNA and 
to human data. 
Accuracy metrics were derived from experimental test results for the complete samples of 
substances (i.e. including the borderline substances) and for reduced samples (i.e. excluding 
the borderline substances). For ease of presentation, we confine the discussion on results 
revealed from experimental data compared to the LLNA as reference test. Results revealed 
from experimental samples using human data as reference are presented in the Appendix D. 
Table 5.2 shows the number of substances in the complete and the reduced samples used for 
calculating predictive accuracy metrics of the non-animal testing method and the “2 out of 3” 
ITS. 
 
Table 5.2: Number of substances (࢔) in the experimental samples used for calculating 
predictive accuracy metrics of non-animal testing methods and the “2 out of 3” ITS *. 
 
Complete samples 
(including borderline 
substances) 
Reduced samples 
(excluding borderline 
substances) 
Number and percentage of 
borderline substances 
DPRA 199 179 20 (10%) 
LuSens 79 74 5 (6%) 
h-CLAT 40 32 8 (20%) 
“2 out of 3”ITS 40 36 4 (10%) 
* Experimental data compared to the LLNA as reference test.  
Experimental data extracted from: Natsch et al., (2011); Bauch et al., (2012); Urbisch et al., (2015a). 
Source: Leontaridou et al. (2017a).  
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Second, accuracy metrics were calculated for randomised samples. This captures 
uncertainty of test results due to varying sample composition. We determined accuracy 
metrics for the complete sample (i.e. including borderline substances, Scenario 2a in Table 
5.1) and for the reduced sample (i.e. excluding borderline samples, Scenario 2b in Table 5.1). 
The latter offers a means to analyse the joint impact of sample composition and precision 
limitations on accuracy metrics. Randomisation was achieved by applying non-parametric 
standard bootstrap resampling analysis (Table 5.3). This method was used earlier by (Worth 
and Cronin, 2001b) to assess the variability of the Draize tissue scores. Our study applies a 
similar approach but focuses on the assessing the combined impact of varying sample 
composition and limited precision on non-animal methods’ accuracy. 
For every non-animal method and the “2 out of 3” ITS a set of m = 10,000 randomised 
samples (Efron and Tibshirani, 1993; Ostaszewski K. and Rempala G.A., 2000) was created by 
random replacement of the binary classifications obtained from experimental test results 
(Table 5.3, Step 1). The number of substances in randomised samples, denoted n, was equal to 
the number of substances in the complete and reduced experimental samples (column 2 and 3 
in Table 5.2). Randomised samples were assumed to be independent and identically 
distributed (Wehrens et al., 2000). For all randomised samples we determined sensitivity, 
specificity and concordance according to Eq. 5.1-5.3. This revealed non-parametric 
distributions of sensitivity, specificity and concordance for the complete samples (i.e. 
including borderline substances), and for the reduced samples (excluding borderline 
substances, see also Table 5.3, Step 2 and 3). For every distribution we determined the mean 
and the standard deviation (SD) according to Eq. (5.4) and (5.5): 
 
ܯ݁ܽ݊௔ =
∑ ௔೤
೤
భ
௠
, (5.4) 
 
ܵܦ = ට
∑ (௔೤ିெ௘௔௡ೌ)
೤
భ
௠ିଵ
, (5.5) 
 
with a denoting the accuracy metric which is determined from the randomised sample (thus 
ܵ݁∗, ܵ݌∗, ܥ݋݊∗), and y denoting the number of random samples (݉ = 10,000).  
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Table 5.3: Steps for conducting non-parametric standard bootstrap resampling analysis  
Step Description 
Step 1 
Bootstrap resampling with random replacement of experimental test results from the 
individual non-animal testing methods and the “2 out of 3” ITS.  
Step 2 
Quantification of a, thus sensitivity (ܵ݁∗), specificity (ܵ݌∗) and concordance (ܥ݋݊∗) for 
the bootstrap sample. 
Step3 m-fold repetition of step 1 and 2; ݉ = 10,000.  
Step 4 
Calculation of the mean, the standard deviation and the 95% confidence interval of the 
distributions obtained for sensitivity (ܵ݁∗), specificity (ܵ݌∗) and concordance (ܥ݋݊∗). 
 
In addition, we calculated confidence limits using the simple percentile method. 
Specifically, the 95% confidence interval (95% CI) was determined by the value 
corresponding to the 2.5% and 97.5% percentile in the bootstrap distribution of sensitivity, 
specificity and concordance, respectively (Table 5.3, Step 4).  
Third, we assessed accuracy metrics for randomised sub-samples of varying sizes 
(Scenario 3a and 3b in Table 5.1) in order to analyse the combined impacts of uncertainty in 
sample size and composition, and of limited precision on non-animal testing methods’ 
accuracy. Following the procedure outlined in Table 5.3 we calculated the mean, the SD and 
the 95% CI of the predictive accuracy metrics for each sub-sample including and excluding 
borderline substances. Sub-samples were ݊ = 10; 50; 100; and 150 substances for the DPRA 
(with random replacement from the experimental sample consisting of 199 substances), ݊= 
10; 20; 40 and 60 substances for LuSens (with random replacement from the experimental 
sample consisting of 79 substances), and of ݊ = 10 and 20 substances for the h-CLAT and the 
“2 out of 3” ITS (with random replacement from the experimental samples consisting of 40 
substances), respectively. 
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5.3 Results  
5.3.1 Impact of precision uncertainty on accuracy metrics of the DPRA, LuSens, the h-
CLAT and the “2 out of 3” ITS 
In this section we present the results from analysing the impact of borderline substances 
on accuracy metrics of the DPRA, LuSens, the h-CLAT and the “2out of 3” ITS. Accuracy 
metrics were derived from experimental results using the LLNA as reference test. Results 
obtained from testing using human reference data are shown in Table D1-D3 in Appendix D. 
Table 5.4: Impact of precision on predictive accuracy metrics of non -animal testing methods 
and the “2 out of 3” ITS* 
DPRA 
Complete samples  
(including borderline substances) 
 ݊ =199 
Sensitivity [%] 
Specificity [%] 
Concordance [%] 
76 
72 
75 
Reduced sample  
(excluding borderline substances) 
 ݊ =179 
Sensitivity [%] 
Specificity [%] 
Concordance [%] 
85 
80 
83 
LuSens 
Complete samples  
(including borderline substances) 
 ݊ =79 
Sensitivity [%] 
Specificity [%] 
Concordance [%] 
75 
70 
73 
Reduced sample  
(excluding borderline substances) 
 ݊ =74 
Sensitivity [%] 
Specificity [%] 
Concordance [%] 
77 
69 
74 
h-CLAT 
Complete samples  
(including borderline substances) 
 ݊ =40 
Sensitivity [%] 88 
Specificity [%] 87 
Concordance [%] 88 
Reduced sample  
(excluding borderline substances) 
 ݊ =32 
Sensitivity [%] 
Specificity [%] 
Concordance [%] 
82 
87 
84 
“2 out of 3” ITS 
Complete samples  
(including borderline substances) 
 ݊ =40 
Sensitivity [%] 
Specificity [%] 
Concordance [%] 
85 
93 
88 
Reduced sample  
(excluding borderline substances) 
 ݊ =36 
Sensitivity [%] 
Specificity [%] 
Concordance [%] 
82 
93 
86 
* Experimental data compared to the LLNA as reference test. 
Source: Own calculations. 
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5.3.2 Impact of uncertainty in sample composition and precision on accuracy metrics 
As a result of the non-parametric bootstrapping procedure we received for each 
individual non-animal testing method a distribution of accuracy metrics. For the DPRA and 
LuSens we found predictive accuracy metrics to be normally distributed, while for the h-CLAT 
and the “2 out of 3” ITS we observed a left-skewed distribution of accuracy metrics (see Table 
C13-C24 in the Appendix C).  
Randomisation causes the composition of substances in the samples to differ. 
Consequently, the number of borderline substances differed as well. The minimum and 
maximum number of substances in the reduced samples (i.e. after borderline substances were 
excluded) is shown in Table 5.5. 
 
Table 5.5: Minimum and maximum number of substances (࢔) in randomised samples resulting 
from bootstrap resampling, after borderline substances were excluded * 
Randomised 
sample size (݊) 
DPRA LuSens h-CLAT “2 out of 3” ITS 
Min 160 65 33 27 
Max 194 79 40 40 
* Experimental data compared to the LLNA as reference test. 
Source: Own calculations. 
 
Table 5.6 presents the mean and the SD (column 3), and the 95% CI (column 5) revealed 
from the distributions of sensitivity, specificity and concordance values. The table shows 
results obtained for the complete samples, i.e. samples including borderline samples 
(Scenario 2a in Table 5.1), reflecting the impact of variations in sample composition on 
accuracy metrics. Furthermore, the table documents the mean, the SD and the 95% confidence 
interval for distributions retrieved from the reduced samples (i.e. excluding borderline 
substances, scenario 2b in Table 5.1). This illustrates the joint impact of a varying sample 
composition and limited precision. 
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Table 5.6: Mean, Standard deviation (SD) and 95% confidence intervals of predictivity values 
of the DPRA, LuSens, the h-CLAT and the “2 out of 3” ITS determined from randomised 
experimental samples* 
  Mean ± SD 95%CI 
DPRA 
Complete samples (including 
borderline substances) 
Sensitivity [%] 76±4 (69;83) 
Specificity [%] 72±6 (60;83) 
Concordance [%] 75±3 (69;81) 
Reduced sample (excluding 
borderline substances) 
Sensitivity [%] 80±4 (73;86) 
Specificity [%] 74±6 (62;86) 
Concordance [%] 78±3 (72;84) 
LuSens 
Complete samples (including 
borderline substances) 
Sensitivity [%] 75±6 (63;87) 
Specificity [%] 71±9 (53;88) 
Concordance [%] 73±5 (64;83) 
Reduced sample (excluding 
borderline substances) 
Sensitivity [%] 77±6 (65;89) 
Specificity [%] 69±9 (51;87) 
Concordance [%] 74±5 (64;84) 
h-CLAT 
Complete samples (including 
borderline substances) 
Sensitivity [%] 88±7 (74;100) 
Specificity [%] 87±9 (67;100) 
Concordance [%] 87±5 (78;98) 
Reduced sample (excluding 
borderline substances) 
Sensitivity [%] 82±9 (62;100) 
Specificity [%] 87±9 (67;100) 
Concordance [%] 84±6 (71;96) 
“2 out of 3” ITS 
Complete samples (including 
borderline substances) 
Sensitivity [%] 85±7 (70;96) 
Specificity [%] 93± 7 (77;100) 
Concordance [%] 87± 5 (78;98) 
Reduced sample (excluding 
borderline substances) 
Sensitivity [%] 82±8 (64;96) 
Specificity [%] 93±7 (77;100) 
Concordance [%] 86±6 (74;97) 
* Experimental data compared to the LLNA as reference test. 
Source: Own calculations. 
 
5.3.3 Assessing the joint impact of uncertainty in sample size, sample composition and 
precision on accuracy metrics 
Determining the mean, the SD and the 95% CI of accuracy metrics allows analysing the 
joint impact of sample size and composition on predictive accuracy metrics of the DPRA, 
LuSens, the h-CLAT and of the “2 out of 3” ITS (scenario 3a in Table 5.1). Results are shown in 
Table 5.7. 
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Table 5.7: Mean, SD and 95% CI of accuracy metrics revealed for the DPRA, LuSens, the h -CLAT 
and the “2 out of 3” ITS for complete samples (i.e. including borderline substances) * 
 Sensitivity [%] Specificity [%]  Concordance [%] 
Sample size (݊) Mean ± SD 95%CI  Mean ± SD 95%CI  Mean ± SD 95%CI  
DPRA  
10 76±16 (43; 100) 71±29 (0; 100) 75±14 (50; 100) 
50 76±7 (61; 90) 72±12 (46; 93) 75±6 (62; 86) 
100 76±5 (66; 86) 72±8 (55; 87) 75±4 (66; 83) 
150 76±4 (68; 84) 72±7 (57 ;84) 75±4 (68; 81) 
199a 76±4 (69; 83) 72±6 (60; 83) 75±3 (69; 81) 
LuSens  
10 75±17 (38; 100) 70±28 (0.0; 100) 73±14 (40; 100) 
20 75±12 (50; 100) 70±19 (33; 100) 74310 (55; 90) 
40 75±9 (57; 91) 71±13 (44; 92) 73±7 (60; 88) 
60 75±7 (61; 88) 70±10 (50; 89) 73±6 (62; 85) 
79a 77±6 (65; 89) 69±9 (51; 87) 74±5 (64; 84) 
h-CLAT 
10 88±14 (56;100) 87±19 (40; 100) 87±10 (60; 100) 
20 88±9 (67; 1000 87±13 (57; 100) 87±7 (70; 100) 
40a 88±7 (74; 100) 87±9 (67; 100) 75±5 (64; 84) 
“2 out of 3” ITS  
10 84±15 (50; 100) 93±15 (50; 100) 87±10 (60; 100) 
20 85±10 (63; 100) 93±10 (67; 100) 88±7 (70; 100) 
40a 85±7 (70; 96) 93± 7 (77; 100) 87± 5 (78; 98) 
* Experimental data compared to the LLNA as reference test. 
a Number of substances in the experimental sample. 
Source: Own calculations. 
 
Finally, the parameters revealed for the distributions of sensitivity, specificity and 
concordance from reduced samples (i.e. after excluding borderline substances, scenario 3b in 
Table 5.1) offer insights into the joint impact of sample size variation and composition, and 
limited precision on predictive accuracy metrics (Table 5.8). Note that due to the 
randomisation of experimental samples the number of borderline substances within sub-
samples could vary. Thus, similar to Table 5.5 we can determine the minimum and maximum 
number of substances for all subsamples after excluding borderline substances, which is 
shown in column 1 of Table 5.8. Distribution parameters of accuracy metrics (columns 2-4) 
capture the range of sample sizes per sub-sample. 
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Table 5.8: Mean, SD and 95% CI of accuracy metrics revealed for the DPRA, LuSens, the h -CLAT 
and the “2 out of 3” ITS for reduced samples (i.e. excluding borderline substances) * 
 Sensitivity [%] Specificity [%] Concordance [%] 
Max. and min. number 
of substances in 
randomised, reduced 
sub-samples 
Mean ± 
SD 95%CI 
Mean ± 
SD 95%CI 
Mean ± 
SD 95%CI 
DPRA 
6-10 (݊  = 10) a 80±16 (43; 100) 74±30 (0; 100) 78±14 (50; 100) 
37-50 (݊ = 50) a 80±7 (65; 93) 74±13 (47; 95) 78±6 (66; 89) 
89-99 (݊ = 100) a 80±5 (70; 89) 74±9 (56; 90) 78±4 (69; 87) 
121-146 (݊ = 150) a 80±4 (72; 88) 74±7 (60; 88) 78±4 (71; 85) 
160-194 (݊ = 199) a 80±4 (73; 86) 74±6 (62; 86) 78±3 (72; 84) 
LuSens  
4-10 (k ݊ = 10) a 77±18 (40; 100) 69±29 (0.0; 100) 75±14 (44; 100) 
14-20 (݊ = 20) a 77±12 (50; 100) 69±19 (30; 100) 74±10 (53; 94) 
30-40 (݊ = 40) a 77±8 (59; 92) 69±13 (40; 93) 74±7 (60; 87) 
48-60 (݊ = 60) a 77±7 (63; 90) 69±11 (47; 89) 74±6 (63; 85) 
65-79 a (݊= 79) a 78±6 (65; 89) 69±9 (50; 86) 75±5 (64; 84) 
h-CLAT 
6-10 (݊ = 10) a 82±20 (33; 100) 87±20 (33; 100) 84±13 (56; 100) 
7-20 (݊ = 20) a 82±13 (50; 100) 87±13 (57; 100) 84±9 (65; 100) 
33-40 a (݊ = 40) a 82±9 (62; 100) 87±9 (67; 100) 84±6 (71; 96) 
“2 out of 3” ITS  
6-10 (݊ = 10) a 81±18 (40; 100) 93±15 (50; 100) 86±12 (60; 100) 
12-20 (݊ = 20) a 82±12 (56; 100) 93±10 (67; 100) 86±8 (68; 100) 
27-40 a (݊ = 40) a 82±8 (64; 96) 93±7 (77; 100) 86±6 (74; 97) 
* Experimental data compared to the LLNA as reference test. 
a Number of substances in the complete sub-samples. 
Source: Own calculations. 
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5.4 Discussion  
5.4.1 Precision uncertainty 
Acknowledging that borderline substances cannot be classified as “positive” or “negative”, 
we expected that predictive accuracy metrics derived from samples including borderline 
substances will differ from those where borderline substances were removed. Indeed, our 
results confirmed that accounting for the limited precision of the non-animal testing methods 
DPRA, LuSens, the h-CLAT, and the “2 out of 3” ITS, changed accuracy metrics (Table 5.4). 
However, this impact was not symmetric across all non-animal testing methods and the “2 out 
of 3” ITS. In particular, whereas for the DPRA, sensitivity, specificity and concordance 
increased after borderline substances were excluded from experimental samples, for the h-
CLAT all accuracy metrics derived from test results compared to the LLNA decreased 
considerably but remained almost unchanged when derived from substances compared to 
human data (see Table D3 in the Appendix D). For LuSens we observed a small increase of 
sensitivity and concordance but even a slight decrease of specificity values, respectively. For 
the “2 out of 3” ITS we found a decrease of sensitivity, whereas specificity remained 
unchanged and concordance slightly decreased when assessed with substances compared to 
the LLNA. Similar results were observed for the accuracy metrics when test results of the non-
animal testing methods were compared to human data (see Table D3 in the Appendix D).  
For individual non-animal testing methods the size and direction of the impact on 
accuracy metrics, when considering limited precision, depends on the composition of 
experimental samples. In addition, it depends on whether test results for borderline 
substances are above or below the classification threshold. If, as in the case of the DPRA, more 
borderline substances revealed results below the classification threshold (thus they would be 
classified as “negative” when ignoring precision), excluding these substances increases the 
faction of substances classified as “positive”, which in turn causes sensitivity to increase (see 
Eq. (5.3)). In contrast, test results of substances identified as borderline in the h-CLAT were all 
above the classification threshold (Leontaridou et al., 2017a). Hence, excluding these 
substances in order to correct for ambiguous classifications decreases specificity for the 
experimental sample with the LLNA as reference test (see Eq. (5.2)). In addition, since 
accounting for the BR changed the fractions of TP, TN, FP and FN classifications of the 
substances remaining in the sample, we also observed a slight decrease of sensitivity and 
concordance. In case of LuSens, only few substances were identified as borderline in the 
experimental sample (5 out of 79 substances, i.e. 6%; Leontaridou et al. 2017a). Due to the 
stringent prediction model of LuSens (Ramirez et al., 2014; Ramirez et al., 2016), the impact of 
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excluding these substances on the values of predictive accuracy metrics was only marginal. 
Likewise, the prediction model of the “2 out of 3” ITS, basing the overall conclusion about the 
skin sensitisation potential of a test substance on at least two concordant test results from the 
DPRA, LuSens or the h-CLAT, and assigning equal weights to each testing method, reduces the 
impact of borderline substances on predictive accuracy metrics. 
5.4.2 Impact of uncertainty in sample composition and precision on non-animal 
methods’ predictivity 
Determining accuracy metrics from randomised samples allows specifying their variation 
within the area under the probability distribution where predictive accuracy metrics are 
expected to lie. Depending on the composition of the randomised sample, accuracy metrics 
can be higher or lower compared to those quantified for the deterministic experimental 
samples. For all individual non-animal testing methods and the “2 out of 3” ITS the mean of 
the distributions of accuracy metrics corresponded to the values in the deterministic 
experimental samples. 
Our results illustrate that accounting for limited precision in combination with 
randomised sampling increased the mean sensitivity, specificity and concordance of the 
DPRA, but did not affect the variation of accuracy metrics. For LuSens, mean sensitivity 
slightly increased, whereas mean specificity decreased, but the SD remained unchanged. For 
the h-CLAT and the “2 out of 3” ITS we observed a clear decrease of mean sensitivity and a 
slight decrease of mean concordance, respectively. Accounting for uncertainty of sample 
composition and precision also led to a higher SD for distributions of sensitivity and 
concordance. Hence, the overall uncertainty of these metrics increased. Furthermore, we 
found the 95% confidence interval to increase for all accuracy metrics and methods 
considered. This underlines that capturing the variation of sample composition and limited 
precision causes the variability of accuracy metrics to increase and, hence, different types of 
uncertainties underlying to non-animal testing methods’ accuracy can accumulate. 
5.4.3 Impact of uncertainty in sample composition, sample size and precision on non-
animal methods’ predictivity 
Assessing the joint impact of varying sample size and composition, our results 
demonstrate that increasing the sample size decreases the variation of predictive accuracy 
metrics (given by the SD) and the 95% confidence limits for all individual non-animal 
methods and “2 out of 3” ITS. More specifically, for all individual methods and the “2 out of 3” 
ITS the SD of accuracy metrics from randomised sub-samples was found to be up to four times 
higher than the SD obtained from randomised full samples (i.e. including ݊ = 199, 79, and 40 
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substances for the DPRA, LuSens and the h-CLAT respectively). Furthermore, the 95% CI of 
predictive accuracy metrics was considerably larger, indicating that for very small sample 
sizes a robust assessment of predictive accuracy metrics cannot be provided. Apparently, 
variations of sample size in combination with varying sample composition (Scenario 3a in 
Table 5.1) had only marginal impact on the mean values of accuracy metrics. Very similar 
results for the SD and the 95% CI were obtained when considering limited precision in 
addition to uncertainty of sample size and composition also (Scenario 3b in Table 5.1, results 
see Table 5.8). This implies that the impact of uncertainty in sample size and sample 
composition has a dominant impact on intra-test variability of accuracy metrics. However, 
including limited precision in the assessment changed the mean of accuracy metrics’ 
distributions. 
Finally for the DPRA, we observed a stabilization of the SD and the 95% CI values at 
samples sizes of ݊≥100 substances, irrespective of whether borderline substances were 
included or excluded from the samples. Our findings suggest, therefore, that predictive 
accuracy metrics of the DPRA are not sufficiently robust when derived from samples 
containing ݊≤100 substances. Our results may have implications for the interpretation of 
predictive accuracy metrics presented in other studies. For instance, experimental samples 
used for validating the DPRA and the h-CLAT included 21 and 24 substances, respectively. In 
both validation reports substances were tested three times with the DPRA (in three different 
labs) (ECVAM, 2012), and four times (in four different labs) with the h-CLAT (ECVAM, 2013). 
Although the assessment of a non-animal testing methods’ predictive accuracy is only one 
component in a validation study, it is an important piece of information for concluding on a 
testing method’s ability to provide correct classifications in relation to a reference test. Our 
findings may, therefore, stimulate a scientific and a policy debate about (the criteria for 
defining) minimum sample sizes. 
5.5 Conclusions  
Predictive accuracy metrics of all testing methods, i.e. non-animal methods and animal 
tests, suffer from different types of uncertainty, causing biased conclusions about substances 
properties. This chapter explored the impact of limited precision, variation of sample 
composition and variation of sample size on accuracy metrics of non-animal testing methods 
for skin sensitisation assessment. We analysed the impact for each individual type of 
uncertainty and for different combinations. The analysis was applied to experimental samples 
of substances tested with the DPRA, LuSens, and the h-CLAT. Furthermore, we included an 
integrated testing strategy composed by these individual methods, the “2 out of 3” ITS, in the 
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assessment. Considering limited precision (due to the BR around classification thresholds in 
non-animal testing methods’ prediction models) changed accuracy metrics whenever 
experimental samples contain borderline substances.  
Accounting for limited precision could have either a positive impact on accuracy metrics 
(i.e. accuracy metrics increase) or a negative impact (i.e. accuracy metrics decrease). 
Generally, we conclude that the direction and the size of this impact cannot be predicted from 
the outset, but depends on the composition of the sample of substances. In particular, the 
impact depends on the number of borderline substances on both sides of a method’s 
classification threshold (i.e. the number of substances which would be classified as TP, TN, FP 
and FN if the BR is ignored) in relation to the number of substances which are not borderline.  
Using randomised instead of deterministic experimental samples allowed determining 
probability distributions of accuracy metrics, illustrating their variation when the 
composition of samples is assumed to be uncertain. When considering the joint impact of 
varying sample composition and limited precision, the mean values of accuracy metrics, but 
also their SD (indicating the variation of data) and the 95% CI limits (indicating the spread of 
the variation) changed. Again, the size and direction of these changes was not pre-defined but 
depended on the fractions of substances on both sides of the prediction model’s classification 
threshold. Finally, we found that the expected bias of accuracy metrics is highest if we account 
for uncertainty due to varying sample composition, sample size and limited precision. Thus, 
impacts of different types of uncertainty on non-animal testing methods’ predictive accuracy 
accumulate. 
Although the precise impacts differed across individual non-animal testing methods and 
the “2 out of 3” ITS, our results warrant a number of general conclusions. First, in order to 
avoid erroneous specifications of testing methods’ accuracy metrics, the BR needs to be 
determined and substances with experimental results falling within this range should be 
detected. Furthermore, assessments of non-animal testing method’s predictive accuracy 
should include complementary information about the potential over- and under-estimation 
error of accuracy metrics due to limited precision. This is particularly relevant because, as our 
results illustrate, there is a clear link between predictive accuracy metrics, limited precision 
and the composition and size of experimental samples. Determining the SD and 95% CI of the 
accuracy metrics is a useful way to report the uncertainties due to sample variation and to 
provide the area which encompasses the predictive accuracy metrics of testing methods if re-
assessed using different experimental samples. Finally, for a more coherent assessment of the 
predictive accuracy of testing methods, experimental samples should be of a sufficient size 
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and of varying composition (i.e. with regard to TP, TN, FP and FN substances). This is 
particularly relevant for regulatory validation processes, which are decisive for the 
acceptance or rejection of non-animal testing methods. Determining the number of 
substances in an experimental sample which is considered sufficient is a matter of further 
research. Also, while this chapter focused on non-animal testing methods assessing skin 
sensitisation potential, it is important to explore the (combined) impacts of varying sample 
composition, sample size and limited precision on the predictive accuracy of testing methods 
for a broader set of endpoints. Such assessments must also include the reference animal tests 
to allow for comparisons of biases in testing methods’ predictive accuracy between animal 
and non-animal testing methods. This is, in our view, a prerequisite for transparent and 
informative evaluations of testing methods. 
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6 Synthesis 
This thesis introduced an economic perspective on the development of non-animal testing 
strategies. The research is embedded in the overall context of increasing information 
requirements for safety assessments of several tens of thousands of chemicals produced or 
marketed within the EU, the existing trade-offs between information requirements, 
constrained testing capacities and the policy objective to phase-out animal testing. From a 
conceptual and methodological perspective, the thesis offered a complementary contribution 
to toxicological research on developing non-animal testing strategies, and the evaluation of 
their performance compared to traditional animal tests. Moreover, the research presented in 
the thesis attempts to integrate fundamental toxicological concepts and approaches, e.g. for 
quantifying information outcomes derived from testing, into a comprehensive framework for 
efficient testing. Section 6.1 summarises the main findings from this research with regard to 
the research questions presented in the first chapter. Section 6.2 discusses the methodological 
approaches used, and a reflection of the general scientific and policy context to which this 
thesis contributes. Section 6.3 discusses limitations of the applied approaches and methods 
with regard to scope, underlying assumptions and data availability. Finally, section 6.4 
concludes and Section 6.5 suggests topics for further research. 
6.1 Answers to the research questions  
RQ1: What are relevant criteria guiding the development of non-animal testing strategies for 
skin sensitisation potential and potency assessment? 
The development of resource-efficient toxicity testing strategies has been driven by the 
need for providing fast, less costly and animal-free testing methods or strategies that offer 
adequate and sufficient information for hazard and risk assessment of chemicals. Focusing on 
the toxicological endpoint of skin sensitisation, Chapter 2 of this thesis reviewed the state-of-
the art regarding the development of non-animal testing strategies, and identified the criteria 
which guide the development of testing strategies as proposed in the recent toxicological 
scientific and policy literature.  
Key findings revealed from this analysis can be summarised as follows: Throughout the 
past decade a large number of individual non-animal testing methods has been developed. 
Notwithstanding, there is general consensus between scientists and regulatory decision-
makers that none of these methods can serve as a suitable replacement of the reference 
animal test (e.g. the LLNA or guinea pig based tests), if performed as standalone methods. For 
those non-animal methods which have been formally validated by the European Centre for 
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Validation of Alternative Methods (ECVAM; Italy) (e.g. the DPRA, the Are-Nrf2 luciferase 
method and the h-CLAT), testing protocols emphasise that the individual methods should be 
used in combination with supplementary information in order to provide suitable information 
for hazard identification and for potency assessment (ECHA, 2016). Therefore, the integration 
of information from different sources into battery or sequential combinations has been 
suggested as a promising solution for solving the problem of developing adequate and 
relevant information in an efficient way. In Chapter 2, we identified the criteria suggested in 
the toxicological literature for developing non-animal testing strategies Furthermore, Chapter 
2 introduced the economic perspective to the issue of “resource-efficient” testing and set the 
conceptual and informational criteria to optimise toxicity testing. Following to this, we 
provided a comprehensive qualitative evaluation on how these criteria were implemented 
into non-animal testing strategies for skin sensitisation potential and potency assessment. In 
Chapter 2, we analysed whether testing strategies suggested as “resource-efficient” in the 
literature can fulfil economic efficiency criteria.  
The current state-of-the art regarding the development of non-animal toxicity testing 
strategies assessing skin sensitising properties of substances is characterised by the 
development of numerous toxicity testing strategies, aiming at integrating information from 
different non-animal testing methods for skin sensitisation. Both deterministic and 
probabilistic toxicity testing strategies are proposed for the assessment of skin sensitisation 
potential and potency. Schemes such as “Integrated Testing Strategies” (ITS), “Integrated 
Approaches to Testing and Assessment” (IATA), “Defined Approaches” (DA) and “Weight of 
Evidence” (WoE) approaches have been proposed, often in similar context, for the 
combination of information derived from different sources such as in vitro testing methods, 
read across or in-silico QSAR methods. A guiding rule, often proposed, for constructing testing 
strategies using different non-animal testing strategies is to follow the consecutive key events 
of the adverse outcome pathway (AOP). Following the key events of the AOP, supports the 
construction of testing strategies based on biological relevance criteria. In order to improve 
the economic efficiency of a testing strategy it is important to balance information gains with 
costs. We observed that the current toxicity testing strategies for the assessment of skin 
sensitisation aim at improving information gains without using animal tests, however, little 
attention has been given to the aspect of costs. Indeed, minimising testing costs and the “costs 
of making errors” is one of the criteria often mentioned in the efficiency criteria proposed in 
the literature. Our findings in Chapter 2 suggested, however, that testing costs are not 
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systematically incorporated into the design of non-animal testing strategies for skin 
sensitisation. 
According to the criteria suggested in the toxicological literature, testing strategies should 
be coherent, transparent, hypothesis-driven, unambiguous and cost effective (Jaworska and 
Hoffmann, 2010; Rovida et al., 2015). However, seeing the development of “‘resource-
efficient” testing strategies from an economic perspective, implies a set of conceptual criteria 
necessary to ensure optimisation in the development of toxicity testing. The conceptual 
criteria are: (i) the valuation of information gains and costs, (ii) the weighing mechanism for 
balancing information gains and costs from testing, (iii) the uncertainty assessment of both 
gains and costs and (iv) the stopping rule indicating when testing should stop. Furthermore, 
to ensure the appropriateness of the information gains and costs from performing testing 
methods as standalones or in a strategy, we set key informational criteria, i.e. predictivity, 
reliability and mechanistic understanding of information from testing methods and associated 
direct and indirect costs.  
Next we investigated how these key conceptual and informational criteria are 
implemented on existing examples of testing strategies suggested as “Defined Approaches” in 
the latest OECD report (OECD, 2016c) for assessing skin sensitisation. We identified testing 
strategies using deterministic approaches such as “2 out of 3” ITS (Bauch et al., 2012; Urbisch 
et al., 2015a) and tiered testing strategies (van der Veen et al., 2014a) or probabilistic 
approaches such as Bayesian networks (Jaworska et al., 2010; Jaworska et al., 2013) and 
artificial neural networks (Hirota et al., 2013; Hirota et al., 2015). For this, economic 
approaches such as value of information (VOI) analysis, cost benefit analysis (CBA) or cost 
effectiveness analysis (CEA) can offer the tools for improving the economic efficiency in 
toxicity testing strategy development. Economic approaches offer guiding rules for developing 
testing strategies for the assessment of skin sensitisation. Balancing informational gains and 
expected economic losses from testing, reveals when an additional testing method should be 
performed and when testing should stop. The development of toxicity testing strategies 
should, therefore, not only be guided by principles from toxicology, but also by criteria, such 
as the costs of testing and the economic costs to society of making incorrect judgements.  
 
RQ2: How can non-animal toxicity testing strategies for assessing skin sensitisation potential be 
optimised?  
Chapter 3 provides a decision-theoretic framework for optimising sequential testing 
strategies. Using a Bayesian Value-of-Information (VOI) analysis approach allows for 
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balancing expected social welfare gains from testing with expected costs, including costs of 
making errors, for individual testing methods and any possible combination of methods into a 
testing strategy. A key assumption of the VOI approach applied is that testing has value if and 
only if it leads to welfare-improving decisions on chemicals´ use. The VOI approach has 
several convenient features. First, it is a quantitative approach. The outcome of the VOI model 
is a testing method’s or a testing strategy’s expected value of test information (denoted EVTI), 
which is a monetary estimate of the expected social net benefit from testing. Comparing the 
EVTI across testing methods and testing strategies allows for ranking testing options 
according their expected social net benefits. This offers the means for determining with which 
testing method to start a testing sequence, the number of testing methods that should be 
included in a testing strategy, and when to stop testing. Furthermore, it allows for comparing 
the EVTI of non-animal testing methods and strategies with that of an animal test. It also 
offers the opportunity to systematically examine if, and to what extent, non-animal testing 
methods for skin sensitisation should follow the order of key events in the skin sensitisation 
adverse outcome pathway (AOP), although this has repeatedly been suggested in the 
literature as a sufficient guiding rule for skin sensitisation testing. Second, the VOI model is a 
probabilistic approach. By applying Bayesian inference it allows for quantifying the 
uncertainty related to the outcomes of any test (including the “gold standard” animal test), 
and for assessing the remaining uncertainty of the outcomes from testing after new 
information (e.g. from a follow-up test) has become available. In addition, the Bayesian 
specification of the VOI model accounts for and allows updating update a decision-maker’s 
beliefs about the properties of a substance. Third, VOI analysis integrates, besides 
toxicological information, also relevant economic information such as testing costs, marketing 
gains from releasing a (safe) substance, forgone marketing benefits in case of an erroneous 
ban, and possible health damage costs (in our case direct and indirect costs arising from 
allergic contact dermatitis) from an erroneous release of a toxic substance.  
The Bayesian VOI approach was applied to selected non-animal testing methods for skin 
sensitisation potential assessment (i.e. the DPRA, LuSens, KeratinoSensTM, the h-CLAT, the 
OECD Toolbox and battery combinations of those methods), and the animal test LLNA. To 
explore the applicability of the model, we used the preservative Kathon CG as a proof-of-
concept case. Though the empirical application was based on a number of simplifying 
assumptions (for example with regard to the assumed marketing volume of Kathon CG, the 
market price of the substance, or the decision-maker’s risk attitudes, see also Section 6.3.2) 
the analysis offers a number of interesting and novel insights into the principles of developing 
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efficient sequential non-animal testing strategies for assessing the skin sensitisation potential 
of substances. First, we can conclude that the expected value of information from testing does 
not only depend on the information outcome from testing, but on the interplay of multiple 
parameters. These are a decision-maker’s prior beliefs upon the hazardous properties of a 
substance, the predictive capacity of non-animal testing methods, the expected payoffs from 
marketing a hazardous or non-hazardous substance, and testing costs. Second, if a decision 
maker has strong beliefs that a substances is a potential skin sensitiser, or if a substance has a 
high sensitisation prevalence, or even a combination of strong beliefs that a substances is a 
sensitiser with a high skin sensitisation prevalence, increase the value of additional 
information from testing, because expected social costs of the release of a hazardous 
substance are high. We found that a 3-step sequential testing strategy consisting of the battery 
of the DPRA and LuSens, followed by the OECD Toolbox, and KeratinoSensTM as third testing 
method revealed the highest EVTI compared to all 236 sequential 2-test and 3-test testing 
strategies analysed. For low prior beliefs, (i.e. a decision-maker assumes that a substance is a 
non-sensitiser), we found the battery combination of the DPRA and LuSens to rank first. 
Third, our results underlined that both battery and sequential combinations of non-animal 
testing methods have a higher EVTI than the animal test, in this case the LLNA. One reason is 
that the predictive capacity of battery combinations of non-animal testing methods is usually 
higher than that of individual non-animal methods, which reduces the probability of adopting 
erroneous decisions. Another reason is that sequential testing strategies offer the possibility 
to save methods and, therefore, testing costs because a follow-up test will only be conducted 
conditional on the outcomes of testing methods at earlier stages of the testing strategy. 
Finally, we observe that the order of non-animal testing methods in a strategy does not have 
to follow the order of key events in the skin sensitisation AOP. Thus, covering all key events in 
the AOP is neither a necessary nor a sufficient condition for efficient testing. In contrast, 
depending on a decision-maker’s prior beliefs it may be preferred to generate more 
information for the same key event in two consecutive steps of the sequential testing strategy.  
 
RQ3: How do technical and biological variability of non-animal testing methods influence the 
precision of non-animal testing methods for assessing skin sensitisation potential?  
In Chapter 4 we assessed the impact of biological and technical variability on the precision 
of non-animal testing methods assessing skin sensitisation potential. Given that any test – 
irrespective of whether it is an animal test, an in vitro method (using cell-cultures), or an in 
chemico method or an in silico method (using computational methods), is a simplified model 
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representation of the processes that are expected to happen in the human body, biological and 
technical variability are inherent characteristics of testing methods. For hazard classification, 
continuous experimental data resulting from testing are usually dichotomised into binary 
“positive/negative” or “hazardous/non-hazardous” data by means of applying a pre-defined 
classification threshold. Earlier studies, i.e. (Kolle et al., 2013; Dimitrov et al., 2016), has 
shown that biological and technical variability influence the ability of the animal test LLNA to 
provide clear-cut conclusions about a substance’s skin sensitising potential when test results 
fall close to the pre-defined classification thresholds. This has been expressed as the range on 
both sides of the classification threshold of the LLNA in which test results can be discordant. 
Thus if a substance tested with the LLNA reveals results which fall within this range, called 
“grey zone” or “borderline range”, drawing conclusions about skin sensitisation potential is 
not possible because repeated testing may ambiguously reveal either positive or negative 
results. The precision of non-animal testing methods is, similarly to the LLNA, influenced by 
the biological and technical variability. Therefore non-animal testing methods also have a 
borderline range around their classification threshold in which their ability to provide clear-
cut conclusions on the skin sensitising properties of substances is not possible with sufficient 
confidence. Substances yielding test outcomes within the borderline range of testing methods 
may require further testing in order to avoid misclassifications. Quantifying the borderline 
range in the prediction models of non-animal testing methods is, therefore, a practical way to 
account for borderline test results and to unravel a testing method’s limited precision.  
We quantified the borderline range for selected non-animal testing methods for assessing 
skin sensitisation, i.e. the DPRA, LuSens, and the h-CLAT, and for the “2 out of 3” ITS. The 
latter has been introduced as an integrated testing strategy consisting of three non-animal 
testing methods. Furthermore, we identified the substances in the experimental samples of 
these methods for which test results fell within the borderline range. Since each prediction 
model applied in each of the non-animal testing methods used is different, specific decision 
rules were defined to guide the identification of borderline substances. Our analyses revealed 
the following results: First, biological and technical variability do not only impact the 
prediction revealed from the animal test LLNA, but also predictions used for the non-animal 
testing methods considered in Chapter 4 for which we quantified their borderline range. The 
borderline range shows the area around the classification threshold, in which non-animal 
testing methods are not precise, i.e. they are likely to reveal discordant results in repeated 
applications. Second, the percentage of borderline substances in the experimental samples 
used in the DPRA, LuSens, the h-CLAT, as well as the “2 out of 3” ITS was less than that of the 
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reference animal test (LLNA). However, since the size and composition of experimental 
samples differed across non-animal testing methods, and between non-animal testing 
methods and the LLNA, our findings do not allow for comparisons between these methods 
(see also Section 6.4). For the “2 out of 3” ITS, we found that the percentage of substances 
yielding borderline test results was equal to the DPRA and lower compared to the h-CLAT. 
The reason is that the “2 out of 3” ITS applies a simple majority rule for concluding on a 
substance’s skin sensitisation potential, i.e. the classification is based on at least two 
concordant results. This majority rule ignores borderline substances in the sample of each 
testing method used in the “2 out of 3” ITS which is not considered for the classification 
decision. The majority rule of the “2 out of 3” ITS, therefore, allows excluding a borderline test 
result if the results from the other two testing methods fall outside the borderline range. 
Hence, one can conclude on the skin sensitisation potential of a substance even if individual 
methods revealed a borderline result.  
 
RQ4: How do limited precision, sample size and sample composition impact the predictive 
accuracy of non-animal testing methods for skin sensitisation?  
In Chapter 5 we analysed the uncertainties in predictive accuracy metrics of non-animal 
testing methods. We analysed the impact of the limited precision of non-animal testing 
methods on their predictive accuracy, i.e. a testing method’s ability to correctly detect an 
adverse effect in comparison to the reference animal test. Further, we analysed the impact of 
variations of sample size and sample composition on testing methods’ predictive accuracy. We 
examined these impacts both separately and in combination with limited precision. Common 
predictive accuracy metrics e.g. sensitivity, specificity and concordance (also called accuracy) 
are calculated by comparing binary “hazardous/non-hazardous” test results from non-animal 
testing methods (e.g. the DPRA, LuSens, the h-CLAT and the “2 out of 3” ITS) to those from a 
reference test (e.g. test results from the LLNA data, and human data when available) for a set 
of substances. As elaborated in Chapter 4, for substances yielding test results within the 
“borderline range” around the classification threshold of a testing method’s prediction model 
such clear-cut classifications into “hazardous/non-hazardous”, is not possible. Consequently, 
borderline substances cannot contribute to the assessment of a testing method’s predictive 
accuracy.  
The impact of considering borderline substances on testing method’s predictive accuracy 
was analysed by comparing sensitivity, specificity and concordance quantified from 
experimental samples including borderline substances with values obtained when borderline 
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substances were excluded. Here we compared results obtained from experimental samples of 
a pre-defined sample size and composition with those obtained from randomised samples of a 
given size and of varying samples Randomised samples were created using non-parametric 
bootstrap resampling analysis. The analysis was performed using the DPRA, LuSens, the h-
CLAT and the “2 out of 3” ITS combining these three methods.  
We can conclude that the limited precision of testing methods s, reflected by the number 
of borderline substances in an experimental sample, can affect the predictive accuracy 
metrics. However, the magnitude and the direction of the impact on the predictive accuracy 
vary across non-animal testing methods. Generally, the impact depends on the number of 
borderline substances on both sides of a method’s classification threshold (i.e. the number of 
substances which would be classified as TP, TN, FP and FN if the BR is ignored) in relation to 
the number of substances which are not borderline. Whereas for the DPRA sensitivity, 
specificity and concordance increased after borderline substances were excluded from 
experimental samples, the accuracy metrics for the h-CLAT were considerably decreased after 
excluding the borderline substances from the experimental samples, when compared to the 
LLNA data. For LuSens we observed a small increase of sensitivity, but no change on 
concordance and even a slight decrease of specificity values. For the “2 out of 3” ITS, we found 
a decrease in sensitivity, whereas specificity remained unchanged and concordance even 
slightly decreased. 
Determining predictive accuracy metrics from randomised samples revealed for each 
non-animal testing method considered distributions of sensitivity, specificity and 
concordance. Based on these distributions we quantified the 95% confidence intervals, the 
mean and the standard deviation of sensitivity, specificity and concordance, respectively. 
Mean values of accuracy metrics derived from experimental samples differed only marginally 
from mean accuracy metrics obtained from randomised samples. However, there can be 
considerable variation of accuracy metrics around the mean of the distributions. For the three 
non-animal testing methods the DPRA, LuSens and the h-CLAT, and for the “2 out of 3” ITS, 
this illustrates that the impact of considering borderline substances on the assessment of a 
non-animal testing method’s predictive accuracy can be either higher or lower based on the 
sample composition. Finally, we observed that the variation of accuracy metrics decreases 
with increasing number of substances in the samples used to assess the predictivity of testing 
methods (sample size). This underlines the relevance of using experimental samples of a 
sufficient size and of a balanced composition (i.e. including a balanced fraction of hazardous 
and non-hazardous substances) for ensuring a coherent assessment of non-animal methods’ 
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predictive accuracy. Moreover, a transparent and coherent assessment of non-animal testing 
methods’ predictive accuracy requires to identify and document borderline substances in 
experimental samples. Finally, due to appropriate standard deviations or confidence limits, 
indicating ranges of expected accuracy metrics, and not as point estimates. 
6.2 General discussion 
This section discusses the wider context of the research conducted in this thesis, briefly 
reflects on the methodological and modelling approaches used in the Chapters 2 to 5 and the 
policy relevance of the thesis. 
6.2.1 Wider context of the thesis 
In the overall context of chemicals’ safety assessment and the development of efficient 
toxicity testing strategies scientific efforts have focused on developing new testing methods 
and conceptual approaches that facilitate the integration of information from different 
experimental and computational sources. The purpose is to support efficient hazard and risk 
assessment of the large numbers of chemicals produced worldwide, while reducing or 
avoiding the use of animal testing. The development and combination of non-animal methods, 
e.g. cell based methods (in vitro) and computational (in silico) approaches, has been 
considered a powerful approach for generating sufficient and relevant hazard information 
using less resources (i.e. time, testing costs, laboratory animals) than with traditional animal 
tests. In addition, integrating information from in vitro and in silico methods is considered to 
better cover the different key events in the AOP of certain endpoints compared to animal 
tests, provided that these events are known (Vinken, 2013). Still, a number of fundamental 
conceptual question have not been addressed systematically as yet, in particular how to 
optimally combine different information outcomes from in vitro and in silico methods, and 
how to arrive at conclusions on the hazardous properties of a substance.  
Regarding the current status of developing integrated approaches to toxicity testing for 
skin sensitisation (Chapter 2) we identified different terminologies describing the effort to 
combine non-animal testing methods into strategies, for example “Integrated Testing 
Strategies” (ITS), “Sequential Testing Strategies” (STS), “Integrated Approaches to Testing and 
Assessment” (IATA), “Defined Approaches” (DA), or “Weight of Evidence approaches” (WoE) 
(Tollefsen et al., 2014; Rovida et al., 2015; Jaworska, 2016; Sauer et al., 2016). The recent 
reports from OECD, provide clear definitions and delineate the differences between the 
concept of IATA and any approach (i.e. DA) to integrate information from different sources 
using a fixed data interpretation procedure (OECD, 2016b; OECD, 2016c). Moreover, we 
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concluded that existing approaches focus predominantly on maximising information 
outcomes from testing. As we argue in this thesis, a prerequisite for optimal testing is to 
balance information gains from testing with costs for generating this information. This holds 
for both individual testing methods and for DAs to integrate information (testing strategies). 
Thus, the development of efficient testing strategies has clear characteristics of an economic 
optimisation problem (Yokota et al., 2004; Yokota and Thompson, 2004; Gabbert and van 
Ierland, 2010; Gabbert and Weikard, 2010; Gabbert and Weikard, 2013). While this thesis 
focuses on skin sensitisation, the problem of developing efficient non-animal testing strategies 
is generic and it applies to any health and environmental endpoint, e.g. liver toxicity (Daston 
et al., 2015; Gocht et al., 2015), aquatic toxicity (Villeneuve et al., 2014; Groh et al., 2015), fish 
toxicity (Nendza et al., 2014) or local tolerance endpoints such as skin corrosion and eye 
irritation (Sauer et al., 2016). We observed that several non-animal testing strategies have 
been developed based on purely toxicological criteria. Although theoretical approaches to the 
optimisation of testing strategies have been suggested earlier (Gabbert and van Ierland, 2010; 
Gabbert and Weikard, 2013; Norlén et al., 2014; Leontaridou et al., 2016), empirical 
applications – requiring in particular a quantification social gains and losses related to testing 
– have been largely lacking. The Bayesian VOI model suggested in Chapter 3 of the thesis is 
therefore a step forward to filling this gap. While the findings from our analysis refer to a 
specific human health endpoint (skin sensitisation), the insights into the conceptual features 
of sequential testing are generic. The thesis, therefore, lays the conceptual grounds for 
optimising toxicity testing for other toxicological endpoints, and also for more types of 
chemicals (e.g. nanoparticles).  
To understand the implications of translating experimental readouts from testing into a 
final conclusion about the hazardous properties of a substance we need to carefully 
investigate the quality of test information. Based on our analysis on the precision of non-
animal testing methods (Chapter 4) we observed that biological and technical variability can 
limit the precision of testing methods. This may lead to erroneous hazard classifications and 
to over- or underestimation errors of a testing method’s predictive capacity. Again, using skin 
sensitisation as an illustrative case we showed that ambiguity of hazard classification is a 
general problem that applies to both animal tests (Kolle et al., 2013; Hoffmann, 2015; 
Dimitrov et al., 2016) and non-animal testing methods. Defining a quantifiable measure for 
this ambiguity, called “borderline range”, Chapter 4 allows assessing its impact on the 
predictive accuracy of (non-animal) testing methods, i.e. the ability of a testing method to 
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provide test results concordant to those of a reference animal test for tested substances as 
described in test guidelines for non-animal testing methods e.g. TG no 442C (OECD, 2015a). 
Currently, a testing method’s predictive accuracy is determined by comparing 
dichotomised test results revealed from testing a pre-selected sample of substances to those 
obtained from a reference animal test. As we showed in this thesis, the borderline range and 
the number of chemicals which are likely to be misclassified due to the borderline range 
depend on the size and composition of these experimental samples. This raises the normative 
question of how to compose experimental samples in order to reduce ambiguity. 
Furthermore, it highlights the need to document complementary information about the 
uncertainty of test information, for example as part of validation reports of new testing 
methods. This holds in particular because the predictive accuracy of non-animal testing 
methods is compared with that of reference animal tests. The concept of using the borderline 
range as an additional measure to evaluate information from testing strengthens the 
appropriateness and trustworthiness of information based on which the use of substances is 
decided. As a consequence, this has implications for the quality of predictive accuracy metrics, 
also used as input into the optimisation framework developed in Chapter 3, and on the 
trustworthiness of hazard classifications for substances yielding test results close to the 
classification thresholds.  
6.2.2 Methodological and modelling approaches  
Although it is common sense among scientists and policy makers that testing costs should 
be minimised, the qualitative review conducted in Chapter 2 revealed that the development of 
existing testing strategies, and in particular of testing strategies for the assessment of skin 
sensitisation, has not been guided by economic efficiency criteria such as a mechanism for 
balancing gains and costs of testing. It was therefore concluded that there is a need for 
developing an optimisation framework to testing. Responding to this need we developed a 
decision theoretic framework using Bayesian VOI analysis that guides the process of 
combining different non-animal testing methods into sequential testing strategies in an 
efficient way. While the Bayesian VOI approach is not new per se (Yokota and Thompson, 
2004), it offers a coherent, theory-based framework for determining (i) with which test to 
start in a testing strategy, (ii) how many non-animal testing methods to include, and (iii) when 
to stop testing. In our analysis the expected value of test information of non-animal testing 
methods and their combinations, EVTI, is compared to that of the reference animal test that 
has been considered a “first choice” in the traditional toxicity testing approach. The Bayesian 
VOI model which we suggested incorporates estimates of social benefits and losses from 
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decisions upon the use of a substance under either outcome from testing. Besides testing costs 
from performing a testing method, it captures monetised health damage costs due to skin 
sensitisation. Furthermore, it includes estimates of (foregone) marketing benefits. The gains 
and losses under either decision option are added in order to determine expected net benefits 
for every decision option (ban or release). We used Kathon CG as a proof of concept case for 
calibrating the model. The Bayesian VOI model offers a tool to link the predictive accuracy of 
testing methods with the expected payoffs from marketing substances by weighing the 
expected payoffs, with the probability of a substance to be hazardous/non-hazardous. This 
model can also be applied for a broader set of substances or endpoints. 
The Bayesian VOI uses measures of a test’s predictive accuracy (i.e. sensitivity and 
specificity) for characterising test information. These are a test’s sensitivity (i.e. the 
proportion of skin sensitisers which were correctly classified) and specificity (i.e. the 
proportion of non-sensitisers which were correctly classified). Predictive accuracy metrics 
were derived by transforming continuous experimental readouts from testing into binary 
hazardous/non-hazardous outcomes, and by determining percentages of correctly and 
erroneously classified substances in the experimental sample as compared to a reference test. 
In a regulatory context, dichotomised test results are sufficient for hazard identification 
purposes required for any toxicological endpoint (EC, 2008; EC, 2016). The classification of 
substances as “hazardous/non-hazardous” is based on pre-defined thresholds applied to the 
continuous experimental readouts. However, using clear-cut thresholds may lead to an over- 
or underestimation of a testing method’s sensitivity and specificity due to the biological and 
technical variability of the testing method. The biological and technical variability constraint 
the testing method’s precision, i.e. its ability to reveal concordant results in repeated runs of 
the testing method. We determined the area around the threshold of testing methods in which 
test results are expected to be ambiguous. This area is called borderline range and we 
proposed this concept as an additional measure to evaluate the appropriateness of 
information from testing. To quantify the borderline range, we used substances that have 
been routinely tested with “in-house” experiments of testing methods. Routinely tested 
substances, in contrast to highly standardised and well-characterised substances used in 
validation experiments of the testing methods, are substances that are intended to be released 
into the market. Therefore, using substances routinely tested is a practical way to examine the 
precision of testing methods and reflect the precision of these methods in “in house” 
laboratory practices.  
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While the uncertainty underlying to predictive accuracy metrics of testing methods has 
been discussed earlier (Worth and Cronin, 2001a), the impact of this uncertainty on (i) the 
correct classification of hazardous and non-hazardous substances, and (ii) the conclusions on 
the predictive accuracy of testing methods, in particular non-animal testing methods, have not 
been systematically addressed. Our analysis, therefore, contributed to a more comprehensive 
understanding of the informational “value” of testing methods (Worth and Cronin, 2001a). As 
a first step we analysed the impact of the borderline range on non-animal testing methods’ 
accuracy metrics (Chapter 5). This was done by comparing accuracy metrics derived from test 
results of a sample of substances which include borderline substances, with those obtained 
after we excluded substances yielding borderline results. Excluding the substances for which 
test results fall within the borderline range implies that the concept of precision is considered 
before the decision makers translate experimental readouts into final conclusions on the 
classification of substances. Furthermore, we examined the impact of the borderline range for 
randomised substances samples, using non-parametric standard bootstrap analysis. 
Randomised samples of the same sample size as the experimental samples and of different 
sample sizes smaller than the size of experimental samples were generated. The bootstrap 
analysis allows defining 95% confidence intervals for the accuracy metrics of no-animal 
testing methods for both cases at which precision of a testing method is first considered and 
second ignored. Providing confidence intervals for accuracy metrics based on randomised 
samples means that decision makers can approximate the range of expected accuracy metrics 
(Worth and Cronin, 2001a). This provided insight into the impact of the borderline range on 
testing methods’ predictive accuracy when considered in combination with varying size and 
composition of experimental samples. The experimental samples used for evaluating a test’s 
predictive accuracy are usually composed on the basis of expert judgment or simply data 
availability, and thus they are neither randomised nor of a pre-defined size. Our analysis 
shows that documenting accuracy metrics as ranges rather than point estimates may be a 
more appropriate way of characterising test information uncertainty raised from number and 
composition of substances in the experimental samples. Predictive accuracy assessment of 
testing methods, irrespectively of the endpoint addressed, has been traditionally based on the 
comparison of test results derived from a testing method to those from a reference animal 
test. Therefore, the methodology used in Chapter 5 contributes to the current practices of 
assessing the predictivity of testing methods by suggesting to consider (i) the impact of 
limited precision on the classification of substances and (ii) the number and composition of 
substances used for assessing the predictivity of testing methods.  
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6.2.3 Policy relevance 
During the past decade scientists and decision makers in industry or regulatory agencies 
have increasingly paid attention to the fundamental problem how toxicity testing strategies 
can be optimised. Regulatory frameworks such as the European REACH legislation (EC, 2006) 
and the Cosmetics Regulation (EC, 2009), but also policy reports such as the report of the U.S. 
National Academy of Sciences “Toxicity testing in the 21st Century: A Vision and a Strategy” 
(Krewski et al., 2010) have spelled-out detailed information requirements in order to ensure 
that the risks of toxic chemicals can be optimally controlled. Information requirements for 
hazard and risk assessment of large numbers of chemicals in a regulatory context have 
triggered the development of alternative testing methods. The development of testing 
methods has been focusing on creating robust, fast and cheap approaches aiming at reducing 
and eventually replacing the animal tests. This thesis contributes to this process by (i) 
surveying the state of the art and the conceptual criteria of developing non-animal testing 
strategies for skin sensitisation hazard and potency assessment, (ii) developing an economic 
framework to optimise non-animal strategies for skin sensitisation potential assessment, and 
(iii) by exploring uncertainties underlying to information outcomes of non-animal testing 
methods. The optimisation framework to developing non-animal testing strategies, using the 
Bayesian VOI analysis, offers a probabilistic tool to analyse the interplay between a decision-
maker’s prior beliefs about the properties of a substance, expected information gains from 
testing, and costs. This acknowledges that the construction of optimised non-animal testing 
strategies must balance different and possibly competing objectives. Furthermore, it 
underlines that solutions to the general problem of “how to test” are not independent of the 
possible set of (regulatory) decisions upon the use of chemicals. 
Although there has been an agreement among scientists and policy makers that animal 
testing should be phased out (Basketter et al., 2013; Jaworska, 2016; Sullivan, 2016; Worth 
and Patlewicz, 2016), there is still a controversial discussion on how this can best be achieved 
(Hartung et al., 2013; Rovida et al., 2015). Non-animal testing methods can be used in 
combination with other complementary information to support final conclusions on the skin 
sensitising properties of substances (ECHA, 2016), however, information from standalone 
non-animal testing methods may be sufficient for the classification of a substance into UN GHS 
category 1 (thus binary classification of a substances as “sensitiser/non-sensitiser”) under 
specific regulatory frameworks as explained in OECD test guidelines e.g. for the DPRA, the 
ARE-Nrf2 Luciferase method and the h-CLAT (OECD, 2015a; OECD, 2015b; OECD, 2016d). 
Scientific discussions, however, suggest integration of information from non-animal testing 
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methods for trustworthy classification of substances. As our results show the expected value 
of animal test information is lower than that of standalone non-animal testing methods. 
Performing non-animal testing methods combined in battery or sequential combinations 
increased the value of information of these methods even further. Moreover, our results 
underline that sequential testing strategies do not necessarily need to follow the order of key 
events of an AOP. Chapter 3, therefore, contributes to evaluating the relevance of non-animal 
testing methods for chemicals’ hazard assessment.  
In addition, results presented in this thesis contribute to the policy debate regarding the 
regulatory acceptance of non-animal testing methods. As we demonstrated in Chapters 4 and 
5, using clear-cut thresholds to translate experimental readouts into binary test results 
ignores the impact of technical and biological variability on the precision of testing methods. 
Ignoring the precision of testing methods may lead to over- or underestimation errors 
regarding a testing method’s predictive accuracy. Assessing the hazardous properties of 
substances for regulatory purposes requires, therefore, accurate as well as precise test 
results. This is an observation relevant for testing methods using in vivo, in vitro or in silico 
approaches. According to the findings in Chapter 4, the documentation of test results should 
be expanded and should include, besides positive (i.e. indicating an adverse effect) and 
negative (i.e. indicating no adverse effect) results, also information for which substances the 
test delivered inconclusive (i.e. borderline) results. If a substance is classified as borderline, 
further testing might become necessary in order to provide sufficient information for safety 
assessment of substances in a regulatory context. Quantifying the borderline range for several 
non-animal testing methods, underlines the need to revise the current way of evaluating and 
documenting testing methods’ predictive accuracy. This is particularly relevant in a 
regulatory context, for example within the validation process of non-animal testing methods 
(Sauer et al., 2016). 
Acknowledging that intra-assay variability of testing methods can affect their precision 
and their predictive accuracy stimulates reflection about the regulatory validation process 
and the criteria for evaluating non-animal testing methods. Specifically, our findings point to 
the need to consider quantitative estimates of a testing method’s precision as an important 
piece of information in the evaluation of a method’s predictive performance. Besides technical 
and biological variability it is important to consider factors affecting the intra- and inter-
laboratory reproducibility of tests for example the absence of robust reference data for 
comparisons between test results (Hothorn, 2002; Hothorn, 2003). Our suggestion to describe 
predictive accuracy metrics using ranges, indicating the expected values of accuracy metrics, 
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rather than with point estimates, contributes to the ongoing discussion on how to assess this 
uncertainty, and the implications for evaluating the relative performance of animal tests in 
comparison to non-animal methods. Comparing information about testing methods’ 
predictive accuracy across different testing methods should be based on a transparent 
documentation of this uncertainty, e.g. within test guidelines and validation reports.  
6.3 Limitations of the thesis  
In the following paragraphs we reflect on limitations with regard to the scope of this 
thesis, the assumptions underlying to the methodologies used, and data availability.  
6.3.1 Scope  
This thesis focused on a specific toxicological endpoint, i.e. skin sensitisation. Though 
being a highly relevant endpoint for safety assessments of chemicals under different 
regulatory frameworks, and although the findings about the features of optimising sequential 
testing strategies are generic, the applicability of the Bayesian VOI approach should be 
explored for different toxicological endpoints. In particular, the expected welfare gains and 
losses from releasing or banning substances used as cosmetic ingredients are highly case 
specific. Moreover, while for human health endpoints such as skin sensitisation, but also 
carcinogenicity, estimates of expected health damage costs can be retrieved from the scientific 
literature, this is more difficult for endpoints such as liver toxicity. Estimates of the 
(monetary) damage costs for environmental endpoints (e.g. aquatic toxicity) usually do not 
exist. Here, revealed or stated preference methods could be used for generating data on 
environmental externalities caused by a release of hazardous substances. Furthermore, the 
presented approach refers to individual substances only and did not account for additive or 
synergistic effects of chemicals which are part of mixtures. Though being beyond the scope of 
this thesis, developing optimised testing strategies for mixtures is an interesting option for 
further research.  
The choice of skin sensitisation as endpoint for assessing the impact of biological and 
technical variability of testing methods (Chapter 4) and the uncertainties underlying to their 
predictivity (Chapter 5) was for illustrative purposes. Assessing the impact of intra-test 
variability on the precision of testing methods is a complex field of research which also has 
implications with regard to the policy-driven process of test validation. Addressing in detail 
different sources of uncertainties underlying to the precision and predictivity of testing 
methods goes beyond the scope of this thesis. Nonetheless, our findings underline that 
accuracy metrics should rather be documented as ranges rather than as point estimates. Using 
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test accuracy metrics as point estimates is a limitation which also applies to the scope of the 
decision-theoretic VOI analysis presented in Chapter 3. The VOI model could, therefore, be 
further expanded by integrating the uncertainty of test information due to the limited 
precision of testing methods into the Bayesian VOI model.  
6.3.2 Assumptions  
The quantitative methods presented in this thesis were based on a number of 
assumptions. For instance, to explore the applicability of the Bayesian VOI model presented in 
Chapter 3, Kathon CG was used as a proof-of-concept case. To quantify the expected payoffs 
from marketing Kathon CG, we made simplifying assumptions about the substance’s 
marketing volume, its market price, and the slope of the supply and demand curves of this 
chemical. Clearly, modifying these assumptions impacts the expected value of information of 
individual non-animal testing methods and that of combinations of these methods into 
sequential or battery strategies. Although the numerical values of the analysis have to be 
treated with care, the VOI model can be straightforwardly used to investigate the impact of 
modified parameter values if better information, e.g. about the marketing volume of a 
substance, becomes available.  
In addition, the Bayesian VOI model assumes risk neutral decision-makers. As a 
consequence, marginal health damage costs are considered to be constant. Given the 
increasing trend of skin allergies worldwide, particularly in children (Jackson et al., 2013), 
this assumption may not be valid and may not appropriately describe risk preferences of 
decision-makers in regulatory agencies. However, little information about decision-makers’ 
risk preferences and risk perceptions regarding the use of specific groups of chemicals has 
become available so far. Further, the Bayesian VOI model was applied to a set of non-animal 
testing methods which are assumed to capture all key events in the skin sensitisation AOP. 
This implies that different key events have equal relevance and that information on different 
key events is of same importance. Relaxing this assumption could change the expected value 
of test information of individual testing methods, and could change the optimal order of 
testing methods in a sequence. In addition, for several toxicological endpoints (e.g. liver 
toxicity, see Landesmann et al., (2013); Vinken, (2013); Perkins et al., (2015)) existing 
knowledge of the events in the AOP is still rudimentary.  
Furthermore, analysing the precision and the uncertainty of accuracy metrics of non-
animal testing methods addresses the informative value of test outcomes. The analysis of the 
precision and implications of testing methods’ precision constraints on the assessment of the 
predictive accuracy of non-animal testing methods was performed under the assumption that 
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the classification threshold is exogenously given. The approach for quantifying the borderline 
range (Chapter 4) around testing methods’ classification threshold could, therefore, be 
generalised by accounting for varying thresholds. This might impact the borderline range, and 
consequently its impact on assessing the predictivity of a testing method. Further, our 
analysis on the impact of precision, sample size and sample composition on testing methods’ 
accuracy assumes that the experimental samples are a representative selection of the entire 
set of chemicals. This assumption, which was underlying to the bootstrap analysis used, is 
difficult to verify. As a consequence, the outcomes of our analysis may not adequately cover 
the entire spectrum of substances. 
6.3.3 Data availability  
To quantify expected health damage costs from Kathon CG we used mean values for direct 
health treatment costs based on empirical estimates published in recent studies for different 
populations groups and in different European countries. Due to lacking data we did not 
account for potential health damage costs from occupational exposure or indirect costs such 
as impacts on the social life patients may suffer due to skin allergies (Both et al., 2007). Also, 
cost components such as a firm’s loss of reputation due to erroneously marketing a skin 
sensitiser could not be included due to lacking information, e.g. about liability fees. For 
quantifying the number of people suffering from skin sensitisation in Europe, we used mean-
estimates of skin sensitisation prevalence. While such estimates could be retrieved for Kathon 
CG, they are not available for many other cosmetic ingredients, and for substances relevant for 
endpoints other than skin sensitisation. Applying the Bayesian VOI model to any of these 
substances requires operating with mean prevalence estimates. This will impact the 
quantification of health damage costs and might affect the “true” optimal order of tests in a 
sequence. Further, key events of the AOP are considered to be equally relevant for causing an 
adverse outcome. Therefore, the non-animal testing methods(i.e. the DPRA, LuSens, the h-
CLAT, and the OECD toolbox), which address different key events in the skin sensitisation AOP 
are treated with equal weights with respect to their relevance on addressing the skin 
sensitising properties of a substance. Finally, due to the lack of non-animal testing methods 
addressing the fourth key event in the skin sensitisation AOP, i.e. T-cell proliferation, the 
Bayesian VOI model as well as the analysis on the precision and accuracy of non-animal 
testing methods focused only on the first three key events in the AOP. 
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6.4 Conclusions  
The main conclusions from this thesis can be summarised as follows: 
1. The optimisation of testing strategies depends on the interplay of different parameters. 
These are a decision-maker’s prior beliefs about the hazardous properties of a 
substance, non-animal testing method’s predictive accuracy, social gains and losses 
corresponding to the set of decisions about the use of a substance, and testing costs.  
2. The expected value of test information revealed from “gold standard” animal tests for 
assessing skin sensitisation is lower than that of individual non-animal methods. This 
result holds for the entire range of a decision maker’s prior beliefs. When individual 
non-animal testing methods are combined into sequential or battery combinations, the 
expected value of test information increases. 
3. Sequential or battery combinations of non-animal testing methods have higher 
expected value than standalone methods because a relative higher shift of posterior 
beliefs is observed when using testing methods in strategies. For strategies assessing 
skin sensitisation the increase of information gains exceeded the increase of testing 
costs. 
4. The order of key events in the skin sensitisation AOP is neither a necessary nor a 
sufficient condition for optimising sequential testing. Furthermore, for a sequential 
testing strategy to be efficient not all key events in the AOP need necessarily to be 
covered. 
5. Integrating information from non-animal testing methods into sequential strategies 
decreases the likelihood to misclassify substances due to the impact of biological and 
technical variability of individual testing methods.  
6. Using clear-cut classification thresholds for transforming experimental readouts from 
testing methods into binary “hazardous/non-hazardous” information may lead to 
ambiguous classifications of substances. Quantifying the area where such ambiguous 
results are likely to occur, thus the borderline range can be used to document a testing 
method’s limited precision.  
7. The borderline range around the classification threshold of a testing method can 
impact a testing method’s predictive accuracy. The size and direction of this impact 
depends on how many of substances of the experimental samples yield test results 
within or outside the borderline range. 
8. Assessing the predictive accuracy of testing methods should be complemented by 
information about the borderline range. For a coherent evaluation of testing methods’ 
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accuracy, the uncertainty of accuracy metrics caused by the limited precision of a 
testing method, captured in the borderline range should be assessed.  
6.5 Suggestions for further research  
In this section we provide suggestions for further research reflecting on the scope, 
assumptions and data availability of this thesis: 
Reflecting on the scope, further research should focus on:  
1. The optimisation of non-animal testing strategies for those substances which are of a 
high expected social relevance. For these substances the value of attaining information 
from testing will be highest. 
2. The influence of the limited precision of testing methods on the optimisation of non-
animal testing strategies. Specifically, one would expect that over- and under- 
estimation errors of accuracy metrics can change the optimal sequence of testing 
methods for given prior beliefs about the true hazardous properties of substances. 
Reflecting on the assumptions, further research should focus on:  
3. The impact of different risk preferences of stakeholders on the optimisation of testing 
strategies. We suggest conducting empirical research using, for example, choice 
experiments, to understand the behavioural drivers of different stakeholders (risk 
assessors in industry, regulatory agencies and consumers) for controlling the risks of 
chemicals.  
4. Expanding the Bayesian VOI model in order to consider information about the AOP and 
the relevance of each key event regarding the formation of an adverse effect. 
Furthermore, uncertainties about key events in an AOP need to be included. 
5. Further assessment of the prediction models of testing methods using the Receiver 
Operating Characteristic (ROC) curve analysis with varying classification thresholds 
while accounting for the impact of biological and technical variability of the precision 
of testing methods thus considering the borderline range.  
Reflecting on data used, further research should focus on:  
6. Compiling a dataset of different types of costs related to testing, e.g. health damage 
costs for consumers or loss of reputation for producers. This research could also 
expand on occupational exposure to substance in order to capture direct and indirect 
health damages costs occurring at workplaces. 
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Appendix A 
Experimental samples of substances used in the borderline range calculation 
Where substance names could not be published for reasons of data confidentiality we 
numbered them consecutively. 
Table A1: Substances in the sample for calculating the BR of the DPRA prediction model 
Chemical name  No. of runs 
Test substance 
concentrations 
considered [mM] 
Study year 
Ethylene glycole dimethacrylate* 
(positive control) 
211 0.5, 1, 5, 10, 50, 100 2014 
Substance 1 24 1, 10, 100 2015 
Substance 2 6 100 2015 
Substance 3 3 100 2015 
Substance 4 12 1, 5, 10, 100 2014 
Substance 5 9 1, 5, 10 2014 
Substance 6 12 1, 5, 10, 100 2014 
Substance 7 12 1, 5, 10, 100 2014 
Substance 8 3 100 2014 
Substance 9 6 1, 10, 100 2015 
Substance 10 6 1, 10, 100 2015 
Substance 11 6 1, 10, 100 2015 
Substance 12 4 1, 10 2015 
Substance 13 6 1, 10, 100 2015 
Substance 14 6 1, 10, 100 2015 
Substance 15 4 1, 10 2015 
Substance 16 4 1, 10 2015 
Substance 17 6 1, 10, 100 2015 
Substance 18 6 1, 10, 100 2015 
Substance 19 4 1, 10 2014 
Substance 20 6 1, 10, 100 2014 
Substance 21 6 1, 10, 100 2014 
Substance 22 6 1, 10, 100 2014 
Substance 23 6 1, 10, 100 2014 
Substance 24 6 1, 10, 100 2014 
Substance 25 6 1, 10, 100 2014 
Substance 26 6 1, 10, 100 2014 
Substance 27 6 1, 10, 100 2014 
Substance 28 6 1, 10, 100 2014 
Substance 29 6 1, 10, 100 2014 
Substance 30 3 100 2014 
Substance 31 3 100 2014 
Substance 32 3 100 2014 
Substance 33 3 100 2014 
Substance 34 3 100 2013 
Substance 35 3 3.76% 2013 
Substance 36 3 3.76% 2013 
Substance 37 3 100 2013 
Substance 38 3 100 2013 
Substance 39 3 100 2013 
Substance 40 3 100 2012 
Substance 41 3 100 2013 
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Table A2: Substances in the sample for calculating the BR of the LuSens prediction model 
Chemical name  No. of runs 
Test substance range of 
concentrations considered 
[μg/mL] 
Study Year 
Lactic Acid (Negative control) 395 450 2013-2015 
Substance 1 36 1.4 - 5.1 2013-2015 
Substance 2 53 0.15 - 0.54 2013-2015 
Substance 3 48 3.9 - 14.0 2013-2015 
Substance 4 144 0.06 - 0.92 2013-2015 
Substance 5 174 0.65 - 16.8 2013-2015 
Substance 6 96 77.0 - 479.0 2013-2015 
Substance 7 96 0.03 - 0.53 2013-2015 
Substance 8 96 0.31 - 4.75 2013-2015 
Substance 9 48 4.5 - 16.2 2013-2015 
Substance 10 48 4.7 - 42.9 2013-2015 
Substance 11 120 4.0 - 176.0 2013-2015 
Substance 12 48 6.0 - 46.0 2013-2015 
Substance 13 72 3.9 - 20.2 2013-2015 
Substance 14 48 4.6 - 16.5 2013-2015 
Substance 15 48 0.44 - 1.57 2013-2015 
Substance 16 48 1283.0 - 7942.0 2013-2015 
Substance 17 48 636.0 - 2278.0 2013-2015 
Substance 18 48 14.0 - 85.0 2013-2015 
Substance 19 48 226.0 - 2012.0 2013-2015 
Substance 20 36 0.59 - 2.02 2013-2015 
Substance 21 72 0.91 - 3.27 2013-2015 
Substance 22 96 6.9 - 106.0 2013-2015 
Substance 23 96 1.8 - 28.0 2013-2015 
Substance 24 72 542.0 - 1941.0 2013-2015 
Substance 25 72 450.0 - 2000.0 2013-2015 
 
Table A3: Substances in the sample for calculating the BR of the h-CLAT prediction model 
Chemical name  No. of runs 
Test substance 
concentrations 
considered [μg/mL] 
Study Year 
Lactic Acid (Negative control) 53 1000 2013-2015 
DNCB (Positive control) 53 4.0 2013-2015 
Substance 1 32 7396.0 - 2064.0 2013-2015 
Substance 2 30 5655.0 - 29176.0 2013-2015 
Substance 3 40 12.3 - 64.0 2013-2015 
Substance 4 32 69.0 - 510.0 2013-2015 
Substance 5 48 14.2 - 73.4 2013-2015 
Substance 6 48 2.2 - 8.0 2013-2015 
Substance 7 32 29.0 - 105.0 2013-2015 
Substance 8 48 1589.0 - 5695.0 2013-2015 
Substance 9 48 13.0 - 48.0 2013-2015 
Substance 10 32 115.0 - 710.0 2013-2015 
Substance 11 32 14.0 - 51.0 2013-2015 
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Table A4: Substances in the sample for calculating the BR of the LLNA prediction model 
Chemical name  CAS no No. of runs 
Test substance 
concentrations 
considered [μg/mL] 
Study Year 
DL-Lactic acid 50-21-5 20 5, 10, 25 2013-2015 
Salicylic acid 69-72-7 20 5, 10, 25 2013-2015 
Chlorobenzene 108-90-7 20 25, 50, 100 2013-2015 
Methyl methacrylate 80-62-6 20 25, 50, 100 2013-2015 
2-Mercaptobenzothiazole 149-30-4 19 0.75, 2.0, 7.5 2013-2015 
Methyl salicylate 119-36-8 20 10, 25, 50 2013-2015 
MCI / MI 
26172-55-4 & 
2682-20-4 
40 
0.005, 0.05, 0.2, 0.1, 0.5, 
1 
2013-2015 
Sodium dodecyl sulfate 151-21-3 20 1, 5, 10 2013-2015 
Imidazolidinyl urea 39236-46-9 20 10, 25, 50 2013-2015 
Ethylenglycolmethacrylate 
(EGDMA) 
97-90-5 20 25, 50, 100 2013-2015 
Nickel(II) chloride 7718-54-9 20 1, 2.5, 5 2013-2015 
Cinnamic alcohol 104-54-1 20 10, 25, 50 2013-2015 
Isopropanol 67-63-0 20 25, 50, 100 2013-2015 
Phenylbenzoate 93-99-2 40 5,10, 15, 25, 40 2013-2015 
Isoeugenol 97-54-1 20 1, 5, 10 2013-2015 
Xylene 1330-20-7 20 25, 50, 100 2013-2015 
Alpha-Hexylcinnamaldehyde 101-86-0 20 5, 10, 25 2013-2015 
p-Phenylenediamine 106-50-3 20 0.05, 0.1, 0.5 2013-2015 
Citral 5392-40-5 20 5, 10, 25 2013-2015 
Cobalt(II) chloride 7646-79-9 20 0.25, 0.5, 1 2013-2015 
Eugenol 97-53-0 20 2.5, 10, 25 2013-2015 
1-Chloro-2,4-dinitrobenzene 
(DNCB) 
97-00-7 20 0.025, 0.1, 0.25 2013-2015 
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Appendix B 
Experimental samples used for identifying borderline substances and calculate the 
predictive accuracy of non-animal testing methods (with including and excluding the 
borderline substances) when compared to the animal test LLNA and to the human data 
as reference  
 
Table B1: Experimental sample tested with the DPRA (borderline substances in bold) 
Chemical name CAS no 
Sensitisation potential1 in mice or 
humans (by conventional approach, 
assessed without BR) 
  LLNA Human 
Salicylic acid 69-72-7 N N 
Geraniol 106-24-1 P - 
Benzyl alcohol 100-51-6 P P 
Tween 80 9005-65-6 N P 
3-Dimethylamino propylamine 109-55-7 N N 
cis-6-Nonenal 2277-19-2 P P 
Ethyl vanillin 121-32-4 P - 
Undecylenic acid 112-38-9 N - 
2-Methoxy-4-Methylphenol 93-51-6 P P 
Ethyl benzoylacetate 94-02-0 P - 
Dihydroeugenol (2-Methoxy-4-Propyl-phenol) 2785-87-7 N - 
α-Hexyl cinnamic aldehyde 101-86-0 P - 
N,N-Diethyl-m-toluanimde 134-62-3 N - 
Penicillin G 61-33-6 P P 
d,l-Citronellol 106-22-9 P N 
Pentachlorophenol 87-86-5 P P 
p-tert-Butyl-alpha-ethyl hydrocinnamal (Lilial) 80-54-6 P P 
1-Bromobutane 109-65-9 N - 
Fumaric acid 110-17-8 N N 
Glucose 50-99-7 N N 
Propyl paraben 94-13-3 TN TN 
4-Methoxyacetophenone (Acetanisole) 100-06-1 TN TN 
6-Methylcoumarin 92-48-8 TN TN 
Nonanoic acid 112-05-0 FN TN 
Isopropanol 67-63-0 FN TN 
Methyl salicylate 119-36-8 TN TN 
Dibutyl phthalate 84-74-2 TN inconclusive 
Pyridine 110-86-1 TN - 
dl-α-Tocopherol 10191-41-0 TN - 
Clotrimazole 23593-75-1 FN - 
Methyl pyruvate 600-22-6 FN - 
1-Butanol 71-36-3 TN TN 
Xylene 1330-20-7 FN TN 
Diethyl phthalate 84-66-2 TN TN 
Vinylidene dichloride 75-35-4 TN - 
Oxalic acid anhydrous 144-62-7 FN - 
Octanoic acid (Caprylic acid) 124-07-2 TN TN 
Coumarin 91-64-5 TN FN 
Dimethyl formamide 68-12-2 TN - 
Glycerol 56-81-5 TN TN 
2,2,6,6-Tetramethyl-3,5-heptanedione 1118-71-4 FN - 
N,N-Dibutylaniline 613-29-6 FN FN 
Resorcinol 108-46-3 FN - 
Chlorobenzene 108-90-7 TN - 
Propylene glycol (1,2-Propanediol) 57-55-6 TN TN 
4-Chloroaniline 106-47-8 FN - 
7,12-Dimethylbenz[α]anthracene 57-97-6 FN - 
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Aniline 62-53-3 FN FN 
Saccharin 81-07-2 TN TN 
Hexadecyltrimethylammonium bromide (Cetrimide) 57-09-0 TN - 
n-Hexane 110-54-3 TN TN 
Benzalkonium chloride 8001-54-5 TN TN 
Lactic acid 50-21-5 TN TN 
Octanenitrile 124-12-9 TN - 
Undec-10-enal 112-45-8 FN - 
Benzyl benzoate 120-51-4 FN TN 
Methyl 4-hydroxybenzoate (Methylparaben) 99-76-3 TN - 
Butylbenzylphthalate 85-68-7 TN - 
4-Hydroxybenzoic acid 99-96-7 TN TN 
Sulfanilamide 63-74-1 TN TN 
Cocamidopropyl betaine 61789-40-0 TN - 
Benzene,1-methoxy-4-methyl-2-nitro (4-Methyl-2-
nitroanisole) 
119-10-8 TN - 
Squaric acid diethyl ester 5231-87-8 FN - 
Clofibrate (Ethyl (2-(4-chlorophenoxy)-2-
methylpropanoate) 
637-07-0 TN - 
α-Amyl cinnamic aldehyde 122-40-7 FN Inconclusive 
Streptomycin sulfate 3810-74-0 TN FN 
α-iso-Methylionone 127-51-5 FN TN 
Carbonic acid, dioctyl ester 1680-31-5 TN - 
Hexyl salicylate 6259-76-3 FN TN 
Benzyl cinnamate 103-41-3 FN - 
Benzyl salicylate 118-58-1 FN TN 
Sulfanilic acid 121-57-3 TN - 
Isopropyl myristate a 110-27-0 FN TN 
p-Aminobenzoic acid 150-13-0 TN TN 
Tartaric acid 87-69-4 TN TN 
Zinc sulfate 7733-02-0 TN - 
Dioctyl ether 629-82-3 TN - 
2,2-Azobis phenol 2050-14-8 FN - 
Benzaldehyde 100-52-7 TN FN 
Farnesol 4602-84-0 FN FN 
3-Aminophenol 591-27-5 FN - 
(+/-) Linalool 78-70-6 FN TN 
Diethylenetriamine 111-40-0 FN FN 
Octanoic acid, 4-methyl-2-pentylbutyl ester 868839-23-0 TN - 
R(+)-Limonene 5989-27-5 TP FP 
Ethylenediamine free base 107-15-3 TP TP 
Vanillin 121-33-5 FP FP 
Cyclamen aldehyde 103-95-7 TP - 
Tropolone 533-75-5 TP - 
Cinnamyl Alcohol 104-54-1 TP TP 
R-Carvone 6485-40-1 TP TP 
Benzocaine 94-09-7 FP TP 
3-Phenoxypropiononitrile 3055-86-5 FP - 
2-Acetyl-cyclohexanone 874-23-7 FP - 
Diethyl sulfate 64-67-5 TP - 
2-Phenylpropionaldehyde 93-53-8 TP TP 
5-Methyl-2,3-hexanedione 13706-86-0 TP TP 
1-Iodohexane 638-45-9 FP - 
2,2-Bis-[4-(2-hydroxy-3-
methacryloxypropoxy)phenyl)]-propane (Bis-GMA) 
1565-94-2 TP - 
Farnesal 502-67-0 TP - 
α-Methyl-trans-Cinnamaldehyde 101-39-3 TP - 
3,4-Dihydrocoumarin 119-84-6 TP TP 
Eugenol 97-53-0 TP TP 
Lyral / 3 and 4-(4-Hydroxy-4-methylpentyl)-3-
cyclohexene-1-carboxaldehyde 
31906-04-4 TP TP 
Nickel chloride 7718-54-9 FP TP 
Bisphenol A-diglycidyl ether 1675-54-3 TP TP 
1,2,4-Benzenetricarboxylic anhydride (Trimellitic 
anhydride) 
552-30-7 TP - 
1-(p-Methoxyphenyl)-1-penten-3-one 104-27-8 TP - 
3-Propylidenephthalide 17369-59-4 TP TP 
Perillaldehyde 2111-75-3 TP TP 
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Tetrachloro-salicylanilide 1154-59-2 TP TP 
2-Fluoro-5-nitroaniline 369-36-8 FP - 
Phthalic anhydride 85-44-9 TP FP 
1,2-cyclohexane dicarboxylic anhydride 85-42-7 TP - 
Squaric acid 2892-51-5 TP TP 
Formaldehyde 50-00-0 TP TP 
2-Hydroxypropyl methacrylate 923-26-2 FP - 
1-Phenyl-1,2-propanedione 579-07-7 TP - 
Cobalt chloride 7646-79-9 TP TP 
Methylmethacrylate 80-62-6 TP TP 
Phenyl benzoate 93-99-2 TP TP 
3-Chloro-4-Methoxybenzaldehyde (3-Chloro-p-
anisaldehyde) 
4903-09-7 FP - 
Butyl glycidyl ether 2426-08-6 TP TP 
Imidazolidinyl urea 39236-46-9 TP TP 
1-Naphthol 90-15-3 TP - 
Ethanol-2-butoxy acetate 112-07-2 FP - 
1-Bromohexane 111-25-1 TP - 
Phenylacetaldehyde 122-78-1 TP TP 
Benzoic acid 65-85-0 FP - 
1-Iodohexadecane 544-77-4 TP - 
Citral 5392-40-5 TP TP 
Bandrowski’s Base (N,N-bis(4-aminophenyl)-2,5-
diamino-1,4-quinone-diimine) 
20048-27-5 TP - 
1,1,3-Trimethyl-2-Formylcyclohexa-2,4-diene 
(Safranal) 
116-26-7 TP TP 
4-Vinyl pyridine 100-43-6 TP - 
Benzylidene acetone (4-Phenyl-3-buten-2-one) 122-57-6 TP TP 
2-Nitro-1,4-phenylendiamine 5307-14-2 TP TP 
2,5-Diaminotoluene sulfate (PTD) 615-50-9 TP TP 
Hydroxycitronellal 107-75-5 TP TP 
MCI/MI 
26172-55-4 & 
2682-20-4 
TP TP 
Sodium lauryl sulfate / sodium dodecyl sulfate (SDS) 151-21-3 TP FP 
Methyl-2-octynoate / Methyl heptine carbonate 111-12-6 TP TP 
2-Methyl-2H-Isothiazol-3-one (MI) 2682-20-4 TP TP 
4-Allylanisole 140-67-0 TP - 
Diphenylcyclopropenone 886-38-4 TP TP 
Lauryl gallate 1166-52-5 TP TP 
Iodopropynyl butylcarbamate 55406-53-6 TP TP 
Furil 492-94-4 FP - 
2-Methylundecanal 110-41-8 TP - 
N,N-dimethyl-4-nitrosoaniline 138-89-6 TP - 
2-Propylheptyl acrylate 149021-58-9 TP - 
trans-2-Hexenal 6728-26-3 TP TP 
5-Amino-2-methylphenol 2835-95-2 TP - 
Chlorothalonil 1897-45-6 TP - 
2-Mercaptobenzothiazole 149-30-4 TP TP 
Methyl 2-nonynoate 111-80-8 TP TP 
Methyl methanesulphonate 66-27-3 TP - 
4-(N-Ethyl-N-2-methan-sulphonamido-ethyl)-2-
methyl-1,4-phenylenediamine (CD3) 
25646-71-3 TP - 
1,2-Dibromo-2,4-dicyanobutane (MDGN, 
Methyldibromo glutaronitrile) 
35691-65-7 TP TP 
Trans-2-Decenal 3913-71-1 TP - 
Tetramethylthiuram disulfide 137-26-8 TP TP 
1,2-Benzisothiazolin-3-One (Proxel active) 2634-33-5 TP TP 
Propanoic acid, 3-Bromo-Mmethyl ester (Methyl-3-
bromopropionate) 
3395-91-3 FP - 
4-Carboxyphenylacetate 2345-34-8 TP - 
Cinnamic aldehyde 104-55-2 TP TP 
2-Aminophenol 95-55-6 TP TP 
Diethyl acetaldehyde 97-96-1 TP 
Glutaraldehyde 111-30-8 TP TP 
Abietic acid 514-10-3 TP TP 
4-Ethoxymethylene-2-phenyl-2-oxazolin-5-one 
(Oxazolone) 
15646-46-5 TP TP 
4-Amino-m-cresol 2835-99-6 TP - 
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Isoeugenol 97-54-1 TP TP 
2-Ethylhexyl acrylate 103-11-7 TP - 
2,4-Heptadienal 5910-85-0 TP - 
2,4-Dinitrobenzenesulfonic acid, sodium salt 885-62-1 TP - 
Benzyl bromide 100-39-0 TP - 
2,4,6-Trinitrobenzenesulfonic acid 2508-19-2 TP - 
Propyl gallate 121-79-9 TP TP 
4-Nitrobenzyl bromide 100-11-8 TP - 
Glyoxal 107-22-2 TP TP 
Ethylene glycol dimethacrylate (EGDMA) 97-90-5 TP TP 
2,3-Butanedione 431-03-8 TP - 
Isophorone diisocyanate 4098-71-9 TP - 
5-Chloro-2-methyl-4-isothiazolin-3-one (MCI) 26172-55-4 TP - 
1,6-hexamethylene diisocyanate 822-06-0 TP - 
Hydroquinone 123-31-9 TP TP 
Maleic anhydride 108-31-6 TP - 
1,4-Phenylenediamine 106-50-3 TP TP 
4-(Methylamino) Phenol sulfate (Metol) 55-55-0 TP TP 
1-Chloro-2,4-Dinitrobenzene (Dinitrochlorobenzene, 
DNCB) 
97-00-7 TP TP 
Fluorescein-5-isothiocyanate 3326-32-7 TP - 
3-Methylcatechol 488-17-5 TP - 
Diethyl maleate 141-05-9 TP TP 
Benzoyl peroxide 94-36-0 TP TP 
2-Hydroxyethyl acrylate 818-61-1 TP TP 
Ethyl acrylate 140-88-5 TP TP 
Methyl acrylate 96-33-3 TP - 
Butyl acrylate 141-32-2 TP - 
p-Benzoquinone 106-51-4 TP TP 
Tosylchloramide sodium (Chloramine T) 127-65-1 TP - 
 
Table B2: Experimental sample tested with LuSens(borderline substances in bold) 
Chemical name CAS no 
Sensitisation potential1 in mice or 
humans (by conventional approach, 
assessed without BR) 
  LLNA Human 
1-Butanol 71-36-3 N N 
Benzoyl peroxide 94-36-0 P P 
4-Allylanisole 140-67-0 P - 
Methyldibromo glutaronitrile (MDGN) 35691-65-7 P P 
Phthalic anhydride 85-44-9 FN TN 
Resorcinol 108-46-3 FN FN 
Sodium lauryl sulfate / sodium dodecyl sulfate 
(SDS) 
151-21-3 FN TN 
Nickel chloride 7718-54-9 TN FN 
Salicylic acid 69-72-7 TN TN 
Farnesal 502-67-0 FN - 
Propyl gallate 121-79-9 FN FN 
Hexadecyltrimethylammonium bromide (Cetrimide) 57-09-0 TN TN 
Lactic acid 50-21-5 TN TN 
Aniline 62-53-3 FN FN 
4-Hydroxybenzoic acid 99-96-7 TN TN 
Glucose 50-99-7 TN TN 
Sulfanilamide 63-74-1 TN TN 
Penicillin G 61-33-6 FN FN 
p-Aminobenzoic acid 150-13-0 TN TN 
Ethylenediamine free base 107-15-3 FN FN 
Phenyl benzoate 93-99-2 FN FN 
Glycerol 56-81-5 TN TN 
Cocamidopropyl betaine 61789-40-0 TN - 
Propylene glycol (1,2-Propanediol) 57-55-6 TN TN 
n-Hexane 110-54-3 TN TN 
Isopropanol 67-63-0 TN TN 
Fumaric acid 110-17-8 TN TN 
Tartaric acid 87-69-4 TN TN 
Xylene 1330-20-7 FN TN 
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Pyridine 110-86-1 FN TN 
Vanillin 121-33-5 TN TN 
Octanoic acid, 4-methyl-2-pentylbutyl ester 868839-23-0 TN - 
Benzyl alcohol 100-51-6 FP TP 
Dioctyl ether 629-82-3 FP - 
Hydroxycitronellal 107-75-5 TP TP 
Methyl salicylate 119-36-8 FP FP 
1,6-hexamethylene diisocyanate 822-06-0 TP - 
p-Benzoquinone 106-51-4 TP TP 
Potassium dichromate 7778-50-9 TP TP 
4-Nitrobenzyl bromide 100-11-8 TP - 
α-Hexyl cinnamic aldehyde 101-86-0 TP inconclusive 
1-Chloro-2,4-dinitrobenzene 
(Dinitrochlorobenzene, DNCB) 
97-00-7 TP TP 
Diethyl phthalate 84-66-2 TN TN 
2-Ethylhexyl acrylate 103-11-7 TP - 
2-Phenylpropionaldehyde 93-53-8 TP TP 
6-Methylcoumarin 92-48-8 FP inconclusive 
Tween 80 9005-65-6 FP FP 
Propyl paraben (propyl-4-hydroxybenzoate) 94-13-3 FP FP 
Formaldehyde 50-00-0 TP TP 
Isophorone diisocyanate 4098-71-9 TP - 
2-Propylheptyl acrylate 149021-58-9 TP - 
Glyoxal 107-22-2 TP TP 
Ethyl acrylate 140-88-5 TP TP 
Imidazolidinyl urea 39236-46-9 TP TP 
Butyl glycidyl ether 2426-08-6 TP TP 
Tetramethylthiuram disulfide 137-26-8 TP TP 
Eugenol 97-53-0 TP TP 
2,4,6-Trinitrobenzenesulfonic acid 2508-19-2 TP - 
Glutaraldehyde 111-30-8 TP TP 
Methyl 4-hydroxybenzoate (Methylparaben) 99-76-3 FP - 
MCI/MI 
26172-55-4 
& 2682-20-4 
TP TP 
Cinnamyl Alcohol 104-54-1 TP TP 
Methylmethacrylate 80-62-6 TP TP 
Cobalt chloride 7646-79-9 TP TP 
4-Ethoxymethylene-2-phenyl-2-oxazolin-5-one 
(Oxazolone) 
15646-46-5 TP TP 
4-(Methylamino)phenol sulfate (Metol) 55-55-0 TP TP 
Undecylenic acid 112-38-9 TP TP 
2,3-Butanedione 431-03-8 TP - 
4-Methoxyacetophenone (Acetanisole) 100-06-1 FP FP 
Butyl acrylate 141-32-2 TP - 
1,4-Phenylenediamine 106-50-3 TP TP 
Methyl acrylate 96-33-3 TP 
Diethyl maleate 141-05-9 TP TP 
Benzylidene acetone (4-Phenyl-3-buten-2-one) 122-57-6 TP TP 
Cinnamic aldehyde 104-55-2 TP TP 
2-Mercaptobenzothiazole 149-30-4 TP TP 
Isoeugenol 97-54-1 TP TP 
Ethylene glycol dimethacrylate (EGDMA) 97-90-5 TP TP 
Citral 5392-40-5 TP TP 
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Table B3: Experimental sample tested with the h-CLAT(borderline substances in bold) 
Chemical name CAS no 
Sensitisation potential1 in mice or 
humans (by conventional 
approach, assessed without BR) 
  LLNA Human 
4-phenylenediamine 106-50-3 P P 
Phenyl benzoate 93-99-2 P P 
Ethylene diamine 107-15-3 P P 
Aniline 62-53-3 P P 
Farnesal 502-67-0 P - 
Methyldibromo Glutaronitrile (MDGN) 35691-65-7 P P 
p-Benzoquinone 106-51-4 P P 
Propyl gallate 121-79-9 P P 
MCI/MI 
26172-55-4 & 2682-20-
4 
TP TP 
1-chloro-2,4-dinitrobenzene 97-00-7 TP - 
Cobalt chloride 7646-79-9 TP TP 
Citral 5392-40-5 TP TP 
Cinnamic alcohol 104-54-1 TP TP 
Methylmethacrylate 80-62-6 TP TP 
Isopropanol 67-63-0 TN TN 
DL-lactic acid 50-21-5 TN TN 
Methyl salicylate 119-36-8 TN TN 
Sodium lauryl sulfate 151-21-3 FP TN 
Ethylene glycol dimethacrylate (EDGMA) 97-90-5 TP TP 
Xylene 1330-20-7 FN TN 
Sulfanilamide 63-74-1 TN TN 
2,4,6-trinitrobenzenesulfonic acid 2508-19-2 FN - 
2,3-butanedione 431-03-8 TP - 
2-phenylpropionaldehyde 93-53-8 TP TP 
4-allylanisole 140-67-0 TP - 
Benzylidene acetone 122-57-6 TP TP 
Diethyl maleate 141-05-9 TP TP 
Fumaric acid 110-17-8 TN TN 
Glucose 50-99-7 TN TN 
Hydroxycitronellal 107-75-5 TP TP 
p-aminobenzoic acid 150-13-0 TN TN 
Phthalic anhydride 85-44-9 FN TP 
Undecylenic acid 112-38-9 TP TP 
Vanillin 121-33-5 TN TN 
Propyl-4-hydroxybenzoate 99-76-3 FP FP 
Tartaric acid 87-69-4 TN TN 
n-hexane 110-54-3 TN TN 
Hexadecyltrimethylammonium bromid 57-09-0 TN TN 
Glycerol 56-81-5 TN TN 
Propylene glycol (1,2-Propanediol) 57-55-6 TN TN 
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Table B4: Experimental sample tested with the ‘2 out of 3’ITS approach (borderline substances in bold) 
Name CAS no 
Sensitisation potential1 in mice or 
humans (by conventional 
approach, assessed without BR) 
  LLNA Human 
Phenyl benzoate 93-99-2 P P 
Ethylene diamine 107-15-3 P P 
Methyldibromo glutaronitrile (MDGN) 35691-65-7 P P 
Propyl gallate 121-79-9 P P 
Propylene glycol (1,2-Propanediol) 57-55-6 TN TN 
Tartaric acid 87-69-4 TN TN 
Glycerol 56-81-5 TN TN 
n-Hexane 110-54-3 TN TN 
Propyl paraben (Propyl-4-Hydroxybenzoate) 99-76-3 FP FP 
Sulfanilamide 63-74-1 TN TN 
Vanillin 121-33-5 TN TN 
Isopropanol 67-63-0 TN TN 
Lactic acid 50-21-5 TN TN 
Methyl salicylate 119-36-8 TN TN 
Fumaric acid 110-17-8 TN TN 
Glucose 50-99-7 TN TN 
p-Aminobenzoic acid 150-13-0 TN TN 
Hexadecyltrimethylammonium bromide 
(Cetrimide) 
57-09-0 TN TN 
Xylene 1330-20-7 FN TN 
Methylmethacrylate 80-62-6 TP TP 
Aniline 62-53-3 FN FN 
Ethylene glycol dimethacrylate (EGDMA) 97-90-5 TP TP 
Undecylenic acid 112-38-9 TP TP 
Hydroxycitronellal 107-75-5 TP TP 
Cinnamyl Alcohol 104-54-1 TP TP 
4-Allylanisole 140-67-0 TP  
Sodium lauryl sulfate / sodium dodecyl sulfate 
(SDS) 
151-21-3 FN TN 
Farnesal 502-67-0 TP  
2,3-Butanedione 431-03-8 TP  
Citral 5392-40-5 TP TP 
2-Phenylpropionaldehyde 93-53-8 TP TP 
Benzylidene acetone (4-Phenyl-3-buten-2-one) 122-57-6 TP TP 
Diethyl maleate 141-05-9 TP TP 
Cobalt chloride 7646-79-9 TP TP 
2,4,6-Trinitrobenzenesulfonic acid 2508-19-2 TP  
Phthalic anhydride 85-44-9 FN TN 
1,4-Phenylenediamine 106-50-3 TP TP 
1-Chloro-2,4-dinitrobenzene 
(Dinitrochlorobenzene, DNCB) 
97-00-7 TP TP 
p-Benzoquinone 106-51-4 TP TP 
MCI/MI 26172-55-4 & 
2682-20-4 
TP TP 
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Table B5: Experimental sample tested with the LLNA (borderline substances in bold) 
Chemical name CAS no 
Sensitisation potential1 in mice or humans 
(by conventional approach, assessed 
without BR) 
  LLNA Human 
Salicylic acid 69-72-7 N TN 
Methyl methacrylate 80-62-6 P P 
Chlorobenzene 108-90-7 N  
Nickel chloride 7718-54-9 N P 
Phenyl benzoate 93-99-2 P P 
Methyl salicylate 119-36-8 N TN 
DL-Lactic acid 50-21-5 N TN 
2-Mercaptobenzothiazole 149-30-4 P TP 
MCI / MI 
26172-55-4 & 2682-20-
4 
P TP 
Sodium dodecyl sulfate 151-21-3 P FN 
Imidazolidinyl urea 39236-46-9 P TP 
Ethylenglycolmethacrylate (EGDMA) 97-90-5 P TP 
Cinnamic alcohol 104-54-1 P TP 
Isopropanol 67-63-0 N TN 
Isoeugenol 97-54-1 P TP 
Xylene 1330-20-7 P FN 
Alpha-Hexylcinnamaldehyde 101-86-0 P TP 
p-Phenylenediamine 106-50-3 P - 
Citral 5392-40-5 P TP 
Cobalt(II) chloride 7646-79-9 P TP 
Eugenol 97-53-0 P TP 
1-Chloro-2,4-dinitrobenzene (DNCB) 97-00-7 P TP 
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Appendix C  
Distributions of accuracy metrics for non-animal testing methods and the “2 out of 3” 
ITS - Using the LLNA as reference test 
DPRA (test results compared to LLNA data) 
  
Figure C1: Distribution of sensitivity, derived 
from randomised samples including borderline 
substances  
Figure C2: Distribution of sensitivity, derived 
from randomised samples excluding borderline 
substances  
  
  
Figure C3: Distribution of specificity, derived 
from randomised samples including borderline 
substances  
Figure C4: Distribution of specificity, derived 
from randomised samples excluding borderline 
substances 
  
  
Figure C5: Distribution of concordance, 
derived from randomised samples including 
borderline substances 
Figure C6: Distribution of concordance, derived 
from randomised samples excluding borderline 
substances 
  
LuSens (using the LLNA as reference test) 
  
Figure C7: Distribution of sensitivity, derived Figure C8: Distribution of the sensitivity, 
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from randomised samples including borderline 
substances 
derived from randomised samples excluding 
borderline substances 
  
  
Figure C9: Distribution of specificity, derived 
from randomised samples including borderline 
substances 
Figure C10: Distribution of the specificity, 
derived from randomised samples excluding 
borderline substances 
  
  
Figure C11: Distribution of the concordance, 
derived from randomised samples including 
borderline substances 
Figure C12: Distribution of the concordance, 
derived from randomised samples excluding 
borderline substances 
  
h-CLAT (using the LLNA as reference test) 
  
Figure C13: Distribution of the sensitivity, 
derived from randomised samples including 
borderline substances 
Figure C14: Distribution of the sensitivity, 
derived from randomised samples excluding 
borderline substances 
  
  
Figure C15: Distribution of the specificity, Figure C16: Distribution of the specificity, 
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derived from randomised samples including 
borderline substances 
derived from randomised samples excluding 
borderline substances 
  
-  
 
Figure C17: Distribution of the concordance, 
derived from randomised samples including 
borderline substances 
Figure C18: Distribution of the concordance, 
derived from randomised samples excluding 
borderline substances 
  
“2 out of 3” ITS (using the LLNA as reference test) 
  
Figure C19: Distribution of the sensitivity, 
derived from randomised samples including 
borderline substances 
Figure C20: Distribution of the sensitivity, 
derived from randomised samples excluding 
borderline substances 
  
  
Figure C21: Distribution of the specificity, 
derived from randomised samples including 
borderline substances 
Figure C22: Distribution of the specificity, 
derived from randomised samples excluding 
borderline substance 
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Figure C23: Distribution of the concordance, 
derived from randomised samples including 
borderline substances 
Figure C24: Distribution of the concordance, 
derived from randomised samples excluding 
borderline substances 
 
Distributions of accuracy metrics for non-animal testing methods and the “2 out of 
3”ITS - Using human data as reference test 
DPRA (using human data as reference test results) 
  
Figure C25: Distribution of sensitivity, derived 
from randomised samples including borderline 
substances  
Figure C26: Distribution of sensitivity, derived 
from randomised samples excluding borderline 
substances  
  
 
 
Figure C27: Distribution of specificity,6 
derived from randomised samples including 
borderline substances  
Figure C28: Distribution of6 specificity, 
derived from randomised samples excluding 
borderline substances 
  
  
Figure C29: Distribution of concordance, Figure C30: Distribution of concordance, 
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derived from randomised samples including 
borderline substances 
derived from randomised samples excluding 
borderline6 substances 
  
LuSens (using human data as reference test results) 
  
Figure C31: Distribution of sensitivity6, 
derived from randomised samples including 
borderline substances 
Figure C32: Distribution of 66the sensitivity, 
derived from randomised samples excluding 
borderline substances 
  
 
 
Figure C33: Distribution of specificity, derived 
from randomised samples including borderline 
substances 
Figure C34: Distribution of the specificity, 
derived from randomised samples excluding 
borderline substances 
  
  
Figure C35: Distribution of the concordance, 
derived from randomised samples including 
borderline substances 
Figure C36: Distribution of the concordance, 
derived from randomised samples excluding 
borderline substances 
  
h-CLAT (using human data as reference test results) 
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Figure C37: Distribution of the sensitivity, 
derived from randomised samples including 
borderline substances 
Figure C38: Distribution of the sensitivity, 
derived from randomised samples excluding 
borderline substances 
  
Figure C39: Distribution of the specificity, 
derived from randomised samples including 
borderline substances 
Figure C40: Distribution of the specificity, 
derived from randomised samples excluding 
borderline substances 
  
  
Figure C41: Distribution of the concordance, 
derived from randomised samples including 
borderline substances 
Figure C42: Distribution of the concordance, 
derived from randomised samples excluding 
borderline substances 
  
“2 out of 3” ITS (using human data as reference test results) 
  
Figure C43: Distribution of the sensitivity, 
derived from randomised samples including 
Figure C44: Distribution of the sensitivity, 
derived from randomised samples excluding 
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borderline substances borderline substances 
  
 
 
Figure C45: Distribution of the specificity, 
derived from randomised samples including 
borderline substances 
Figure C46: Distribution of the specificity, 
derived from randomised samples excluding 
borderline substances 
  
 
 
Figure C47: Distribution of the concordance, 
derived from randomised samples including 
borderline substances 
FigureC48: Distribution of the concordance, 
derived from randomised samples excluding 
borderline substances 
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Appendix D 
Accuracy metrics of testing methods when compared to human reference data  
Table D1: Number of substances in the experimental samples (n) used for calculating accuracy 
metrics of non-animal testing methods and the “2 out of 3”ITS (test results compared to hu man 
data) 
 Including borderline substances Excluding borderline substance 
DPRA 107 95 
LuSens 62 58 
h-CLAT 35 28 
“2 out of 3”ITS  35 32 
 
 
Table D2: Minimum and maximum number of substances in randomised samples resulting 
from bootstrap resampling, after borderline substances  were excluded (test results compared 
to human data) 
Randomised 
sample size (n) DPRA LuSens h-CLAT “2 out of 3” ITS  
Min 80 52 19 24 
Max 105 62 35 36 
Source: Own calculations. 
 
  
Appendix 
138 
 
Table D3: Accuracy metrics of the DPRA, LuSens, the h-CLAT and the “2 out of 3”ITS approach 
derived from experimental test results and randomised samples using bootstrap resampling 
(test results compared to human data) 
 
Experimental 
samples of 
substances 
Randomised samples from 
bootstrap resampling 
 Mean ± SD 95%CI 
DPRA n=107   
 
Sensitivity [%] 85 85±4 (76;93) 
Specificity [%] 80 80±7 (66;93) 
Concordance [%] 83 83±4 (76;90) 
  n=95   
Reduced sample 
(excluding borderline 
substances) 
Sensitivity [%] 89 89±4 (81;96) 
Specificity [%] 87 87±6 (73,97) 
Concordance [%] 88 88±4 (82,95) 
LuSens n=62   
Complete samples 
(including borderline 
substances) 
Sensitivity [%] 79 79±7 (65;91) 
Specificity [%] 83 83±8 (67;96) 
Concordance [%] 81 81±5 (69;90) 
  n=58   
Reduced sample 
(excluding borderline 
substances) 
Sensitivity [%] 80 80±7 (66;92) 
Specificity [%] 82 83±8 (65;96) 
Concordance [%] 81 81±5 (71;91) 
h-CLAT n=35   
Complete samples 
(including borderline 
substances) 
Sensitivity [%] 100 100±0 (100;100) 
Specificity [%] 94 94±6 (80;100) 
Concordance [%] 97 97±3 (91;100) 
  n=28   
Reduced sample 
(excluding borderline 
substances) 
Sensitivity [%] 100 100±0 (100;100) 
Specificity [%] 94 94±6 (80;100) 
Concordance [%] 96 96±4 (88;100) 
“2 out of 3” ITS  n=35   
Complete samples 
(including borderline 
substances) 
Sensitivity [%] 95 95±5 (82,100) 
Specificity [%] 94 94± 8 (80,100) 
Concordance [%] 94 94±4 (86,100) 
  n=32   
Reduced sample 
(excluding borderline 
substances) 
Sensitivity [%] 93 93±7  (78,100) 
Specificity [%] 94 94±6  (80,100) 
Concordance [%] 94 94±4  (84,100) 
Source: Own calculations. 
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Summary  
Nowadays large amounts of chemicals are in use worldwide. Still, detailed knowledge 
about the hazardous properties has become available for just few chemicals. This has 
stimulated discussions among scientists and policy-makers on how adequate information 
about the hazards and risks of chemicals can be provided within a realistic time-frame while 
reducing testing costs and avoiding animal testing. During the past decade, much progress has 
been made in the development of non-animal testing methods for several toxicological 
endpoints. None of the existing non-animal testing methods, however, is considered to 
provide sufficient and adequate information to fully replace an animal test if applied as a 
standalone method. Using information from different non-animal methods integrated in forms 
of testing strategies, also called “Defined Approaches” (DAs), has been proposed as a 
promising solution to replace animal testing. Moreover, DAs have been widely considered to 
allow for an economically efficient way to assess hazards and risks, because they are assumed 
to deliver information about substances’ hazardous properties faster and cheaper than the 
“gold standard” animal tests, and to avoid the use of laboratory animals.  
Efforts to develop non-animal testing strategies have given specific attention to the 
assessment of skin sensitisation which is the toxicological endpoint assessing a substance’s 
potential to cause acute contact dermatitis (ACD) in humans. This can be explained by several 
reasons. First, within the European Union, the REACH (Registration, Evaluation, Authorisation 
and Restriction of Chemicals) legislation prescribes skin sensitisation testing for industrial 
chemicals produced or imported in amounts more than one tonne per year. Second, 
substances used as ingredients in cosmetic products require skin sensitisation testing as a 
default. The Cosmetics Regulation, which entered into force in 2009, has enforced a marketing 
ban on all cosmetic products that contains chemicals tested in animal tests. This stimulated a 
scientific movement to develop non-animal methods and strategies for skin sensitisation 
assessment, based on in vitro, in silico and in chemico methods. Third, the adverse outcome 
pathway (AOP) which describes the sequence of biological and mechanistic events leading to 
the adverse outcome (i.e. the manifestation of ACD) is well-explored for skin sensitisation. The 
AOP has, therefore, been suggested as a guiding tool for the construction of testing strategies 
covering some or all key event in the skin sensitisation AOP. Still, there has been a need to 
gain better understanding in the conceptual requirements to develop resource-efficient 
testing strategies from an economic perspective. In this context, key conceptual challenges 
focus on (i) which non-animal testing methods to select in order to provide adequate hazard 
information, (ii) how to combine these methods into a testing strategy, and (iii) when testing 
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should stop. This also requires that non-animal testing methods’ precision, and uncertainties 
underlying to their predictivity, need to be well- understood and transparently documented.  
The objective of this thesis is to develop and apply an economic approach to the 
development of optimised non-animal testing strategies used for skin sensitisation potential 
(hazard) assessment. Furthermore, the thesis examines the uncertainty of test information 
due to the biological and technical variability and explores the impact of this uncertainty on 
non-animal testing methods predictive accuracy. Predictive accuracy is the ability of a non-
animal testing method to predict the test result of a reference animal test for tested 
substances.  
To provide a systematic overview of the current state-of-work regarding non-animal 
testing for skin sensitisation, Chapter 2 surveys the criteria suggested in the toxicological 
literature for the development of testing strategies. Furthermore, Chapter 2 suggests 
conceptual criteria and informational requirements in order to develop resource-efficient 
testing strategies. As a follow-up step existing testing strategies (i.e. DAs) combining 
information from different (non-animal) testing methods for skin sensitisation potential or 
potency, are qualitatively evaluated applying conceptual and informational criteria. We 
observe that existing testing strategies for skin sensitisation assessment focus predominantly 
on the maximisation of information, which is related to mechanistic criteria e.g. either 
covering the key events in the AOP or increasing the predictive accuracy estimates. Although 
the need to account for direct and indirect costs of testing has been widely acknowledged in 
the literature, cost components have been largely ignored in the development of integrated 
testing strategies. Optimising toxicity testing requires, however, balancing information 
outcomes with costs. The challenge is, therefore, to develop a methodological approach that 
guides the construction of resource efficient non-animal testing strategies. 
Chapter 3 introduces a Bayesian Value of Information (VOI) model as an economic 
approach to the optimisation of non-animal testing strategies for the assessment of skin 
sensitisation potential. A set of non-animal testing methods (i.e. the DPRA, LuSens, 
KeratinoSensTM, the h-CLAT and the OECD toolbox) are evaluated according to their Expected 
Value of Test Information (EVTI), which quantifies the expected net welfare gains from 
decision-making upon the use of a substance with additional information from testing. The 
EVTI is quantified for all individual non-animal testing methods, and their combinations into 
battery- and sequential combinations. Results are compared to those of the reference animal 
test (LLNA). Expected welfare gains or losses from using a (toxic) substance substances are 
approximated by estimating health damage costs from ACD caused, using the case of cosmetic 
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ingredients (i.e. Kathon CG) as an illustrative example. The Bayesian VOI model is offers a 
probabilistic method guiding (i) the selection of testing methods, (ii) the order of testing 
methods and (iii) when testing should stop. The stopping rule is an endogenous component of 
the VOI model. Testing has a positive (economic) value if and only if the information gains net 
of testing costs are positive. Chapter 3 concludes that combinations of non-animal testing 
methods into either batteries or sequential strategies reveal a higher EVTI than the reference 
animal test. Furthermore, it can be shown that resource efficient testing strategies do not 
need to cover all key events and do not have to follow the order of key events in the skin 
sensitisation AOP. Rather, the optimal selection of testing methods depends on the interplay 
of multiple parameters, such as a decision-maker’s prior beliefs upon the true properties of a 
substance, the predictive accuracy of testing methods, the expected welfare gains from 
marketing a substance, and, finally, testing costs.  
Chapter 4 examines the impact of biological and technical variability on the precision of 
testing methods for assessing skin sensitisation potential. Precision denotes a non-animal 
testing method’s ability to show concordant results in repeated applications. In general, for 
classification purposes conclusions on the hazardous properties of chemicals are based on 
binary “positive/negative” outcomes. Binary outcomes are derived by applying classification 
thresholds into continuous readouts from testing. However, for substances for which test 
results are close to the classification threshold non-animal testing methods, but also animal 
tests, can deliver discordant results in repeated testing. More specifically, we can quantify a 
range to the left and the right of the classification threshold within which discordant results 
can be expected with a certain probability. This range is called “grey zone” or “borderline 
range” around the classification thresholds of testing methods’ prediction models. In Chapter 
4 we quantify the borderline range for the LLNA as the reference animal test, the DPRA, 
LuSens, and the h-CLAT as non-animal testing methods, and for a combination of these 
methods into an integrated testing strategy i.e. the “2 out of 3” ITS. Furthermore, we identify 
the number of substances in the experimental samples of these methods for which test 
outcomes fall within the borderline range. Chapter 4 concludes that the technical and 
biological variability of testing methods impacts the precision of testing methods. Substances 
which are borderline, i.e. which revealed test results in the borderline range of the testing 
method, cannot unambiguously be classified as “hazardous/non-hazardous” thus indicating 
its ability to cause an effect or not. For such substances, a clear-cut classification is, therefore, 
not possible. Rather, further testing might be required to gain additional evidence on a 
substance’s intrinsic properties. Chapter 4 suggests that the borderline range should be 
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quantified and documented as a default for non-animal testing methods and the animal tests 
to provide transparent information about testing methods’ precision.  
Chapter 5 examines the impact of different types of uncertainties in testing methods’ 
predictive accuracy. In particular, the impact of limited precision, and the impact of varying 
sample  size and composition is examined in three steps. First, we examine the impact of non-
animal testing methods’ limited precision on predictive accuracy metrics. This is done by 
comparing sensitivity, specificity and concordance derived from experimental substances’ 
samples including borderline substances (i.e. the “complete” samples) with accuracy metrics 
derived after excluding borderline substances (i.e. the “reduced” samples). Second, we 
examine the impact of sample composition on accuracy metrics. Comparing accuracy metrics 
from randomised “complete “and “reduced” samples capture the joint effect from sample 
composition and limited precision. Third, we examine the joint impact of limited precision, 
variations in sample composition and variations of sample size on non-animal testing 
methods’ accuracy. To create randomised samples we use the non-parametric bootstrap 
analysis. The analysis is applied to experimental samples tested with the DPRA, LuSens, the h-
CLAT and the “2 out of 3” ITS. Results suggest that the impact of limited precision, sample size 
and composition on non-animal testing methods’ predictive accuracy depends on the 
relationship of borderline substances and substances with a clear-cut classification (non-
borderline) in experimental samples. Chapter 5 suggests using ranges for the accuracy 
metrics, rather than point estimates, to better reflect uncertainties, and to facilitate a 
transparent comparison, of non-animal methods’ predictive accuracy in a regulatory context.  
Using skin sensitisation as an illustrative example, this research has shown the 
importance of applying an economic approach to the development of testing strategies. 
Furthermore, this thesis has offered novel insights regarding the impact of different types of 
uncertainty on non-animal testing methods’ predictive accuracy, which is a key parameter for 
determining the information outcomes and, thus, the “informational value” from testing. 
These aspects are relevant for the evaluation of individual testing methods and for guiding the 
optimisation of non-animal testing strategies, for both scientific and regulatory purposes. The 
insights offered in this thesis, therefore, support the development of optimised, i.e. resource 
efficient, approaches to toxicological testing ensuring better-informed decision-making for a 
safe use of chemicals.  
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